

Ref. No.: F.02(425)/RMSCL/ED (P) EMPANELMENT/DTL/NIB-04/2025/1306 Dated: 23.06.2025

RAJASTHAN MEDICAL SERVICES CORPORATION LTD.
(A Govt. of Rajasthan Undertaking)
Gandhi Block, Swasthya Bhawan, Tilak Marg, Jaipur – 302005,
India
Tel No: 0141-2228066, 2228064, E-mail: edprmsc@rajasthan.gov.in

**E-BID FOR THE RATE CONTRACT CUM EMPANELMENT OF
ANALYTICAL TESTING LABORATORIES FOR THE TEST
AND ANALYSIS OF DRUGS
(Two Years RC ending on **31.10.2027**)**



!! सर्वे सन्तु निरामया:!!

LAST DATE OF SUBMISSION OF ONLINE BIDS	24.07.2025 & 6.00 PM
DATE AND TIME OF OPENING OF ONLINE TECHNICAL BIDS	25.07.2025 & 11.30 AM



RAJASTHAN MEDICAL SERVICES CORPORATION LTD.

(A Govt. of Rajasthan Undertaking)

Gandhi Block, Swasthya Bhawan, Tilak Marg, Jaipur – 302005, India

Phone No: 0141-2228066, 2228064

Website: www.rmhc.health.rajasthan.gov.in

CIN:U24232RJ2011SGC035067

E-mail : edprmc@rajasthan.gov.in

Ref. No.: F.02(425)/RMSCL/ED (P) EMPANELMENT/DTL/NIB-04/2025/1306 Dated: 23.06.2025

Notice Inviting e-bids

e-bids are invited up to 6.00 PM of **24.07.2025** from NABL accredited Drugs Testing Laboratories situated in India for rate contract cum empanelment for analysis of Drugs & Medicines.

Details of NIB may be seen at the website of State Public Procurement Portal <https://sppp.rajasthan.gov.in/>, <http://eproc.rajasthan.gov.in>., <http://rmhc.health.rajasthan.gov.in> and may be downloaded from there.

UBN.No

Executive Director (Procurement)
RMSCL

**RAJASTHAN MEDICAL SERVICES CORPORATION
LTD. RAJASTHAN**

**e-BID FOR RATE CONTRACT CUM EMPANELMENT OF
ANALYTICAL TESTING LABORATORIES FOR THE TEST
AND ANALYSIS OF DRUGS**

(Rate contract for two years ending on **31.10.2027)**

Bid Reference	:	F.02(425)/RMSCL/ED (P) EMPANELMENT/DTL/NIB-04/2025/1306 Dated: 23.06.2025
Pre- bid conference	:	30.06.2025 at 11.30 P.M.
Date and time for downloading bid document	:	23.06.2025 from 06.00 PM
Last date and time of submission of online bids	:	24.07.2025 at 6.00 PM
Date and time of opening of Online technical bids	:	25.07.2025 at 11.30 AM
Cost of the Bid Document	:	Rs. 2360/- (Including GST@ 18%)
RISL Processing Fees	:	Rs. 590/- (Including GST @ 18%)
Bid Security	:	Rs. 25000/-

**RAJASTHAN MEDICAL SERVICES CORPORATION LTD.
RAJASTHAN**

**E-BID FOR RATE CONTRACT CUM EMPANELMENT OF
ANALYTICAL TESTING LABORATORIES FOR THE TEST
AND ANALYSIS OF DRUGS (Rate contract for two years ending on
31.10.2027)**

“CONFIDENTIALITY IS THE ESSENCE OF THIS BID”

**1. LAST DATE FOR RECEIPT OF BIDS, BID FORM FEES, BID SECURITY
& RISL PROCESSING FEES**

- a) E-Bids [In Two Separate Bids (Technical Bid & Price Bid)] Shall Be Received Till 06.00 PM on **24.07.2025** By The Rajasthan Medical Services Corporation Ltd, For The Rate contract cum Empanelment Of Analytical Testing Laboratories For The Test And Analysis Of DRUGS (Rate contract for two years ending on **31.10.2027**) in English language. Proposal received after the closing date and time shall not be considered.
- b) The bids shall be valid for a Period of 120 days from the date of opening of Technical Bid and prior to the expiration of the bid validity the Bid Inviting Authority may request the Bidders to extend the bid validity for another period of 30 days. The Bidder may refuse extension of bid validity without forfeiting the Bid Security deposit. No refund of tender fee is claimable under any circumstances to any of the bidder.
- c) The e-Bids will be received on web-portal of e-procurement of GoR i.e. <http://eproc.rajasthan.gov.in>. Every Bidder will be required to pay the Bid form fee Rs. 2360/- (Including GST@ 18%) for downloaded forms from the website, Bid Security as applicable in Bid condition no. **6** and processing fee of Rs. 590/- (Including GST@ 18%) of R.I.S.L. through three separate prescribed challans (*format enclosed in Annexure- I*) in any branch of the **Bank of Maharashtra (M.I. Road, Jaipur)** into Account no. **60460019022 & IFSC Code no. MAHB0000389** throughout the country upto or through D.D. / Bankers Cheque in favour of M.D. RMSCL (tender fees and Bid Security) and MD, RISL (tender processing fees) physically in the office of RMSCL by 6.00 PM on **24.07.2025** The bidders shall submit/upload scanned copy of all the challans in Technical Bid. Bids will be opened only after ensuring receipt of Bid fees along with processing fees and Bid Security.

In the absence of Bid fees, processing fees and Bid security the Bids shall be rejected and shall not be opened.

2. Eligibility Criteria for Empanelment :-

(1) Drug Testing Laboratories should have valid Approval for carrying out test on drugs under the Drugs and Cosmetics Act, 1940 and Rules there under. Three years standing in the test & analysis of **drug items** and the lab shall be entitled for empanelment for the categories of items for which lab has bid and having approval. Bid is invited from approved Drugs Testing Laboratories situated in India.

(2) *The laboratory should be GLP compliant under the provisions of Drugs and Cosmetics Act, 1940 and Rules there under and should hold schedule L-1 certificate or should have approval from Drug Control Department and NABL accreditation with proper scope of accreditation to undertake testing of drug items.*

(3) For drug items falling in the Non Biological category, laboratory's should have an average annual turnover of **not less than Rs. 50 Lakh** for past preceding three years (2021-22, 2022-23 & 2023-24 or 2022-23, 2023-24 & 2024-25).

For drug items falling in the Biological category, laboratory's should have an average annual turnover of **not less than Rs. 1.00 Crore** for past preceding three years (2021-22, 2022-23 & 2023-24 or 2022-23, 2023-24 & 2024-25).

Only audited accounts would be considered provisional accounts would not be considered in any case.

(4) The lab should have undertaken test and analysis of drugs and supplies of similar nature of drugs for at least three government institutions/corporation/reputed manufacturers of drug formulations.

(5) The lab should not stand banned / debarred or blacklisted by any State or Central Government or its Organizations or its procurement agencies on the due date of bid submission. If a bidder or an approved bidder will be found defaulter for concealing this fact, then following actions may be taken.

(i) Bid rejection

(ii) Bid Security forfeiture

(iii) Agreement rejection

(iv) Performance Security forfeiture

(v) Blacklisting

(6) The laboratory and its responsible persons should not have been convicted under the provisions of applicable laws with regard to the activities and conduct of the laboratory.

(7) The laboratory should have all necessary instruments/equipments/machines for testing of drugs with HPLCs with UV detector, HPLCs with fluorescence, HPLC with RI detector {Minimum 01 Each}.

3 TECHNICAL BID

The Bidder must furnish the following in technical bid.

- a. Bidders are allowed the option to quote for anyone item or more items as mentioned in bid (list of medicines proposed to be analyzed tested as at Annexure-VII).
- b. The bidders shall submit/upload in Technical Bid scanned copies of all the challans / DD/ BC of deposits of Bid form fees, RISL processing fee and Bid Security Money.
- c. Attested Photocopy of Analytical approval duly renewed up to date, issued by the State Licensing Authority.
- d. **Compliance of Schedule L-1 of Drugs & Cosmetics Rules, 1945 (GLP certificate) and Copy of NABL accreditation with scope for testing of drug formulations.**
- e. Documentary evidence of having analysed Drug and medical items for last three years with a statement in the proforma as given in Annexure III.
- f. Attested copy of certificate of GST registration.
- g. GST returns file of last 3 month from last date of bid submission
- h. Non- Conviction Certificate by the State Licensing Authority/ competent authority.
- i. Annual turnover statement for 3 year i.e. (2021-22, 2022-23 & 2023-24 or 2022-23, 2023-24 & 2024-25) certified by the practicing Chartered Accountant with UDIN No.
- j. Copies of the Balance Sheet and Profit and Loss Account for three years i.e. (2021-22, 2022-23 & 2023-24 or 2022-23, 2023-24 & 2024-25) duly audited or certified by the practicing Chartered Accountant. No provisional balance sheet or Profit and Loss account would be entertained.
- k. The following information in the form given in Annexure IV (a) to IV (d).

- a) The list of permanent technical qualified personnel employed in the laboratory.
- b) The list of sophisticated instruments available in the laboratory.
- c) Micro Biological facilities available in the laboratory.
- d) List of Reference Samples along with their date of procurement and quantities.
- e) In the case of Non- Pharmacopoeial Products the Method of Analysis Should be appended to the Report, especially if the sample is declared as “Not of the Standard Quality”.
- l. A declaration in the proforma given in Annexure V duly signed and Notarized.
- m. Details of Laboratory in Annexure – VI.
- n. A copy of PAN issued by Income Tax Department.
- o. Documentary evidence for the constitution of the company / concern.
- p. At any time prior to opening of price bid, RMSC either at their own initiate or in response to
- q. requested by prospective tender, may modify tender by issuing an amendment. Such amendments shall be uploaded on e-Proc site and will be part of the tender.
- r. A bidder has to fill up the checklist enclosed at Annexure VIII indicating the infrastructure and testing facilities available in the lab.

4 PRICE BID:

The price bid shall also be known as financial document and every bidder will be required to submit its price in excel format attached to the bid document (BOQ). **BOQ template must not be modified/ replaced by the bidder and the same should be uploaded after filling the relevant columns, else the bid is liable to be rejected for the particular item. Bidders are allowed to enter the bidder name and values only. The bidder should quote rate for the complete tests as applicable to the item. The rate for sterility test for sterile products should also be quoted separately at last entry of BOQ. Any type of uncalled clarifications on prices or rebates shall not be accepted.**

5 OPENING OF TECHNICAL BID AND FINANCIAL BID EVALUATION

The technical bids would be opened on scheduled date and time on eproc website i.e. <https://eproc.rajasthan.gov.in>. After technical evaluation physical inspection of the laboratories may be carried out by the designated team. Thereafter financial bids would be opened of those bidders who are found finally responsive on technical criteria. The acceptable rates for analysis will be decided and communicated accordingly.

6 BID SECURITY

The Bid Security Money Deposit shall be Rs. 25,000/- (Rs Twenty Five Thousand only) The Earnest Money Deposit shall be paid in through separate prescribed challans (format enclosed in Annexure-I) in any branch of the **Bank of Maharashtra (M.I. Road, Jaipur)** into Account no. **60460019022 & IFSC Code no. MAHB0000389** throughout country or through D.D. / bankers cheque in favour of M.D. RMSCL physically in the office of RMSC by 6.00 PM on **24.07.2025** Bid Security Deposit in any other form will not be accepted

The Bids submitted without sufficient Bid Security will be summarily rejected. The Bid Security will be forfeited, if the Bidder withdraws its Bid after last time & date fixed for receiving bids or in the case of a successful Bidder, if the Bidder fails to sign the contract agreement or fails to furnish the security deposit within the stipulated time.

Government undertaking PSU are exempted from Bid Security deposition on producing the certificate issued by the competent authority.

7 GENERAL CONDITIONS

1. The details of the Drugs, to be analysed shall be given in **Annexure VII**.
2. *The Bidder should quote the rates for complete analysis of each product and name of test to be performed, methodology to be used for each test. **However wherever rates for individual test are demanded, they should be furnished accordingly in BOQ.***
3. The rates quoted should be exclusive of taxes, though the applicable taxes are to be mentioned separately.
4. The rates quoted and accepted will be binding on the Bidder for the stipulated period and on no account any revision will be entertained till the completion of the rate contract period including extensions, if any given.
5. Analytical Laboratory, which also has its manufacturing activity, if empanelled by RMSC, then Samples of its own manufacturing unit shall not be sent to its empanelled laboratory for testing.
6. The laboratory will not be permitted to outsource any test to any other laboratory.

7. RMSCL shall have the right to cause inspection of the laboratory by the members of its technical committee before opening of price bid and subsequently as and when considered appropriate and based on the finding, the Bidder may be disqualified or de-empanelled, as the case may be.
8. Conditional tender will not be accepted and rejected immediately.
9. ***GST at applicable rate should be mentioned by the bidder where ever applicable.***

8. ACCEPTANCE OF BID

1. The Bid evaluation committee formed by Managing Director, Rajasthan Medical Services Corporation Ltd. will evaluate the Bid with reference to various criteria specified in bid document.
2. The Managing Director, Rajasthan Medical Services Corporation Limited reserves the right to accept or reject any BID for any one or more of the items Bided for, without assigning any reason.
3. The Managing Director, Rajasthan Medical Services Corporation Limited has the right to accept one or more bids depending on the volume of analytical work.

9. AGREEMENT

1. **The agreement with empanelled laboratories shall remain valid up to 31.10.2027. If Required period of contract can be extended upto 3 months on same rate, terms and condition without any prior consent of the bidder and shall be binding on approved bidder.**
2. RMSCL will issue letters of Intent (LOIs) to successful bidders and bidders who are empanelled will have to execute an agreement on a non-judicial stamp paper of value **Rs. 500** /- (Stamp duty to be paid by the Bidder), in favour of Managing Director, Rajasthan Medical Services Corporation Limited Jaipur within 15 days from the date of receipt of the intimation to them informing that their BIDs have been accepted. The format of agreement will be issued by RMSCL. (Annexure IX)
3. The Bidder shall not, at any time, assign, sub-let or make over the contract or the benefit therefore or any part thereof to any other person or persons whatsoever.
4. All notices or communication relating to, or arising out of this agreement or any of the terms thereof shall be considered duly served on or given to the

Bidder if delivered to him or emailed on its email address or left at the premises, places of business or abode.

10. PERFORMANCE SECURITY

1. The successful Bidders shall be required to pay a Performance Security of **Rs. 62,500/-** (Rs Sixty Two Thousand Five Hundred only) ***in the form of demand draft*** at the time of execution of the agreement. **Performance security will be refunded three month after expiry of rate contract subject to successful completion of services.**

11. COMPLETE ANALYSIS & REPORTING CONDITIONS

1. (a) On empanelment and entrustment of the job, the Analytical Laboratory should furnish the test reports within:
 - i. **10 days from the receipt of the sample in case of Tablets, Capsules, Pessaries, Ointments, Powder and Liquid Oral Preparations (non – sterile products)**
 - ii. **21 days from the receipt of the sample in the case of I.V. Fluids and injectables and other items requiring test for sterility.**
- b) All the tests mentioned in IP/BP/USP/Drugs & Cosmetics Act. etc. including addendus, (as the case may be) should be carried out for each and every sample. The results obtained in the test should be mentioned in numerical value (wherever possible). However this condition will not apply when only specific testing is called for/desired on any particular sample. If any drug is not included in the pharmacopeia at the time of bid opening and letter on it is including in any pharmacopeia the drug should be tested as per pharmacopeia specification.
- c) Mentioning only “COMPLIES” or “PASSES” in the result column of the report would be treated as incomplete report, if the result has some numerical value.

	for past
	for past
	for past
- d) Every test report must have remarks either as “Standard Quality” or “Not of Standard Quality”. Any ambiguity/cutting in reports will not be accepted (clear mention of “standard quality or not of standard quality” should be stated in bold letters and crossing/cutting of one of these will not be accepted).
- e) Reports should be in A4 size (8.27” X 11.69”) paper of good quality.
- f) Report should be issued on form 39 A and should have S. no. , name of drug

sample, code no., batch no., mfg. date, exp. date, description of tests, protocol of test specified & applied, findings & results obtained and should be signed by person-in-charge of testing. In case of Not of Standard Quality Reports the reports shall be release on Pink/Red colored paper for easy identification of NOSQ drugs.

- g) Reports should be attached along with Spectra/ Chromatography data sheets, if applicable and it will be considered incomplete if spectra or chromatograms are not attached.
2. All test reports of each batch of sample should be submitted to the RMSC in triplicate. In case of failure of a sample, the result should be communicated immediately to the Executive Director (Q.C.) through phone / e-mail and the report should be sent along with protocol.
 3. If in any circumstances (like break down of instrument, non-availability of reference standard etc.) the Analytical Laboratory is unable to undertake analysis for a sample, the same should be reported within 24 hours of receipt of such a sample by phone or E-mail and the sample should be returned to the Executive Director (Quality Control), Rajasthan Medical Services Corporation Limited, Jaipur after taking necessary telephonic or mail consent. In case of inability of laboratory to undertake the testing, a penalty of 25% of testing charges applicable for that product / products will be recovered.
 4. If placebo or standard test procedure of any product is required the same should be demanded within 48 hours with return request. Period lapsed/taken in providing placebo or standard testing procedure will be condoned from prescribed time limit for that sample.
 5. If any sample is received in a damaged condition by the laboratory, the sample should not be analyzed and the information should be sent immediately to the E.D. (Quality Control), Rajasthan Medical Services Corporation Limited Jaipur by Fax or E-mail.
 6. The Managing Director, Rajasthan Medical Services Corporation Limited or his authorized representative(s) has / have the right to inspect the laboratories of the Bidders who have submitted BIDs, before taking any decision regarding empanelment. Similarly, the Managing Director, Rajasthan Medical Services Corporation Limited or his authorized representatives may also inspect any empanelled laboratory, at any point of time during the continuance of the BID and

terminate / cancel its empanelment or any orders issued to the laboratory, not to entrust any further testing job to the laboratory based on facts brought out during such inspections.

7. The successful lab shall have to make own arrangement for collection of sample, from RMSC Headquarters.
8. It will be sole discretion of RMSC to allot the samples to any empanelled lab in case when there are more than one lab approved for an item. (One or more Laboratories may be empanelled by this tender.)

12. PAYMENT PROVISIONS

1. No advance payment towards any analysis will be made to the empanelled Bidder.
2. No payment will be made for the incomplete analysis or incomplete report. Deliberate omission of any critical test will be viewed seriously and shall invite action against the laboratory as deemed fit by RMSCL.
3. Payments towards the analysis of Drugs will be made as per approved rate plus tax on it will be along with Tax at the prevailing rate as applicable at the time of payment.
4. **GST shall be applicable as per prevailing rates notified by the Government.**

13. PENALTIES

1. If the successful Bidder fails to execute the agreement and deposit security amount within the time specified or withdraws the BID after intimation of the acceptance of the BID or owing to any other reasons, is unable to undertake the contract, the empanelment will be cancelled and the Earnest Money amount deposited by the Bidder shall stand forfeited in favour of the Rajasthan Medical Services Corporation Limited. Such Bidder(s) will also be liable for all damages sustained by the Rajasthan Medical Services Corporation Limited due to breach of BID conditions. Such damages shall be assessed by the Managing Director, Rajasthan Medical Services Corporation Limited whose decision shall be final and binding.
2. After entering into Rate contract, if the laboratory does not as per the terms and conditions, it may be disqualified to participate in the BID for the period as decided by RMSCL.

3. To assess the correctness of the test results being given by the Empanelled laboratories, samples at random, would also be sent to the Government Analyst for testing and if any variation is found the result would be informed to empanelled laboratories. If there is any gross variation in the analytical reports furnished by the empanelled laboratories (either pass or fail) with Government Lab for 3 times in assay test and 4 times for any other specification, in a year, the empanelled laboratory shall be considered for blacklisting for a period as considered proper after following the due process.
4. If it is revealed that the analytical Laboratory is involved in any form of fraud and collusion with the suppliers of Rajasthan Medical Services Corporation Limited, the Analytical Laboratory will be black listed for a period considered suitable. The Bidders shall also be liable for action under criminal law and the matter will be notified to the concerned Director of Drugs Control for suitable action against them under Drugs & Cosmetics Act & Rules.
5. The Managing Director, Rajasthan Medical Services Corporation Limited will be at liberty to terminate, the empanelment of any laboratory either wholly or in part at one month's notice without assigning any reasons. The Bidder will not be entitled for any compensation whatsoever in respect of such termination.
6. In all matters pertaining to the BID, the decision of the Managing Director, Rajasthan Medical Services Corporation Limited shall be final and binding.
7. (i) If the laboratory requires an extension in time for submission of test report, on account of occurrence of any hindrance it shall apply in writing for extension on occurrence of hindrance but not after the stipulated date of ***furnishing the test report.***
(ii) The Executive Director (QC)/ Drug Controller/ADC (QC) may extend the testing period with or without liquidated damages in case they are satisfied that the delay in the submission of test reports is on account of any hindrances, he shall apply in writing for extension on occurrence of hindrance but not after the stipulated date of submission of report. Reasons shall be recorded.

(iii) **Extension in testing period:-** In case of extension in the testing period with liquidated damages the recovery shall be made on the basis of following percentages of **testing charges** which the Bidder has failed to submit:-

- (a) Delay upto one fourth period of the prescribed testing period; 2.5%
- (b) Delay exceeding one fourth but not exceeding half of the prescribed testing period; 5%
- (c) Delay exceeding half but not exceeding three fourth of the prescribed testing period; 7.5%
- (d) Delay exceeding three fourth of the prescribed testing period; 10%

Note: Fraction of a day in reckoning period of delay in ***furnish the test report*** shall be eliminated if it is less than half a day. The maximum amount of liquidated damages shall be 10%.

iv. If, at any time during the continuance of this Agreement, the **laboratory** has, in the opinion of the Purchaser, delayed in submitting any test report, by the reasons of any riots, mutinies, wars, fire, storm, earthquakes, tempest or other exceptional cause, on a specific request made by the laboratory, the time for submitting test report may be extended by the **RMSCL** purely at his discretion for such period as may be considered reasonable. No further representation from the **laboratory** will be entertained on this account.

14. CORRECTION OF ARITHMETIC ERRORS:

Provided that a financial bid is substantially responsive, the procuring Entity will correct arithmetical errors during evaluation of Financial Bids on the following basis:

- (i) If there is a discrepancy between the unit price and the total price that is obtained by multiplying the unit price and quantity, the unit price shall prevail and the total price shall be corrected, unless in the opinion of the Procuring Entity there is an obvious misplacement of the decimal point in the unit price, in which case the total price as quoted shall govern and the unit price shall be corrected;
- (ii) If there is an error in a total corresponding to the addition or subtraction of subtotals, the subtotals shall prevail and the total shall be corrected; and.

- (iii) If there is a discrepancy between words and figures, the amount in words shall prevail, unless the amount expressed in words is related to an arithmetic error, in which case the amount in figures shall prevail subject to clause (a) and (b) above.

If the Bidder that submitted the lowest evaluated bid does not accept the correction of errors, its Bid shall be disqualified and its Bid Security shall be forfeited or its Bid Securing Declaration shall be executed.

15. GRIEVANCE REDRESSAL DURING EMPANELMENT PROCESS:

First Appellate Authority:- MD, NHM, Rajasthan, Jaipur.

Second Appellate Authority:- The Additional Chief Secretary/ Principal Secretary/ Secretary Department of Medical Health and Family Welfare, Government of Rajasthan, Jaipur.

i. Filing an appeal

If any Bidder or prospective bidder is aggrieved that any decision, action or omission of the Procuring Entity is in contravention to the provisions of the Act or the Rules of the Guidelines issued there under, he may file an appeal to First Appellate Authority, as specified in the Bidding Document within a period of ten days from the date of such decision or action, omission, as the case may be, clearly giving the specific ground or ground on which he feels aggrieved:

Provided that after the declaration of a Bidder as successful the appeal may be filed only by a Bidder who has participated in procurement proceedings:

Provided further that in case a Procuring Entity evaluates the Technical Bids before the opening of the Financial Bids, an appeal related to the matter of Financial Bids may be filed only by a Bidder whose Technical Bid is found to be acceptable.

- ii.** The Officer to whom an appeal is filed under Para (1) shall deal with the appeal as expeditiously as possible and shall Endeavour to dispose it of within thirty days from the date of the appeal.
- iii.** If the officer designated under Para (1) fails to dispose of the appeal filed within the period specified in Para (2), or if the Bidder or prospective bidder or the Procuring Entity is aggrieved by the order passed by the First Appellate Authority, the Bidder or prospective bidder or the Procuring Entity, as the case may be, may file a second appeal to second Appellate

Authority specified in the Bidding Document in this behalf within fifteen days from the expiry of the period specified in Para (2) or of the date of receipt of the order passed by the First Appellate Authority, as the case may be.

iv. Appeal not to lie in certain cases

No appeal shall lie against any decision of the Procuring Entity relating to the following matters, namely:-

- (a) Determination of need of empanelment;
- (b) Provision limiting participation of Bidders in the Bid process; (c) The decision of whether or not to enter into negotiations;
- (d) Cancellation of a empanelment process;
- (e) Applicability of the provisions of confidentiality.

v. Form of Appeal

- (a) An appeal under Para (1) or (3) above shall be in the annexed Form along with as many copies as there are respondents in the appeal.
- (b) Every appeal shall be accompanied by an order appealed against, if any, affidavit verifying the facts stated in the appeal and proof of payment of fee.
- (c) Every appeal may be presented to First Appellate Authority or Second Appellate Authority, as the case may be, in person or through registered post or authorised representative.

vi. Fee for filling appeal

- (a) Fee for first appeal shall be rupees two thousand five hundred and for second appeal shall be rupees ten thousand, which shall be non-refundable.
- (b) The fee shall be paid in the form of bank demand draft or banker's cheque of a Scheduled Bank in India payable in the name of Appellate Authority concerned.

vii. Procedure for disposal of appeal

- (a) The First Appellate Authority or Second Appellate Authority, as the case may be, upon filling of appeal, shall issue notice accompanied by copy of appeal, affidavit and documents, if any, to the respondents and fix date of hearing.
- (b) On the date fixed for hearing, the First Appellate Authority or Second Appellate

Authority, as the case may be, shall,-

- (i) Hear all the parties to appeal present before him; and
- (ii) Peruse or inspect documents, relevant records or copies thereof relating to the matter.

(c) After hearing the parties, perusal or inspection of documents and relevant records or copies thereof relating to the matter, the Appellate Authority concerned shall pass an order in writing and provide the copy of order to the parties free of cost.

(d) The order passed under sub-clause (c) above shall be placed on the State Public procurement Portal.

16. COMPLIANCE WITH THE CODE OF INTEGRITY AND NO CONFLICT OF INTEREST:

Any person participating in a empanelment process shall-

- a) Not offer any bribe, reward or gift or any material benefit either directly or indirectly in exchange for an unfair advantage in procurement process or to otherwise influence the procurement process;
- b) Not misrepresent or omit misleads or attempts to mislead so as to obtain a financial or other benefit or avoid an obligation;
- c) Not indulge in any collusion, Bid rigging or any-competitive behaviour to impair the transparency, fairness and progress of the procurement process;
- d) Not misuse any information shared between the procuring Entity and the Bidders with an intent to gain unfair advantage in the procurement process;
- e) Not indulge in any coercion including impairing or harming or threatening to do the same, directly or indirectly, to any part or to its property to influence the procurement process;
- f) Not obstruct any investigation or audit of a procurement process;
- g) Disclose conflict of interest, if any; and
- h) Disclose any previous transgressions with any Entity in India or any other country during the last three years or any debarment by any other procuring entity.

17. Conflict of interest:-

The Bidder participating in a bidding process must not have a Conflict of Interest.

A Conflict of interest is considered to be a situation in which a party has interests that could improperly influence that party's performance of official

duties or responsibilities, contractual obligations, or compliance with applicable laws and regulations.

I. A Bidder may be considered to be in Conflict of interest with one or more parties in bidding process if, including but not limited to:

- a. Have controlling partners/shareholders in common; or
- b. Receive or have received any direct or indirect subsidy from any of them; or
- c. Have the same legal representative for purposes of the Bid; or
- d. Have a relationship with each other, directly or through common third parties, that puts them in a position to have access to information about or influence on the Bid of another Bidder, or influence the decisions of the Procuring Entity regarding the bidding process; or
- e. The Bidder participates in more than one Bid in a bidding process. Participation by a Bidder in more than one Bid will result in the disqualification of all Bids in which the Bidder is involved. However, this does not limit the inclusion of the same subcontractor, not otherwise participating as a Bidder, in more than one Bid; or
- f. The Bidder or any of its affiliates participated as a consultant in the preparation of the design or technical specification of the Goods, Works or Services that are the subject of the Bid; or
- g. Bidder or any of its affiliates has been hired (or is proposed to be hired by the Procuring Entity as engineer-in-charge/ consultant for the contract.

18. JURISDICTION

1. In the event of any legal dispute arising out of the BID such dispute would be subject to the jurisdiction of the Civil courts within the city of Jaipur only.+

19. APPLICABILITY OF RULES

Besides above conditions all the provisions of RTPP Act 2012 & RTPP Rules 2013 shall be applicable.

Managing Director
Rajasthan Medical Services Corporation

Annexure I



Format of Challan

Annexure - 1

BANK OF MAHARASHTRA DIST. NO. Customer Copy

M. I. ROAD BRANCH

Rajasthan Medical Services Corporation, Jaipur
60460019022

Date of Deposit: DD MM YY

DETAILS OF THE SUPPLIER

Supplier Name: _____
Tender Ref. No.: _____
Type of Deposit: Select any one out of - Tender Fees/EMD/SD/Tender Processing Fees/Others

Mobile No.: _____

Cash Deposit:		Cheque Deposit:	
Denomination	Rs	Chq No	Date of Chq
1000 *			
500 *			
100 *			
50 *			
20 *			
10 *			
5 *			
Total			

Total fee payable ₹ Commission Total amount

Amount (in words): ₹ _____

Name of the Depositor: _____
Signature: _____
Address for communication: _____

Acknowledgement: _____ For Bank use only Cashier/Officer

Annexure - 1

BANK OF MAHARASHTRA DIST. NO. Bank Copy

M. I. ROAD BRANCH

Rajasthan Medical Services Corporation, Jaipur
60460019022

Date of Deposit: DD MM YY

DETAILS OF THE SUPPLIER

Supplier Name: _____
Tender Ref. No.: _____
Type of Deposit: Select any one out of - Tender Fees/EMD/SD/Tender Processing Fees/Others

Mobile No.: _____

Cash Deposit:		Cheque Deposit:	
Denomination	Rs	Chq No	Date of Chq
1000 *			
500 *			
100 *			
50 *			
20 *			
10 *			
5 *			
Total			

Total fee payable ₹ Commission Total amount

Amount (in words): ₹ _____

Name of the Depositor: _____
Signature: _____
Address for communication: _____

Acknowledgement: _____ For Bank use only Cashier/Officer

ANNEXURE- II
Ref. Clause No. 2 (3),
3(h)

ANNUAL TURN OVER STATEMENT

The Annual Turnover of M/s. _____ for the past three years are given below and certified that the statement is true and correct.

Address: _____

Types of Samples Analysed No. of Samples Analysed during

(2021-22, 2022-23 & 2023-24 or 2022-23, 2023-24 & 2024-25)

01. Tablets / Capsules / Pessaries/Dry Powders

02. Injectables

03. Liquid Preparations

04. Ointments / Creams / Gels

05. Others (Specify)

06. Surgicals (Specify item names)

07. Sutures (Specify types)

08. Implants

09. Devices

Signature :

Date :

Name of the Lab :

Office Seal :

ANNEXURE – IV (a)
Ref. Clause No: 3 (j) (a)

PERSONNEL IN QC DEPARTMENT

Name of the Technical Staff approved by State Licensing Authority along with his Designation, Highest Qualification, Experience (Experience relevant to analysis of drug items)

Signature :

Date :

Name of the Lab :

Office Seal :

ANNEXURE – IV (b)
Ref. Clause No: 3(j) (b)

**LIST OF SOPHISTICATED EQUIPMENT/INSTRUMENT/APPARATUS
 AVAILABLE IN THE LAB**

S.No.	Name of the Equipment Approved	Make & Description	Date of Installation	Date of last Validation	Date of testing of drugs from licensi Authorit since...
State					
ng					
y					
.....					

Signature :

Name of the Lab :

Date :

Official Seal:

ANNEXURE – IV (C)
Ref. Clause No: 3(j) (c)

FACILITIES IN THE MICROBIOLOGICAL SECTION

I. LIST OF STOCK CULTURES AVAILABLE

II. LIST OF EQUIPMENT / APPARATUS AVAILABLE WITH DATE OF INSTALLATION, make and approval from State Licensing Authority to permit microbiological testing in the Lab.

Signature :

Name of the Lab :

Date :

Official Seal:

ANNEXURE – IV (d)
Ref. Clause No: 3(j) (d)

**LIST OF REFERENCES SAMPLES ALONG WITH THEIR DATE OF
PROCUREMENT AND QUANTITIES**

Signature :

Name of the Lab :

Date :

Official Seal:

Affidavit

(on Non Judicial Stamp of Rs.500/-)

ANNEXURE – V
Ref. Clause No: 3(k)

DECLARATION FORM

1. I (Name of the Bidder) S/O _____, Age _____, resident of _____, am proprietor /Partner/Director having our office at _____ and the approved drug testing laboratory at _____ do hereby declare that I have carefully read all the conditions of BID of Rajasthan Medical Services Corporation Ltd., Jaipur, for the BIDs floated for empanelment of approved drugs testing laboratories for analysis of drugs. (Rate contract for two years ending on **31.10.2027**) and shall abide by all the conditions set forth therein.
2. I further declare that I possess valid approval for testing of all the drug items for which Price Bid have been submitted by me/us in Cover B and permission on Form 37 have been obtained for testing of these items from State Licensing Authority where ever applicable.
3. That the approval to test drug items have been obtained on Form 37 bearing No. _____ which is valid/renewed up to _____.
4. That the Bidder firm is a proprietorship/Partnership/Pvt. Ltd./ltd. firm and following are the other partners/directors:-

S.No.	Name of Partner/Director	Age	Present & Permanent Address
-------	--------------------------	-----	-----------------------------

5. That our laboratory/Firm/Company does not stand blacklisted /debarred or banned on any ground either by Bid Inviting Authority or Govt. of Rajasthan on the date of bid submission.

Our laboratory/Firm/Company also does not stand blacklisted, debarred or banned on the ground of **wrong reporting of test results** or on the ground of submission of fake or forged documents or false information / facts, by any State or Central Government or by its central drug procurement agencies, on the date of bid submission for supply of drugs/medicines in India.

That I/We have carefully read all the conditions of bid in Ref. No.: F.02(420)/RMSCL/ED (P) EMPANELMENT/DTL/NIB-03/2025/ Dated :-

6. That we have testing facilities as per testing parameters mentioned in respective pharmacopoeias (IP/BP/USP etc.) and quoted for products as given below:-

Sr No.	Quoted item Code No. (as per mention in Annexure-VII)
1.	For Example 2
2.	
3.	

7. For the empanelment of analytical testing laboratories for the test and analysis of DRUGS (Rate contract for two years ending on **31.10.2027**) for Rajasthan medical services corporation and accept all conditions of bid, including amendments if any.
8. I/ we hereby declare under Section 7 & 11 of Rajasthan Transparency in Public Procurement Act, 2012. that:
- a. I/we possess the necessary professional, technical, financial and managerial resources and competence required by the Bidding Document issued by the Procuring Entity;
 - b. I/we have fulfilled my/our obligation to pay such of the taxes payable to the Union and the **State Government or any local authority** as specified in the Bidding Document;
 - c. I/we are not insolvent, in receivership, bankrupt or being wound up. not have my/our affairs administered by a court or a judicial officer, not have my/our business activities suspended and not the subject of legal proceedings for any of the foregoing reasons;
 - d. I/we do not have, and our directors and officers not have, been convicted of any criminal offence related to my/our professional conduct or the making of false statements or misrepresentations as to my/our qualifications to enter into a procurement contract within a period of three years preceding the commencement of this procurement process, or not have been otherwise disqualified pursuant to debarment proceedings;
 - e. I/we do not have a conflict of interest as specified in the Act, Rules and the Bidding Document, which materially affects fair competition.
 - f. I/we have complied and shall continue to comply with the Code of Integrity as specified in the Rajasthan Transparency in Public Procurement Act, the Rajasthan Transparency in Public Procurement Rules and this Bidding Document, till completion of all our obligations under the Contract.
9. Our complete address for communication with phone no.:-

10. E mail address :- -----

11. Bank detail for e banking :-

Name of account holder

Full name of Bank with Branch

A/c no. with full digits.....

IFSC code

(Deponent)

Signature :

Date :

Name of the Lab :

Office Seal :

Verification

I.....S/o.....(Designation).....

Affirm on oath that the contents/information from para 1 to 11 as mentioned above, are true & correct to the best of my knowledge and nothing is hidden. I also declare on oath, that if any information furnished by me as above is found wrong, false, forged or fabricated; the Corporation will be at liberty to cancel the Bid and forfeiting the Bid Security deposit and or performance security, for which I shall be solely responsible and the laboratory / firm may be Debarred/Banned/ prosecuted for the same

(Name of Deponent & Signature)

(I)

DETAILS OF LABORATORY

1. Name of the Laboratory & Full Address :
Phone No (landline) :
Fax :
E-mail :
2. Other Branches & their Address (if any) :
3. Whether the firm has it own manufacturing unit? :
If yes give details of address, license number etc.
4. Date of Inception :
5. Approval No. & Date :
6. Issued by :
7. Valid up to :
8. Schedule L-1 certificate its no. and date of issue (GLP) :
or
9. (i) NABL Accreditation no. & date
(ii) Scope of Accreditation
(iii) Its validity.
10. Name of the authorized signatory :
11. Specimen Signature of the authorized Signatory :
12. Names & Specimen Signatures of the Approved technical Staff who are authorized to sign the test reports :

ANNEXURE –VII
Ref: Clause no. 3 (a),7(1)

NOTE:-

- **Bidders have to mention quoted item code in annexure V for which have testing facility as per respective pharmacopoeias (IP/BP/USP etc).**

S.NO.	DRUG CODE	DRUG NAME
1	4	Bupivacaine Inj IP 0.5% [4]
2	5	Drotaverine Hydrochloride Inj 40 mg/2 ml [5]
3	6	Halothane BP [6]
4	7	Isoflurane USP [7]
5	8	Ketamine Inj IP 50 mg/ml [8]
6	9	Lignocaine Ointment 5 o/o [9]
7	10	Lignocaine and Adrenaline Inj IP Each ml. Contains Lignocaine Hydrochloride IP 20 mg Adrenaline IP 0.01 mg [10]
8	12	Lignocaine Gel IP 2% [12]
9	13	Lignocaine Inj IP 2 o/o [13]
10	14	Propofol Inj IP 10 mg/ml [14]
11	15	Thiopentone Inj IP 0.5 g [15]
12	19	Diclofenac Sodium Inj IP 25 mg/ ml (IM/IV Use) [19]
13	20	Diclofenac Gastro Resistant Tablet IP 50 mg(Enteric Coated) [20]
14	21	Fentanyl Citrate Injection IP 2 ml [21]
15	22	Ibuprofen and Paracetamol Tablets IP Ibuprofen 400 mg+Paracetamol 325 mg [22]
16	23	Ibuprofen Tab IP 200 mg (Coated) [23]
17	24	Ibuprofen Tab IP 400 mg (Coated) [24]
18	25	Morphine Sulphate Inj IP 10mg/ml [25]
19	26	Paracetamol Drops Paediatric Paracetamol Oral Suspension IP(Each ml contains Paracetamol 150mg) [26]
20	27	Paracetamol Syrup IP 125 mg/5ml (Detail in RC) [27]
21	28	Paracetamol Tab IP 500 mg [28]
22	29	Paracetamol Inj. 150 mg/ml [29]
23	30	Pentazocine Inj IP 30mg/ml (IM/IV use) [30]
24	32	Tramadol Cap IP 50 mg [32]
25	33	Tramadol Inj 50 mg/ml [33]
26	34	Adrenaline Injection IP 1mg/ml IM/IV use [34]
27	35	Betamethasone Tab IP 0.5mg [35]
28	37	Chlorpheniramine Maleate Tab IP 4mg [37]
29	39	Dexamethasone Inj IP 8mg/2ml [39]
30	40	Dexamethasone Tab IP 0.5 mg [40]
31	42	Hydrocortisone Sodium Succinate Injection IP 100 mg base / vial (IM/IV use) [42]
32	43	Hydroxyzine Tab IP 25 mg [43]
33	44	Methyl Prednisolone Sodium Succinate for Injection USP 500 mg

S.NO.	DRUG CODE	DRUG NAME
		[44]
34	45	Pheniramine Inj IP 22.75mg /ml [45]
35	47	Prednisolone Tab IP 5 mg [47]
36	48	Promethazine Syrup IP 5 mg/5ml [48]
37	49	Promethazine Inj IP 25mg/ml [49]
38	50	Promethazine Tab IP 25 mg [50]
39	51	Naloxone Inj IP 0.4mg/ ml [51]
40	52	Pralidoxime Chloride Injection IP 25 mg/ml / 500 mg [52]
41	53	Carbamazepine Tab IP 200 mg [53]
42	54	Carbamazepine Tab IP 100 mg [54]
43	56	Phenobarbitone Tab IP 30 mg [56]
44	57	Phenytoin Injection BP 50mg/ml [57]
45	58	Phenytoin Oral suspension IP 25mg/ml [58]
46	59	Phenytoin Tab IP 100 mg (Film Coated) [59]
47	61	Sodium Valproate Gastro resistant Tablets IP 200 mg [61]
48	62	Acyclovir Oral Suspension IP 400mg/5ml [62]
49	63	Acyclovir Tab IP 200 mg [63]
50	64	Acyclovir Tab IP 800 mg [64]
51	65	Albendazole Oral suspension IP 400 mg/10ml [65]
52	66A	Albendazole Tablets IP 400 mg(Detail in RC) [66A]
53	67	Amikacin Inj IP 100 mg [67]
54	68	Amikacin Inj IP 500 mg [68]
55	69	Amoxycillin and Cloxacillin Cap 250 + 250 mg [69]
56	70	Amoxycillin and Potassium Clavulanate Tabs IP 500 mg + 125 mg [70]
57	71	Amoxycillin Cap IP 250mg [71]
58	72	Amoxycillin Cap IP 500mg [72]
59	73	Amoxycillin Dispersible Tablets IP 125 mg [73]
60	74	Amphotericin B Inj IP 50 mg [74]
61	75	Ampicillin Injection IP 500 mg [75]
62	78A	Azithromycin Tab 100 mg Dispersible Tabs (3 tab strip 10x3x3) [78A]
63	79A	Azithromycin Tablets IP 250mg [79A]
64	80A	Azithromycin Tab IP 500 mg [80A]
65	82	Benzathine Benzylpenicillin Inj IP 6 lac units [82]
66	84	Cefixime Tab IP 100 mg/Cefixime Dispersible Tab IP 100 mg [84]
67	85	Cefixime Tab IP 200 mg [85]
68	86	Cefoperazone and Sulbactam for Inj (Cefoperazone Sodium eq.to Cefoperazone 1gm and Sulbactam Sodium eq. to Sulbactum 0.5gm)(IM/IV use) [86]
69	87	Cefotaxime Injection IP 1 g [87]
70	88	Cefotaxime Inj IP 250 mg [88]
71	89	Ceftazidime Inj IP 1g [89]
72	90	Ceftazidime Inj IP 250 mg [90]
73	91	Ceftazidime Inj IP 500 mg [91]

S.NO.	DRUG CODE	DRUG NAME
74	93	Ceftriaxone Inj IP 1g /vial [93]
75	94	Ceftriaxone Inj IP 250 mg/vial [94]
76	95	Ceftriaxone Inj IP 500mg/vial [95]
77	96	Cephalexin Cap IP 250 mg [96]
78	97	Cephalexin Cap IP 500 mg [97]
79	98	Chloroquine Phosphate Inj IP 40 mg/ ml [98]
80	99	Chloroquine Phosphate Tab. IP 250mg Eq to 155 mg of Chloroquine base Film Coated [99]
81	100A	Chloroquine Phosphate Suspension IP 50 mg/5ml [100A]
82	101	Ciprofloxacin Injection IP 200mg/100ml [101]
83	102	Ciprofloxacin Tablets IP 250 mg Film Coated [102]
84	103	Ciprofloxacin Tablet IP 500 mg Film Coated [103]
85	104	Clotrimazole Cream IP 2% w/w [104]
86	105	Clotrimazole Vaginal Tab IP 500mg [105]
87	106	Compound Benzoic Acid Ointment IP Benzoic Acid 6 o/o + Salicylic Acid 3 o/o [106]
88	107	Co-trimoxazole oral suspension IP Each 5 ml contains Trimethoprim 40 mg and Sulphamethoxazole 200 mg [107]
89	108	Co-trimoxazole Tablets IP Trimethoprim 40 mg and Sulphamethoxazole 200 mg [108]
90	110	Diethylcarbamazine Tab IP 100 mg [110]
91	111	Doxycycline Cap IP 100 mg [111]
92	114A	Fluconazole Tablets IP 150mg [114A]
93	116	Gentamycin Injection IP 80mg/2ml (IM/ IV use) [116]
94	118	Itraconazole Cap 100 mg [118]
95	119	Meropenem Inj IP 500 mg [119]
96	120	Metronidazole Inj IP 500 mg/100ml [120]
97	121	Metronidazole Benzoate Oral Suspension IP 100 mg of base/5ml [121]
98	122	Metronidazole Tablets IP 200 mg (Film Coated) [122]
99	123	Metronidazole Tablets IP 400 mg (Film Coated) [123]
100	124	Norfloxacin Tab IP 400mg Film Coated [124]
101	125	Ofloxacin Tab IP 200 mg [125]
102	128	Primaquine Tab IP 2.5 mg [128]
103	129	Primaquine Tab IP 7.5 mg [129]
104	131	Quinine Dihydrochloride Inj IP 300 mg/ml [131]
105	132	Quinine Sulphate Tablets IP 300 mg (Film Coated) [132]
106	133	Azathioprine Tab IP 50 mg [133]
107	134	Bleomycin Injection IP 15mg (Bleomycin Sulphate Injection 15 units) [134]
108	137	Cisplatin Inj IP 50 mg/ 50 ml [137]
109	138	Cyclophosphamide Inj IP 200 mg [138]
110	139	Cyclophosphamide Inj IP 500 mg [139]
111	141	Cytarabine Injection BP 500mg [141]
112	142	Danazol Cap IP 50 mg [142]
113	143	Daunorubicin Inj IP 20 mg [143]

S.NO.	DRUG CODE	DRUG NAME
114	144	Doxorubicin Inj IP 50 mg/ 25 ml [144]
115	146	Etoposide Inj IP 100 mg [146]
116	147	Flunarizine Tab 5 mg [147]
117	148	Fluorouracil Inj IP 250 mg/ 5ml [148]
118	150	Leucovorin Calcium Inj IP / Calcium Folate Inj IP 10 mg /ml [150]
119	151	Melphalan Tab IP 5 mg [151]
120	152	Mercaptopurine Tab IP 50 mg [152]
121	153	Methotrexate Inj IP 50 mg/2 ml [153]
122	154	Methotrexate Tab IP 2.5 mg [154]
123	155	Paclitaxel Inj IP 260 mg [155]
124	156	Paclitaxel Inj IP 100 mg [156]
125	157	Tamoxifen Tab IP 10 mg [157]
126	158	Vinblastine Inj IP 10mg/ 10ml [158]
127	159	Vincristine Inj IP 1mg(vial)/Vincristin Injection USP 1mg/ml (Amp) [159]
128	160	Levodopa and Carbidopa Tablets IP Levodopa 100 mg + Carbidopa 10 mg [160]
129	161	Levodopa and Carbidopa Tab 250 mg+ 25 mg [161]
130	162	Trihexyphenidyl HCl Tab IP 2 mg [162]
131	163	Acenocoumarol Tab IP/ Nicoumalone Tab IP 2 mg [163]
132	165	Deferasirox Tab 100 mg [165]
133	166	Deferasirox Tab 500 mg [166]
134	167	Deferiprone Cap 250 mg [167]
135	168	Deferiprone Cap 500 mg [168]
136	169	Desferrioxamine Injection IP 500 mg / Vial (For I.M. Inj and I.V S.C. Infusion) [169]
137	173	Ethamsylate Inj 250 mg/ 2ml (IM/IV) [173]
138	180	Vitamin K Injection Each ml Contains Menadione Sodium Bisulphite 10mg Equivalent to 5.2 mg of Menadione. (Aqueous Solution) [180]
139	181	Amiodarone Tab IP 100 mg [181]
140	182	Amiodarone Tab IP 200 mg [182]
141	183	Amiodarone Hydrochloride Inj 50 mg/ml [183]
142	184	Amlodipine Tab IP 2.5 mg [184]
143	185	Amlodipine Tablets IP 5 mg [185]
144	186	Atenolol Tab IP 50 mg [186]
145	187	Atorvastatin Tab IP 10mg [187]
146	189	Digoxin Inj IP 0.25 mg/ml [189]
147	190	Digoxin Tab IP 0.25 mg. [190]
148	191	Diltiazem Tabs IP 30 mg Film Coated [191]
149	192	Dobutamine Inj IP 50mg/ml/250mg (Vial)/Dobutamine Inj IP 250 mg/5ml(AMP) [192]
150	193	Dopamine Hydrochloride Inj IP 40 mg/ml [193]
151	194	Enalapril Maleate Tab IP 5mg [194]
152	195	Enalapril Maleate Tab IP 2.5mg [195]

S.NO.	DRUG CODE	DRUG NAME
153	197	Isosorbide dinitrate Tab IP 5 mg [197]
154	198	Isosorbide mononitrate Tabs IP 20 mg [198]
155	199	Lisinopril Tab IP 5 mg [199]
156	200	Losartan Tab IP 50 mg [200]
157	201	Magnesium Sulphate Inj. IP 500mg/ml (50%w/v) [201]
158	203	Nifedipine Cap IP 5mg [203]
159	204	Nifedipine Tablets IP 10 mg (Sustained Release) [204]
160	205	Nitroglycerin Inj 5 mg/ ml [205]
161	207	Propranolol Tab IP 40 mg [207]
162	211	Verapamil Tab IP 40 mg Film Coated [211]
163	213	Acyclovir Cream 5% [213]
164	215A	Cetrimide Cream IP 0.50 o/o [215A]
165	216A	Fusidic Acid Cream IP 2% [216A]
166	217	Glycerin IP 400 gm [217]
167	218	Liquid Paraffin IP 400 ml [218]
168	219	Ointment containing Lidocaine IP 3 o/o Zinc oxide IP 5 o/o , Hydrocortisone IP 0.25 o/o, Allantoin IP 0.5 o/o [219]
169	220	Miconazole Nitrate Cream IP 2% [220]
170	221	Povidone Iodine ointment 5% 15 gm [221]
171	222	Povidone Iodine solution IP 5 % 500 ml [222]
172	223	Neomycin Bacitracin and Sulphacetamide Powder (Neomycin 5 mg, Bacitracin 250 units, Sulphacetamide 60 mg) [223]
173	224	Silver Sulphadiazine cream IP 1% 50gm Tube [224]
174	232	Diatrizoate Meglumine & Diatrizoate Sodium Inj USP 60% (iodine Conc.= 292 mg/ml) [232]
175	233	Diatrizoate Meglumine and Diat Sod Inj USP 76%w/v (iodine = 370 mg/ml) [233]
176	241	Tropicamide eye drop IP 1o/o [241]
177	245	Formaldehyde solution (34.5 Per. - 38 Per.) [245]
178	246	Gentian Violet Topical Solution USP 1o/o [246]
179	247	Gluteraldehyde Solution 2% [247]
180	248	Hydrogen Peroxide Solution IP 6 o/o (20 Vol) [248]
181	249	Lysol (Cresol with Soap Solution) IP (Cresol 50 o/o + Soap 50 o/o) [249]
182	250	Povidone Iodine Scrub Solution / cleansing solution 7.5 o/o w/v Povidone Iodine (suitable for hand wash) [250]
183	252	Surgical Spirit IP (500 ml) [252]
184	253	Acetazolamide Tab IP 250mg [253]
185	254	Frusamide Tab IP 40 mg [254]
186	255	Furosemide Injection IP 10mg/ml (IM and IV use) [255]
187	256	Hydrochlorthiazide Tab IP 12.5 mg [256]
188	257A	Mannitol Inj IP 20% w/v [257A]
189	258	Spirolactone Tab IP 25mg [258]
190	259	Torseamide Tab 10 IP mg [259]
191	260A	Antacid Tablets.Formula,Each chewable tablet contains

S.NO.	DRUG CODE	DRUG NAME
		Magnesium Trisilicate 250 mg, Dried Aluminium Hydroxide Gel 120 mg, Peppermint Oil [260A]
192	261A	Antacid Liquid, Each 5ml contains Dried Aluminium Hydroxide Gel 250 mg, Magnesium Hydroxide 250mg, Activated polydimethyl siloxane 50mg [261A]
193	262	Bisacodyl Tab IP 5 mg [262]
194	263	Dicyclomine Tab IP 10 mg [263]
195	264	Dicyclomine Inj IP 10 mg /ml [264]
196	265	Dicyclomine Hydrochloride Oral Solution IP 10mg /5ml [265]
197	266	Domperidone Suspension IP 5mg/5ml [266]
198	267	Domperidone Tab IP 10 mg [267]
199	268	Hyoscine Butylbromide Inj IP 20 mg/ ml [268]
200	269	Loperamide Tab IP 2 mg [269]
201	270	Metoclopramide Inj IP 10mg/2ml [270]
202	271	Metoclopramide Tab IP 10 mg [271]
203	272	Omeprazole Cap IP 20 mg [272]
204	273	Ondansetron Inj IP 2mg/ml [273]
205	274	ORS Powder IP [274]
206	275	Pentoprazole Inj 40 mg [275]
207	276	Ranitidine HCL Injection IP 50mg/2ml [276]
208	277	Ranitidine Tab IP 150mg Film Coated [277]
209	278	Sodium Phosphates Enema BP Each 100ml contains Sodium Dihydrogen phosphate Dihydrate 10 o/o Disodium Hydrogen Phosphate Dodecahydrate 8 o/o [278]
210	280	Carbimazole Tabs IP 5 mg [280]
211	282	Clomifene Tab IP 25 mg [282]
212	283	Clomiphene Tab IP 50 mg [283]
213	284	Conjugated Estrogen Tabs USP 0.625 mg. [284]
214	285	Dinoprostone Cream/ Gel 0.5 mg Dinoprostone in Syringe [285]
215	286	Ethinylloestradiol Tabs IP 50 mcg [286]
216	287	Glibenclamide Tab IP 5 mg [287]
217	288	Gliclazide Tab IP 40 mg [288]
218	289	Glimepiride Tab IP 2 mg [289]
219	290	Glimepiride Tab IP 1mg [290]
220	291	Glipizide Tab IP 5mg [291]
221	293	Hydroxyprogesterone Inj IP 250mg /ml [293]
222	295	Metformin Tab IP 500 mg [295]
223	296	Norethisterone Tab IP 5 mg [296]
224	297	Pioglitazone Tab IP 15 mg [297]
225	301	Thyroxine Sodium Tablets IP 100mcg [301]
226	311	Atracurium Inj 10 mg/ml [311]
227	312	Glycopyrrolate Inj IP 0.2 mg/ml [312]
228	313	Midazolam Inj IP 1 mg/ml [313]
229	314	Neostigmine Inj IP 0.5 mg/ml [314]
230	317	Succinylcholine Inj. IP 50 mg/ml (IV use) [317]

S.NO.	DRUG CODE	DRUG NAME
231	318	Valethamate Bromide Inj 8mg / ml [318]
232	319	Atropine Eye Ointment IP 1% [319]
233	320	Atropine Sulphate Ophthalmic Solution USP 1% [320]
234	321	Chloramphenicol Eye Drops IP 0.5 0/0 [321]
235	322	Ciprofloxacin Eye Drops IP 0.3 o/o w/v /Ciprofloxacin Eye/Ear Drops IP 0.3 o/o w/v [322]
236	323	Ciprofloxacin Ophthalmic Ointment USP 0.3% [323]
237	324	Hydroxypropylmethyl cellulose solution 20 mg/ ml [324]
238	330	Tobramycin and Dexamethasone Ophthalmic Suspension USP 0.3 o/o +0.1 o/o [330]
239	331	Tobramycin Eye Drops 0.3% [331]
240	332	Tobramycin Ophthalmic Ointment USP 0.3% [332]
241	333	Isoxsuprine Inj IP 5 mg/ml [333]
242	334	Isoxsuprine Tab IP 20 mg [334]
243	335	Methylergometrine Inj IP 0.2 mg/ml [335]
244	336	Methylergometrine Tab IP 0.125 mg [336]
245	337	Misoprostol Tab IP 200 mcg [337]
246	338	Oxytocin Inj IP 5 IU/ml [338]
247	339	Alprazolam Tab IP 0.25 mg [339]
248	340	Alprazolam Tab IP 0.5mg [340]
249	341	Amitriptyline Tab IP 25mg Film Coated [341]
250	342	Chlordiazepoxide Tablets IP 10mg [342]
251	343	Chlorpromazine Tablets IP 100 mg (Coated Tablet) [343]
252	344	Chlorpromazine Tablets IP 25 mg [344]
253	345	Chlorpromazine Tablets IP 50 mg (Coated Tablets) [345]
254	349	Diazepam Inj IP 10mg/2ml (1M/IV use) [349]
255	350	Diazepam Tab IP 5 mg [350]
256	351	Escitalopram Tab IP 10 mg [351]
257	352	Fluoxetine Cap/Tab IP 20mg [352]
258	353	Haloperidol Inj IP 5 mg/ml [353]
259	354	Haloperidol Tab IP 1.5 mg [354]
260	355	Haloperidol Tab IP 5 mg [355]
261	356	Imipramine Tab IP 25 mg (Coated Tab) [356]
262	357	Imipramine Tab IP 75 mg (Coated) [357]
263	358	Lithium Carbonate Tab IP 300 mg [358]
264	359	Lorazepam Inj IP 2 mg/ml [359]
265	360	Olanzapine Tab IP 5 mg [360]
266	361	Risperidone Tab 2mg [361]
267	362	Risperidone Tab 1 mg [362]
268	363	Sertraline Tab IP 50 mg [363]
269	364	Trifluoperazine Tab IP 5 mg Coated [364]
270	365	Aminophylline Inj IP 25 mg/ml [365]
271	366	Beclomethasone Inhalation IP 200 mcg/dose [366]
272	367	Budesonide Nebulizer Suspension 0.25mg/ml [367]
273	368	Cough Syrup Each 5ml contains Chloropheniramine Maleate IP

S.NO.	DRUG CODE	DRUG NAME
		3mg Ammonium Chloride 130mg, Sodium Citrate 65 mg, Menthol 0.5 mg, Syrup Q.S.
274	369	Ipratropium Bromide Nebulizer Solution 250 mcg/ ml [369]
275	370	Salbutamol Tablet IP 4 mg [370]
276	371	Salbutamol Inhalation 100 mcg /dose [371]
277	372	Salbutamol Nebuliser solution BP 5 mg/ml [372]
278	373	Salbutamol Tab IP 2 mg [373]
279	374	Theophylline and Etofylline Injection (Anhydrous Theophylline 50.6mg + Etofylline 169.4 mg) [374]
280	375	Theophylline and Etofylline Tablets IP (Theophylline IP 23mg + Etofylline IP 77 mg) [375]
281	376	Theophylline Tablet 400mg Sustained Release/ Controlled Release (Theophylline Prolonged Released Tablet IP) [376]
282	377	Compound Sodium Lactate Inj. IP [377]
283	378	Dextrose Inj IP 25% w/v [378]
284	379	Dextrose Inj IP 10% [379]
285	380	Dextrose Inj IP 5% [380]
286	381	Multiple Electrolytes and Dextrose Injection Type I IP (Electrolyte P Injection) [381]
287	382	Multiple Electrolytes and Dextrose Injection Type III IP Electrolyte M Injection (I.V.) [382]
288	383	Potassium Chloride Inj. IP 0.15 gm/ml [383]
289	384	Potassium chloride Oral Solution U.S.P 500mg/ 5ml [384]
290	385	Sodium Chloride and Dextrose Injection IP 0.9 o/o + 5 o/o [385]
291	386	Sodium Chloride Inj IP 500 ml [386]
292	387	Ascorbic Acid Tab IP 500 mg [387]
293	388	Calcium Gluconate Inj IP 10% (IV use) [388]
294	390	Ferrous Sulphate with Folic Acid Tab IP Each film coated Tab. Containing Dried Ferrous Sulphate IP-equiv 100 mg Elemental Iron and Folic Acid IP 0.5 mg [390]
295	391	Ferrous Sulphate with Folic Acid Tab (Paediatric) IP Each film coated Tab. Containing Dried Ferrous Sulphate IP-equivalent to 20mg Elemental Iron and Folic Acid IP-100 mcg [391]
296	392	Folic Acid Tab IP 5 mg [392]
297	393	Multivitamin Drops Each ml contains Vit A 3000 IU, Vit D3 300 IU, Vit B1 1mg, Riboflavine Phosphate Sodium 2mg, D-Panthenol 2.5mg, Niacinamide 10mg, Pyridoxine HCL 1mg, Cyanocobalamin 1mcg, Lysine HCL 10mg [393]
298	394	Multivitamin Tablets NFI Formula Sugar coated Vit A 2500 IU Vit B1-2mg Vit-B6-0.5mg Vit-C-50mg Calcium Pantothenate-1mg Vit-D3-200IU Vit-B2-2 mg Niacinamide-25mg Folic Acid-0.2 mg [394]
299	395	Vitamin B Complex Inj NFI [395]
300	397	Vitamin B complex tablet NFI (prophylactic) B1 2mg B2-2mg B6-0.5mg Niacinamide 25mg Calcium pantothenate 1mg (With appropriate overages) [397]
301	398	Black Disinfectant Fluid (Phenyl) As per Schedule O Grade III [398]

S.NO.	DRUG CODE	DRUG NAME
302	399	Conc Haemodialysis Fluid B.P Acetate concentrate 10 Litre Can [399]
303	401	Peritoneal Dialysis Solution IP [401]
304	402	Sodium Bicarbonate Inj IP 7.5% w/v [402]
305	404	Water for Inj IP [404]
306	405	Polygeline 3.5% Solution with electrolytes for I.V. Infusion [405]
307	409	Vitamin A Paediatric Oral Solution IP(Vitamin A Concentrate Oil IP)Each ml Contains Vitamin A 100000 IU [409]
308	410	Labetalol Tab IP 100mg [410]
309	411	Labetalol HCl Inj IP 20mg/4ml [411]
310	412	Ampicillin Cap IP 500mg [412]
311	413	Nitrofurantoin Tab IP 100mg [413]
312	414	Hyoscine Butyl bromide Tablets IP 10mg [414]
313	415	Drotaverine Tab IP 40 mg [415]
314	416	Hydroxyethyl Starch (130/0.4) 6 o/o w/v with Sodium Chloride 0.9 o/o w/v Intravenous Infusion / Balanced Electrolyte solution of sodium chloride, sodium acetate, potassium chloride, magnesium chloride Intravenous Infusion [416]
315	417	Cloxacillin Sodium Inj IP 500mg [417]
316	418	Betamethasone Sod Phos Inj IP 4mg/ml [418]
317	419	Vecuronium Bromide for Injection 4mg (Freeze Dried) [419]
318	420	Phenobarbitone Inj IP 200mg/ml [420]
319	421	Flurbiprofen Sodium Ophthalmic Solution IP 0.03 o/o w/v [421]
320	424	Lidocaine HCl Topical Solution USP 4% [424]
321	425	Fluconazole Eye/Ear Drops 0.3% [425]
322	427	Cephalexin Oral Suspension IP (Cephalexin Dry Syrup IP) 125mg/ 5 ml [427]
323	428	Ofloxacin Oral Suspension IP 50mg/ 5ml [428]
324	430	Tinidazole Tab IP 300 mg (Film Coated) [430]
325	431	Tinidazole Tab IP 500 mg (Film Coated) [431]
326	432	Salbutamol Syrup IP 2mg/ 5ml [432]
327	433	Ranitidine Tab IP 300mg Film Coated [433]
328	436	Indomethacin Cap IP 25 mg [436]
329	437	Diclofenac Prolonged Release Tablet IP 100 mg [437]
330	438	Dicyclomine Hydrochloride and Activated Dimethicone suspension Each ml contains Dicyclomine Hydrochloride 10mg Activated Dimethicone 40mg [438]
331	439A	Dicyclomine and Paracetamol Tablets Dicyclomine Hydrochloride 20 mg + Paracetamol 325 mg Tablets [439A]
332	440	Dextromethorphan HBr Syrup IP 13.5mg / 5ml [440]
333	441	Calcium and Vitamin D3 Suspension (Each 5 ml contains Calcium Carbonate equivalent to elemental Calcium 250 mg, Vitamin D3 125 IU) [441]
334	442	Saline Nasal Solution (Drops) (Sodium chloride 0.65 o/o) [442]
335	443	Clotrimazole mouth paint (Clotrimazole 1 o/o w/v) [443]
336	444	Aspirin Delayed Release Tablet / Aspirin Gastroresistant Tab IP (Each enteric coated tablet contains acetyl salicylic acid 75 mg)

S.NO.	DRUG CODE	DRUG NAME
		[444]
337	445	Beclomethasone, Neomycin and Clotrimazole Cream (Beclomethasone Dipropionate 0.025 %, Neomycin Sulphate 0.5 % and Clotrimazole 1 %) [445]
338	446	Gamma Benzene Hexachloride Lotion 1%(Lindane Lotion USP) [446]
339	447	Chlorhexidine Gluconate Solution 5% 250 ml [447]
340	448	Iron and Folic Acid Suspension. Each 5ml contains Ferrous Fumerate equivalent to elemental iron 100mg, Folic Acid 500 mcg [448]
341	449	Surgical Spirit IP (100 ml) [449]
342	450	Povidone Iodine solution IP 5% 100ml bottle [450]
343	451	Metformin Hydrochloride(Sustained Release Tablets IP 1000 mg [451]
344	452	Glipizide and Metformin Hydrochloride Tablets USP (Glipizide 5 mg, Metformin Hydrochloride 500 mg) [452]
345	453	Glibenclamide and Metformin Hydrochloride (SR) Tablets Glibenclamide 5 mg, Metformin Hydrochloride 500 mg (Sustained Release) [453]
346	454	Metformin HCL (Sustained Release) and Glimepiride Tab Metformin HCL (Sustained Release) 500mg ,Glimepiride 1mg [454]
347	455	Metformin Hydrochloride (Sustained Release) and Glimepiride Tablets IP (Metformin Hydrochloride(Sustained Release) 500 mg, Glimipiride 2mg) [455]
348	456	Glimepiride, Pioglitazone and Metformin Hydrochloride (Sustained release) Tablets Each Tablet contains Glimepiride 2mg, Pioglitazone 15 mg, Metformin Hydrochloride (Sustained Release) 500 mg [456]
349	457	Amlodipine and Enalapril Maleate Tablets (Amlodipine Besilate equivalent to Amlodipine 5 mg, Enalapril Maleate 5 mg) [457]
350	458	Losartan Potassium and Amlodipine Tablets IP (Losartan Potassium 50 mg, Amlodipine Besilate eq to Amlopdipine 5mg) [458]
351	459	Losartan Potassium and Hydrochlorothiazide Tablets IP(Losartan Potassium 50 mg, Hydrochlorothiazide 12.5 mg) [459]
352	460	Amlodipine and Lisinopril Tablets Amlodipine Besilate equivalent to Amlodipine 5 mg, Lisinopril eq to Lisinopril (anhydrous) 5 mg [460]
353	461	Amlodipine and Atenolol Tablet (Amlodipine Besilate Equivalent to Amlodipine 5mg,Atenolol 50mg) [461]
354	462	Atenolol Tab IP 25 mg [462]
355	463	Enalapril Maleate Tablets IP 10 mg [463]
356	464	Hydrochlorthiazide Tab IP 25mg [464]
357	465	Lisinopril Tablets IP 10 mg [465]
358	466	Lisinopril Tab IP 2.5 mg [466]
359	467	Losartan Tab IP 25 mg [467]
360	468	Piperacillin + Tazobactam for Injection IP 4gm+500mg [468]
361	469	Prednisolone Tablet IP 10 mg [469]

S.NO.	DRUG CODE	DRUG NAME
362	470	Prednisolone Tab IP 20 mg [470]
363	472	Zinc Sulphate Dispersible Tablets IP Elemental Zinc 10 mg [472]
364	473	Amoxicillin Oral Suspension IP (Dry syrup) 125 mg/5ml [473]
365	474	Carbamazepine Oral Suspension USP 100 mg/5ml [474]
366	475	Cefpodoxime Dispersible Tab 50 mg [475]
367	476	Cephalexin Tablets 125 mg (Dispersible Tablets) [476]
368	477	Ibuprofen Oral Suspension BP /USP 100 mg/ 5 ml [477]
369	478	Metoclopramide Hydrochloride Syrup IP 5 mg/ 5ml [478]
370	479	Sodium Valproate Oral Solution IP 200 mg / 5 ml [479]
371	481	Meropenem Inj. IP 1gm [481]
372	482	Iohexol USP (Solution For Injection) Non Ionic Contrast Medium in Sterile aqueous Solution 300 mg Iodine/ml [482]
373	483	Diclofenac Sod + Paracetamol Tablets IP Diclofenac Sod 50 mg + Paracetamol 325 mg [483]
374	484	Timolol Eye Drops IP 0.5 o/o w/v [484]
375	485	Homatropine Eye Drops IP 2% [485]
376	486	Travoprost Eye Drops IP 0.004 o/o [486]
377	487	Brimonidine Tartrate & Timolol Maleate Eye Drops 0.15% + 0.5% [487]
378	488	Iron Sucrose Injection USP/BP 20mg/ml (For IV use) Each ml contains Ferric Hydroxide in complex with Sucrose equiv. to elemental Iron 20 mg [488]
379	491	Sevoflurane [491]
380	492	Aceclofenac and Paracetamol Tablets Aceclofenac 100 mg and Paracetamol 325 mg [492]
381	493	Diclofenac Gel: Diclofenac diethylamine 1.16%, Methyl salicylate 10%, Linseed oil 3%, Menthol 5% [493]
382	495	Etoricoxib Tab IP 120mg [495]
383	496	Mefenamic Acid Tablets BP 500 mg [496]
384	497	Anticold syrup Each 5 ml contains Phenylephrine Hydrochloride 2.5mg , Chlorpheniramine maleate 1 mg, and Paracetamol 125 mg [497]
385	498	Cetirizine, Phenylephrine & Paracetamol Tablets Cetirizine 5 mg, Phenylephrine 10 mg & Paracetamol 325 mg
386	499	Cetirizine syrup IP 5mg/5 ml [499]
387	500	Acetylcystine Solution USP (Injection) 200 mg/ml [500]
388	502	Acyclovir Intravenous Infusion IP 250mg [502]
389	503	Acyclovir Intravenous Infusion IP 500mg [503]
390	504	Amikacin Inj IP 250 mg [504]
391	505	Amoxicillin and Potassium Clavulanic IP Inj 600mg [505]
392	506	Amoxicillin and Potassium Clavulanate Inj IP 1.2gm [506]
393	507	Amoxicillin and Potassium Clavunate oral suspension Ip 200 mg +28.5 mg/5 ml (30ml Bottle) [507]
394	508A	Artesunate Injection 60 mg (I.M. I.V.USE) Each Combo Pack contains Artesunate Injection 60 mgVial, Sodium Bicarbonate Injection IP 5 o/o w/v (1ml ampoule),Sodium chloride Injection IP 0.9o/o w/v (5ml ampoule) [508A]

S.NO.	DRUG CODE	DRUG NAME
395	509	Aztreonam Injection USP 500 mg [509]
396	510	Cefepime Injection IP 500 mg [510]
397	511	Cefixime Oral Suspension IP 25mg/ml (Paediatric Drops) [511]
398	512	Cefuroxime Axetil Tab IP 250 mg [512]
399	513	Clindamycin Capsule IP 150mg [513]
400	514	Clindamycin Capsule Ip 300 mg [514]
401	515	Levofloxacin Tablets IP 250 mg [515]
402	516	Linezolid Tablets IP 600 mg [516]
403	517	Linezolid Inj 200mg/100ml [517]
404	518	Mefloquine Tablets IP 250 mg [518]
405	520	Ofloxacin and Ornidazole Tablets Ofloxacin 200 mg and Ornidazole 500 mg [520]
406	521	Ofloxacin Infusion IP 200mg / 100 ml(in NaCl Inj) [521]
407	523	Vancomycin for Intravenous Infusion IP 500 mg [523]
408	524	Vancomycin For Intravenous Infusion IP 1 gm [524]
409	526	Carboplatin Injection IP 150 mg [526]
410	527	Carboplatin Injection IP 450 mg [527]
411	528	Cisplatin Inj IP 10 mg/10 ml [528]
412	529	Dacarbazine Injection 500 mg IP [529]
413	531	Gemcitabine for Injection 200 mg [531]
414	532	Gemcitabine for Injection IP 1gm [532]
415	533	Ifosfamide Injection IP 1gm [533]
416	534	Imatinib Tab IP 400mg [534]
417	536	Methotrexate Tablets IP 10 mg [536]
418	538	Oxaliplatin Injection USP 50 mg [538]
419	540	Bromocriptine Tablets IP 2.5 mg [540]
420	541	Betahistine Tab IP 8 mg [541]
421	542	Betahistine Tab IP 16 mg [542]
422	543	Cinnarizine Tablets IP 25 mg [543]
423	544	Cinnarizine Tablet IP 75 mg [544]
424	545	Tranexamic Acid Tablets IP 500 mg [545]
425	546	Warfarin Sodium. Tab IP 5mg [546]
426	547	Adenosine Injection IP 6 mg/2ml [547]
427	548	Atorvastatin Tablets IP 40 mg [548]
428	549	Clopidogrel and Aspirin Tables, Clopidogrel 75 mg and Aspirin 75 mg [549]
429	552	Metoprolol Tablets IP 25 mg [552]
430	553	Metoprolol Succinate Extended Release Tablets IP 50 mg [553]
431	554	Noradrenaline Injection IP 2 mg/ml [554]
432	555	Prazosin Tablets (Extended Release) 2.5 mg [555]
433	556	Telmisartan Tablets IP 40 mg [556]
434	558	Betamethasone Dipropionate Cream IP 0.05% [558]
435	559	Betamethasone Lotion IP 0.05 o/o [559]
436	560	Clindamycin Phosphate Gel USP 1 o/o [560]
437	561	Clobetasol Propionate Cream IP 0.05 o/o [561]

S.NO.	DRUG CODE	DRUG NAME
438	564	Glycerin IP [564]
439	565	Ketoconazole Cream BP 2% [565]
440	568	Permethrin Lotion 5% [568]
441	569	Permethrin Cream 5% [569]
442	570	Tretenoin cream USP 0.025% [570]
443	571	Povidone Iodine Ointment USP 5 o/o 250 gm [571]
444	572	Povidone Iodine Solution IP 10 % [572]
445	573	Silver Sulphadiazine cream IP 1% 500 gm Jar [573]
446	574	Spirolactone Tablets IP 50 mg [574]
447	575	Finasteride Tablets IP 5 mg [575]
448	576	Tamsulosin HCl Tablets/capsule 0.4 mg [576]
449	579	Flavoxate Tablets IP 200 mg (Coated Tablet) [579]
450	580	Chlorhexidine Mouthwash IP 0.2 o/o [580]
451	581	Dental Gel Choline salicylate 8.7 o/o, Benzalkonium Chloride 0.01 o/o, Lignocaine HCl 2 o/o (flavoured gel base) [581]
452	582	Tooth Gel Sodium Monofluorophosphate 0.7 o/o and Potassium Nitrate 5 o/o (in flavoured base) [582]
453	583	Gum Paint containing Tannic acid 2%, Cetrimide 0.1%, Zinc Chloride 1% [583]
454	584	Metronidazole 1% and Chlorhexidine Gluconate 0.25% Gel [584]
455	585	Ciprofloxacin 0.3 o/o and Dexamethasone 0.1 o/o Ear Drops Ciprofloxacin and Dexamethasone Otic Suspension USP/Ciprofloxacin 0.3 o/o and Dexamethasone 0.1 o/o Eye Drops/Ear Drops [585]
456	586	Clotrimazole 1 o/o with Beclomethasone Dipropionate 0.025 o/o Ear Drops [586]
457	588	Neomycin, Polymixin B and Hydrocortisone Ear Drops Neomycin sulphate 3400 IU, Polymixin B Sulphate 10000 IU, and Hydrocortisone 10 mg per ml Neomycin and Polymixin B Sulfate and Hydrocortisone Otic Solution USP [588]
458	589	Ceruminolytic Drops (Wax dissolving ear drops) Paradichlorobenzene 2 o/o , Benzocaine 2.7 o/o , Chlorbutol 5 o/o, Turpentine oil 15 o/o [589]
459	590	Domperidone Oral Drops IP 10mg/ ml (10ml) [590]
460	591	Drotaverine and Mefenamic Acid Tablets Drotaverine 80 mg and Mefenamic Acid 250 mg [591]
461	592	Lactic Acid Bacillus Tab 60 million spores [592]
462	593	Lactulose solution USP/BP 10gm/15ml or 3.35 gm/5ml [593]
463	594	Liquid Paraffin IP 100 ml [594]
464	595	Ondansetron Orally Disintegrating Tablets IP 4mg [595]
465	596	Pantoprazole 40mg and Domperidone 30mg SR Cap IP Pantoprazole as enteric coated pellets and Domperidone as SR Pellets [596]
466	597	Ursodeoxycholic Acid Tablets IP 300 mg [597]
467	598	Allopurinol Tablets IP 100 mg [598]
468	599	Hydroxychloroquine Sulphate Tablets IP 200mg [599]
469	600	Leflunomide Tablets IP 10mg(Film Coated) [600]

S.NO.	DRUG CODE	DRUG NAME
470	601	Leflunomide Tablets IP 20mg (Film coated) [601]
471	602	Sulfasalazine Gastroresistant Tablets IP 500 mg IP [602]
472	603	Gliclazide and Metformin Tablets (Gliclazide 80 mg and Metformin HCL 500 mg) [603]
473	604	Glucagon for Injection USP 1 mg [604]
474	605	Medroxyprogesterone acetate Tablets IP 10 mg [605]
475	607	Thyroxine Tablets IP 50 mcg [607]
476	608	Octreotide Injection 50 mcg/ml [608]
477	610	Chlorzoxazone , Diclofenac sodium & Paracetamol Tablets (Chlorzoxazone 250mg , Diclofenac sodium 50mg Paracetamol 325 mg) [610]
478	613	Carboxymethylcellulose Eye drops IP 0.5% [613]
479	615	Mifepristone Tab IP 200mg [615]
480	616	Formoterol Fumerate & Budesonide Powder For Inhalation IP 6 mcg + 200 mcg [616]
481	617	Budesonide Powder for Inhalation IP 200 mcg [617]
482	618	Ipratropium Powder For Inhalation IP 40 mcg [618]
483	619	Terbutaline Tablets IP 2.5 mg [619]
484	620	Xylometazoline Nasal Drops IP 0.1% [620]
485	621	Sodium Chloride Injection IP 100 ml [621]
486	622	Calcium with Vitamin D Tablets USP /Calcium and Colecalciferol Tablets BP/Calcium and Vitamin D3 Tablets IP(Elemental Calcium 500 mg, Vitamin D3-250 IU) (Non-Chewable) [622]
487	623	Cholecalciferol granules 60,000 IU /gm [623]
488	624	Mecobalamin Inj 500 mcg/ml [624]
489	627	Pyridoxine Tablet IP 40mg [627]
490	629	Thiamine Tablets IP 100 mg [629]
491	630	Calcitriol Capsules IP 0.25 mcg [630]
492	631	Alendronate Sodium Tablets USP / BP 35 mg [631]
493	632	Mannitol with Glycerin Injection 10 o/o + 10 o/o w/v (For Intravenous Infusion) [632]
494	634	Pregabalin Cap IP 75 mg [634]
495	636	Ramipril Tablets IP 2.5 mg [636]
496	638	Neostigmine Injection IP 2.5mg/5ml [638]
497	639	Oseltamivir Capsule IP 75 mg Capsule(each Capsule Contains Oseltamivir Phosphate equivalent to Oseltamivir 75 mg) [639]
498	640	Oseltamivir Capsule IP 45 mg Capsule(each Capsule Contains Oseltamivir Phosphate equivalent to Oseltamivir 45 mg) [640]
499	641	Oseltamivir Capsule IP 30 mg (Each Capsule Contains Oseltamivir Phosphate equivalent to Oseltamivir 30 mg) [641]
500	642	Oseltamivir Phosphate for Oral Suspension IP 12 mg/ml (Each ml contains 12 mg Oseltamivir base after reconstitution) [642]
501	644	Vitamin K-1 (Phytomenadione) IP 1mg/0.5ml injection (Detail in RC) [644]
502	645	ACT Kit Containing 3 tablets of Artesunate(25mg each) and 1 tablet of Sulphadoxine and Pyrimethamine(250mg+12.5mg) [645]

S.NO.	DRUG CODE	DRUG NAME
503	646	ACT Kit Containing 3 tablets of Artesunate(50 mg each) and 1 tablet of Sulphadoxine and Pyrimethamine(500mg+25mg) [646]
504	647	ACT Kit Containing 3 tablets of Artesunate(100 mg each) and 1 tablet of Sulphadoxine and Pyrimethamine(750mg+37.5mg) [647]
505	648	ACT Kit Containing 3 tablets of Artesunate(150 mg each) and 2 tablet of Sulphadoxine and Pyrimethamine(500mg+25mg) [648]
506	649	Each Combi Blister pack: Containing 3 tablets of Artesunate(200 mg each) and 2 tablet of Sulphadoxine Pyrimethamine(750mg+37.5mg)each or 3 Tablets of Sulphadoxine Pyrimethamine(500+25)mg [649]
507	650	Glyceryl Trinitrate Tablets 2.6 mg Controlled Release tablets [650]
508	651	Artemether and Leumefantrine Tablet (80 mg and 480 mg) [651]
509	652	Methyl Cobalmine Tablet 500mcg [652]
510	653	Methyl Cobalmine Tablet 1500mcg [653]
511	654	Atropine Sulphate Injection 0.6mg/ml [654]
512	655	Fentanyl Citrate Injection 50mcg/ml [655]
513	656	Naproxen Tablet IP 500mg [656]
514	657	Naproxen Tablet IP 250mg [657]
515	658	Etoricoxib Tablet IP 90 mg [658]
516	659	Levoceitazine Tablet 5mg [659]
517	660	Montelukast(10mg) + Levocetirizine Tablet (5mg) [660]
518	661	Sodium Valproate Tablet(Gastro Resistant) IP 500mg [661]
519	662	Clobazam Tablet IP/Capsule 5 mg [662]
520	663	Clobazam Tablet/Capsule 10 mg [663]
521	664	Levetiracetam Tablet IP 500 mg [664]
522	665	Levetiracetam Oral Solution/Suspension 100mg/ml [665]
523	666	Levetiracetam Injection 500mg/5ml [666]
524	667	Gabapentine Tablet/Capsule 100mg [667]
525	668	Gabapentine Tablet/Capsule 300mg [668]
526	669	Co-trimoxazole Tablet IP (Trimethoprim 160mg+Sulphamethoxazole 800mg) [669]
527	670	Coal tar 6% & Salicylic Acid 3% Ointment [670]
528	671	Calamine Lotion IP 100ml [671]
529	672	Iohexol USP(Solution for Injection) Non Ionic contrast medium in Sterile aqueous solution 350 mg Iodine/ml [672]
530	674	Quetiapine Tablet IP 50mg [674]
531	675	Quetiapine Tablet IP 25mg [675]
532	676	Vitamin D3 Oral Solution 60000 IU [676]
533	677	Cyclosporin Capsule IP 50 mg [677]
534	678	Clonazepam Tablet 0.5 mg [678]
535	679	Aspirin Tablet IP (Gastro-Resistant) 150 mg [679]
536	682	Teneligliptin Tablet IP 20mg [682]
537	683	Aztreonam Injection 1gm [683]
538	684	Framycetin Sulphate Cream 1 o/o 30gm Pack [684]
539	685	Framycetin Sulphate Cream 1 o/o 100 gm pack [685]

S.NO.	DRUG CODE	DRUG NAME
540	686	Artemether and Leumefantrine Tablet (40 mg and 240 mg) [686]
541	687	Concentrated Solution for Hameodialysis BP Sodium Hydrogen Carbonate Concentrate in 10 Litre Cans [687]
542	692	Cough Syrup/Expectorant(50) ml [692]
543	791	Intravenous Fat Emulsion 20% w/v 250ml [791]
544	797	Dasatinib TAb 100 mg [797]
545	NRD-186	Ceftriaxone 1000mg And Sulbactam 500mg Injection (Detail in RC) [NRD-186]
546	NRD-188	Cefuroxime 750mg Injection [NRD-188]
547	NRD-233	Fentanyl Transdermal patch 25 mcg/hour [NRD-233]
548	NRD-234	Fentanyl Transdermal patch 50mcg/hour [NRD-234]
549	NRD-241	Folic Acid Cynocobalamine and Nicotinamide Injection (Each ml contains Folic Acid 200 mcg Cynocobalamine 5 mcg and Nicotinamide 20 mg [NRD-241]
550	NRD-259	Mefenamic Acid 250Mg and Dicyclomine Hydrochloride10Mg Each Tablet Contain Mefenamic Acid 250Mg and Dicyclomine Hydrochloride10Mg [NRD-259]
551	NRD-275	Lignocaine (Preservative Free) 2% Injection [NRD-275]
552	NRD-284	Enoxaparin Sodium Injection (Low Molecular Wt. Heparin) 40mg/0.4ml 0.4ml injection [NRD-284]
553	NRD-288	Methotrexate 250 mg Inj. IP [NRD-288]
554	NRD-292	Methylprednisolon Acetate 125Mg Injection [NRD-292]
555	NRD-293	Metotrexate 15Mg/ml (each ml contains Metotrexate 15 mg) Injection [NRD-293]
556	NRD-315	Sodium Chloride 0.9 o/o 500 MI Glass Bottle Injection IP [NRD-315]
557	NRD-316	Normal Saline 1000 MI Glass Bottle Injection [NRD-316]
558	NRD-324	Paracetamol Infusion 500 Mg With Both Temper Evident Caps Spray 10% Injection [NRD-324]
559	NRD-362	Ropivacaine 0.75% 3 MI Ampule (Heavy) Injection [NRD-362]
560	NRD-369	Streptomycin 500Mg Injection [NRD-369]
561	NRD-424	Formoterol 6 mcg. and Budesonide 400 mcg. MDI IP [NRD-424]
562	NRD-438	Neomycin, Polmyxin And Bacitracin Zinc Ophthalmic 15 Gm Ip Ointment [NRD-438]

S.NO.	DRUG CODE	DRUG NAME
563	NRD-444	Paint Mercurium Chloride 10ml
564	NRD-534	6-Mercaptopurine Tablet 20Mg [NRD-534]
565	NRD-608	Diltiazem CR/Prolonged Released Tablet 90mg [NRD-608]
566	NRD-677	Methimazole Tablet 5Mg [NRD-677]
567	NRD-762	Rifampicin 450 mg Tab. I.P. [NRD-762]
568	NRD-763	Rifampicin 600 mg Tab. I.P. [NRD-763]
569	NRD-811	Verapamil Hydrochloride Tablet Sustained Release 120Mg [NRD-811]
570	NRD-901	Dapagliflozin 5mg Tablet [NRD-901]
571	NRD-902	Chlorthalidone 12.5 mg Tab [NRD-902]
572	NRD-903	Chlorthalidone 25mg Tablet [NRD-903]
573	448W	Iron and Folic Acid Flavoured Syrup IP Each ml of Syrup contains Ferrous Sulphate IP Equivalent to elemental ferrous iron 20mg, Folic Acid IP 0.1mg with any flavour [448W]
574	489B	Iron and Folic Acid tablet Each-Sugar coated tablet containing 60mg element iron+500mcg folic acid,blue color [489B]
575	490W	Iron and Folic Acid Tablets (WIFS Junior) Each sugar coated tablet contain Dried Ferrous Sulphate IP equivalent to Ferrous Iron 45mg Folic Acid IP 0.4mg The Tablet are Pink Coloured. [490W]
576	490R	Iron and Folic Acid tablet Each-Sugar coated tablet containing 60mg element iron+500mcg folic acid,red color [490R]
577	NE1	Buprenorphine 2mg + Naloxone 0.5 mg Tablets
578	NE2	Misoprostol Tablets IP 200 mcg
579	NE11	Post exposure prophylaxis drugs for HIV- Drug Combination : Tenofivir 300 mg+ Lamivudine 300 mg + Efavirenz 600 mg IP
580	NE75	Morphine Sulphate 30mg SR Tablet [NE75]

ANNEXURE –VII (A)

Sr	Code No.	Name of item with specification	Test proposed to be carried out
1	4	Bupivacaine Injection IP 0.5%	Description
			Identification A (IR)
			Identification B
			pH
			Related substances (TLC)
			2,6-Dimethylaniline
			Bacterial endotoxins
			Extractable volume
			Particulate matter
			Assay: (by HPLC)
			Sterility (by MF)
2	5	Drotaverine Hydrochloride Injection 40 mg/2 ml	Description
			Identification of Drotaverine hydrochloride (by HPLC)
			pH
			Particulate matter
			Extractable volume
			Assay: (by HPLC)
			Sterility (by MF)
3	6	Halothane BP 250 ml	Description
			Appearance
			Solubility
			Identification (by IR)
			Acidity or Alkalinity
			Relative Density
			Distillation Range
			Volatile related substances
			Thymol
			Bromides or chlorides
			Bromine or Chlorine
			Non-volatile matter
			Uniformity of Container Content
4	7	Isoflurane USP	Description
			Identification (IR)
			Refractive Index
			Water
			Chloride
			Nonvolatile Residue
			Limit of Fluoride
			Related Compounds By GC
			Uniformity Of Container
Assay by GC			
5	8	Ketamine Injection IP 50 mg/ ml	Description
			Identification A (by UV)

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Identification B (by UV)
			pH
			Extractable volume
			Particulate matter
			Bacterial endotoxins
			Related substances (by HPLC)
			Assay: (by UV)
			Sterility (by MF)
6	9	Lignocaine Ointment 5%	Description
			Identification A (by IR)
			2,6-Dimethylaniline (by HPLC)
			Uniformity of mass
			Assay: (by HPLC)
7	10	Lignocaine and Adrenaline Inj. IP Each ml contains: - Lignocaine Hydrochloride IP 20 mg. Adrenaline IP 0.01 mg	Description
			Identification A
			Identification B
			Identification C
			pH
			Extractable volume
			Particulate matter
			Assay:
			Lignocaine hydrochloride
			Adrenaline (by HPLC)
			Sterility (by MF)
8	12	Lignocaine Gel IP 2%	Description
			Identification A (by IR)
			Identification B
			Identification C
			2,6-Dimethylaniline
			pH
			Contents of Packaged Dosage Forms
			Assay: Lignocaine hydrochloride
			Sterility (by MF)
9	13	Lignocaine injection IP 2%	Description
			Identification A
			Identification B: Melting Point
			Identification C
			pH
			Bacterial endotoxins
			Extractable volume
			Particulate matter
			2,6-Dimethylaniline
			Assay:
			Lignocaine hydrochloride (titration)
			Sterility (by MF)

Sr	Code No.	Name of item with specification	Test proposed to be carried out
10	14	Propofol Injection IP/BP/USP 10 mg/ ml	Description
			Identification by IR
			Identification by HPLC
			pH
			Propofol Quinone and Propofol Dimer (HPLC)
			Globule Size
			Free Fatty Acid
			Lysolecithin (By HPLC)
			Bacterial endotoxins
			Particulate Matter
			Sterility
			Extractable volume
Assay by HPLC			
11	15	Thiopentone Injection IP 0.5 g	Description
			Identification A (by IR)
			Identification C: Melting Point
			Identification E
			Appearance of solution
			Average net content
			Uniformity of weight
			Loss on drying
			Clarity of solution test a & b
			Particulate matter
			Related substances (by TLC)
			Assay:
			For Thiopentone
For Sodium			
Sterility (by MF)			
12	19	Diclofenac Sodium Injection IP 25 mg/ ml (IM/IV use)	Description
			Identification (by TLC)
			pH
			Particulate matter
			Extractable volume
			Sterility
			Assay: (by HPLC)
13	20	Diclofenac Gastro Resistant Tablets IP 50 mg (Enteric Coated)	Description
			Identification (by TLC)
			Average weight
			Uniformity of weight
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms
			Disintegration time
			Assay: (by HPLC)
Identification of colour			

Sr	Code No.	Name of item with specification	Test proposed to be carried out
14	21	Fentanyl Citrate Injection IP 50 mcg /ml	Description
			Identification A by UV
			Identification B by HPLC
			Identification C
			Related Substances by HPLC
			Bacterial endotoxins
			Particulate Matter
			Extractable volume
			Sterility
15	22	Ibuprofen and Paracetamol Tablets Ibuprofen 400 mg +Paracetamol 325mg	Assay by HPLC
			Description
			Identification of Ibuprofen
			Identification of Paracetamol
			Average weight
			Uniformity of weight
			Disintegration Time
			Contents of Packaged Dosage Forms
			Assay:
Ibuprofen			
Paracetamol (by UV)			
16	23	Ibuprofen Tablets IP 200 mg (Coated)	Description
			Identification A (by IR)
			Identification B: Melting Point
			Average weight
			Uniformity of weight
			Contents of Packaged Dosage Forms
			Dissolution (by UV)
			Related Substances (by TLC)
			Assay: Ibuprofen
Identification of colour			
17	24	Ibuprofen Tablets IP 400 mg (Coated)	Description
			Identification A (by IR)
			Identification B: Melting Point
			Average weight
			Uniformity of weight
			Contents of Packaged Dosage Forms
			Dissolution (by UV)
			Related Substances (by TLC)
			Assay: Ibuprofen
Identification of colour			
18	25	Morphine Sulphate Injection IP 10mg/ml	Description
			Identification A
			Identification B

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			pH
			Bacterial endotoxins
			Particulate matter
			Extractable volume
			Assay: (by HPLC)
			Sterility (by MF)
19	26	Paracetamol Drops [Paediatric Paracetamol Oral Suspension IP], (Each ml contains Paracetamol 150 mg)	Description
			Identification A (by TLC)
			Identification B (by HPLC)
			Weight per ml
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms
			Identification of colour
			Assay: (by HPLC)
			Microbial Examination
			Total aerobic count
			Total fungal count
			E. coli
20	27	Paracetamol Syrup IP 125 mg/5ml (40% Sugar base with strawberry flavour and carmoisine colour)	Description
			Identification A (by TLC)
			Identification B (by HPLC)
			Weight per ml
			4-Aminophenol (by HPLC)
			Contents of Packaged Dosage Forms
			Identification of colour
			Assay: (by HPLC)
			Microbial Examination
			Total aerobic count
			Total fungal count
			E. coli
			Sugar Content test
21	28	Paracetamol Tablets IP 500 mg	Description
			Identification A (by IR)
			Identification B
			Average weight
			Uniformity of weight
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms
			Dissolution (by UV)
			Assay: (by UV)
22	29	Paracetamol Inj. 150 mg/ml	Description
			Identification of paracetamol (by HPLC)
			pH

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Particulate matter
			Extractable volume
			Bacterial endotoxines
			Assay: (by HPLC)
			Sterility (by MF)
23	30	Pentazocine Injection IP 30mg/ml (IM/IV Use)	Description
			Identification A (By IR)
			Identification B (By UV)
			Identification C
			pH
			Related Substances (by TLC)
			Particulate matter
			Bacterial endotoxins
			Extractable volume
			Assay:
			Pentazocine Lactate (By UV)
			Sterility (by MF)
24	32	Tramadol Capsules IP 50 mg	Description
			Identification A (by TLC)
			Identification B (by HPLC)
			Average net content
			Uniformity of weight
			Related substances (by HPLC)
			Disintegration time
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
25	33	Tramadol Injection 50 mg/ ml	Description
			Identification (by HPLC)
			pH
			Bacterial endotoxines
			Extractable volume
			Particulate matter
			Assay: (by HPLC)
			Sterility (by MF)
26	34	Adrenaline Injection IP 1mg/ml (IM/IV use)	Description
			Identification A (by UV)
			Identification B
			Identification C
			pH
			Extractable volume
			Particulate matter
			Appearance of solution
			Noradrenaline (by HPLC)
			Assay: (by HPLC)
			Sterility (by MF)

Sr	Code No.	Name of item with specification	Test proposed to be carried out			
27	35	Betamethasone Tablets IP 0.5mg	Description			
			Identification A (by IR)			
			Identification B (by UV)			
			Identification C (by TLC)			
			Average weight			
			Related substances (by TLC)			
			Uniformity of content (by HPLC)			
			Dissolution (by HPLC)			
			Contents of Packaged Dosage Forms			
			Assay: (by HPLC)			
28	37	Chlorpheniramine Maleate Tablets IP 4 mg	Description			
			Identification (by TLC)			
			Average weight			
			Related substances (by TLC)			
			Uniformity of content (by UV)			
			Disintegration Time			
			Contents of Packaged Dosage Forms			
						Assay:
						Chlorpheniramine maleate (by UV)
29	39	Dexamethasone Injection IP 8 mg/2ml	Description			
			Identification (by TLC)			
			pH			
			Free Dexamethasone (by HPLC)			
			Bacterial endotoxins			
			Extractable volume			
			Particulate matter			
						Assay: (by HPLC)
						Sterility (by MF)
30	40	Dexamethasone tablets IP 0.5mg	Description			
			Identification A (by IR)			
			Identification B (by TLC)			
			Identification C			
			Average weight			
			Related substances (by HPLC)			
			Uniformity of content (by HPLC)			
			Disintegration Time			
			Contents of Packaged Dosage Forms			
			Assay: (by HPLC)			
31	42	Hydrocortisone Sod. Succinate Injection IP 100 mg base / vial (IM/IV use)	Description			
			Identification A (by IR)			
			Identification B (by TLC)			
			pH			
			Related substances (by HPLC)			

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Bacterial endotoxins
			Average weight
			Uniformity of weight
			Particulate matter
			Clarity of solution A and B
			Sterility
			Assay (by UV)
32	43	Hydroxyzine Tablets IP 25 mg	Description
			Identification A (by HPLC)
			Identification B (by TLC)
			Average weight
			Uniformity of weight
			Dissolution (by UV)
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
33	44	Methyl Prednisolone Sodium Succinate for Injection USP 500 mg	Description
			Constituted solution
			Identification (by IR)
			Average net content
			Uniformity of dosage units (weight variation)
			pH
			Loss on drying
			Free methylprednisolone (by HPLC)
			Bacterial endotoxins
			Particulate matter (by Particle counter)
			Assay: (by HPLC)
			Sterility (by MF)
34	45	Pheniramine Injection IP 22.75mg/ml	Description
			Identification (by TLC)
			pH
			Related substances (by TLC)
			Extractable volume
			Particulate matter
			Assay: (by UV)
			Sterility (by MF)
35	47	Prednisolone Tablets IP 5 mg	Description
			Identification A (by IR)
			Identification B (by TLC)
			Average weight
			Related substances (by HPLC)
			Uniformity of content (by UV)
			Dissolution (by UV)

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
36	48	Promethazine Syrup IP 5 mg/5ml	Description
			Identification A (by TLC)
			Contents of Packaged Dosage Forms
			Assay:
			Promethazine Hydrochloride (by UV)
			Identification of colour
			Microbial Examination
			Total aerobic count
			Total fungal count
			E. coli
37	49	Promethazine Injection IP 25mg/ml	Description
			Identification A (by IR)
			Identification B: Melting Point
			Identification C
			pH
			Related substances (by TLC)
			Bacterial endotoxins
			Particulate matter
			Extractable volume
			Assay: (by UV)
			Sterility (by MF)
38	50	Promethazine Tablets IP 25 mg	Description
			Identification A (by IR)
			Identification B (Melting Range)
			Identification C
			Average weight
			Disintegration Time
			Contents of Packaged Dosage Forms
			Related substances (by TLC)
			Assay: (by UV)
			Identification of colour
39	51	Naloxone Injection IP 0.4mg/ ml	Description
			Identification A (by HPLC)
			Identification B (by TLC)
			pH
			Related substances (by TLC)
			Bacterial endotoxins
			Particulate matter
			Extractable volume
			Assay: (by HPLC)
			Sterility (by MF)

Sr	Code No.	Name of item with specification	Test proposed to be carried out
40	52	Pralidoxime Chloride Injection IP 500 mg	Description
			Identification A (by IR)
			Identification B (by UV)
			Identification C
			Identification D
			Average net content
			Uniformity of weight
			pH
			Heavy metals
			Bacterial endotoxins
			Clarity of solution test a and b
			Particulate matter
			Assay:
			Pralidoxime chloride (by UV)
Sterility (by MF)			
41	53	Carbamazepine Tablets IP 200 mg (Film Coated)	Description
			Identification (by IR)
			Average weight
			Uniformity of weight
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms
			Disintegration time
			Assay: (by HPLC)
			Identification of colour
42	54	Carbamazepine Tablets IP 100 mg (Film Coated)	Description
			Identification (by IR)
			Average weight
			Uniformity of weight
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms
			Disintegration time
			Assay: (by HPLC)
			Identification of colour
43	56	Phenobarbitone Tablets IP 30 mg	Description
			Identification A (by IR)
			Identification B
			Average weight
			Uniformity of weight
			Contents of Packaged Dosage Forms
			Disintegration time
			Assay: Gravimetric
44	57	Phenytoin Injection 50mg/ml IP	Description
			Identification A (HPLC)

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			pH
			Extractable volume
			Particulate matter
			Assay (HPLC)
			Sterility (by MF)
45	58	Phenytoin Oral suspension IP 25mg/ml	Description
			Identification (by IR)
			pH
			Weight/ml
			Uniformity of mass
			Benzil and benzophenone (by TLC)
			Assay: Phenytoin (by Gravimetric)
			Identification of colour
			Microbial Examination
			Total Aerobic Microbial Count
			Total Combined Yeast & Mould Count
			E. coli
46	59	Phenytoin Tablets IP 100 mg (Film Coated)	Description
			Identification A (by IR)
			Identification B
			Identification C
			Average weight
			Uniformity of weight
			Related substances (by TLC)
			Disintegration time
			Contents of Packaged Dosage Forms
			Assay: Phenytoin sodium (Titration)
47	61	Sodium Valproate Tablets 200 mg (Enteric Coated)	Description
			Identification A (by IR)
			Identification B
			Average weight
			Uniformity of weight
			Related substances (by GC)
			Disintegration time
			Content of package dosage form
			Assay: by Chemical
48	62	Acyclovir oral Suspension 400mg/5ml	Description
			Identification A (by UV)
			Identification B (by TLC)
			pH
			Guanine (by TLC)
			Contents of Packaged Dosage Forms
			Assay: (by UV)

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Microbial Examination
			Total Aerobic Count
			Total fungal Count
			E. coli
49	63	Acyclovir Tablets IP 200 mg	Description
			Identification A (by UV)
			Identification B (by TLC)
			Average weight
			Uniformity of weight
			Disintegration Time
			Related substances (by TLC)
			Guanine (by TLC)
			Contents of Packaged Dosage Forms
			Assay: (by UV)
50	64	Acyclovir Tablets IP 800 mg	Description
			Identification A (by UV)
			Identification B (by TLC)
			Average weight
			Uniformity of weight
			Disintegration Time
			Related substances (by TLC)
			Guanine (by TLC)
			Contents of Packaged Dosage Forms
			Assay: (by UV)
51	65	Albendazole Oral suspension 400 mg/10ml	Description
			Identification A (by UV)
			Identification B (by UV)
			Identification C (by HPLC)
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms
			pH
			Assay: (by HPLC)
			Microbial Examination
			Total Aerobic Count
			Total fungal Count
			E. coli
52	67	Amikacin Injection IP 100 mg	Description
			Identification A by TLC
			Identification B
			Identification C
			pH
			Bacterial endotoxins
			Related substances by HPLC

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Particulate matter
			Extractable volume
			Sterility
			Assay: Microbiological assay
53	68	Amikacin Injection IP 500 mg	Description
			Identification A by TLC
			Identification B
			Identification C
			pH
			Bacterial endotoxins
			Related substances by HPLC
			Particulate matter
			Extractable volume
			Sterility
			Assay: Microbiological assay
54	69	Amoxicillin and Cloxacillin Capsules 250mg + 250 mg	Description
			Identification of amoxicillin (by HPLC)
			Identification of cloxacilline (by HPLC)
			Average net content
			Uniformity of weight
			Disintegration time
			Contents of Packaged Dosage Forms
			Assay:
			Amoxicillin (by HPLC)
			Cloxacilline (by HPLC)
55	70	Amoxicillin and Potassium Clavulanate Tablets IP, 500 mg + 125 mg	Description
			Identification (by HPLC)
			Average weight
			Uniformity of weight
			Water
			Uniformity of content: Clavulanic acid (by HPLC)
			Dissolution
			Amoxicillin (by HPLC)
			Clavulanic acid (by HPLC)
			Contents of Packaged Dosage Forms
			Assay:
			Amoxicillin (by HPLC)
			Clavulanic acid (by HPLC)
56	71	Amoxicillin Capsules IP 250mg	Description
			Identification A (by IR)
			Identification B (by HPLC)
			Average net content

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Uniformity of weight
			Contents of Packaged Dosage Forms
			Dissolution (by UV)
			Assay: (by HPLC)
57	72	Amoxicillin Capsules IP 500mg	Description
			Identification A (by IR)
			Identification B (by HPLC)
			Average net content
			Uniformity of weight
			Contents of Packaged Dosage Forms
			Dissolution (by UV)
			Assay: (by HPLC)
58	73	Amoxicillin Dispersible Tablets IP 125mg	Description
			Identification (by IR)
			Average weight
			Uniformity of weight
			Contents of Packaged Dosage Forms
			Uniformity of dispersion
			Disintegration time
			Assay: (by HPLC)
59	74	Amphotericin B Injection IP 50 mg	Description
			pH
			Loss on drying
			Bacterial endotoxins
			Average weight
			Uniformity of weight
			Particulate matter
			Clarity of solution A and B
			Sterility
			Assay Microbiology
60	75	Ampicillin Injection IP 500 mg	Description
			Identification A (by IR)
			Identification B (by HPLC)
			Identification C
			Appearance of solution (by UV)
			Heavy metals
			pH
			Specific optical rotation
			Dichloromethane (by GC)
			Related substances (by HPLC)
			N,N-Dimethylaniline (by GC)
			Bacterial endotoxins
			Average net content

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Uniformity of weight
			Water
			Clarity of solution test a and b
			Particulate matter
			Assay: (by HPLC)
			Sterility (MF)
61	82	Benzathine Benzylpenicillin Inj IP 6 lac units	Description
			Identification A
			Identification B Melting point
			Identification C (by HPLC)
			pH
			Related substances (by HPLC)
			Consistency
			Water
			Bacterial endotoxins
			Average weight
			Uniformity of weight
			Assay: (by HPLC)
			Sterility (by MF)
62	84	Cefixime Tablets IP 100 mg	Description
			Identification (by HPLC)
			Average weight
			Uniformity of weight
			Water
			Contents of Packaged Dosage Forms
			Dissolution (by UV)
			Assay: (by HPLC)
63	85	Cefixime Tablets IP 200 mg	Description
			Identification (by HPLC)
			Average weight
			Uniformity of weight
			Water
			Contents of Packaged Dosage Forms
			Dissolution (by UV)
			Assay: (by HPLC)
64	86	Cefoperazone and Sulbactam for Injection Cefoperazone Sodium eq. to Cefoperazone 1 g and Sulbactam Sodium eq. to Sulbactam 0.5 g (IM/ IV use)	Description
			Identification of Cefoperazone sodium (by HPLC)
			Identification of Sulbactam sodium (by HPLC)
			Average net content
			Uniformity of weight
			Clarity of solution test a and b
			Particulate matter
			Bacterial endotoxins

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Assay:
			Cefoperazone (by HPLC)
			Sulbactam (by HPLC)
			Sterility (by MF)
65	87	Cefotaxime Injection IP 1gm	Description
			Identification A (by HPLC)
			Identification B
			pH
			Bacterial endotoxins
			Average net content
			Uniformity of weight
			Water
			Clarity of solution test a and b
			Particulate matter
			Assay: (by HPLC)
			Sterility (by MF)
66	88	Cefotaxime Injection IP 250 mg	Description
			Identification A (by HPLC)
			Identification B
			pH
			Bacterial endotoxins
			Average net content
			Uniformity of weight
			Water
			Clarity of solution test a and b
			Particulate matter
			Assay: (by HPLC)
			Sterility (by MF)
67	89	Ceftazidime Injection IP 1 gm	Description
			Identification A (by HPLC))
			Identification B
			pH
			Bacterial endotoxins
			Average net content
			Uniformity of weight
			Loss on drying
			Clarity of solution test a and b
			Particulate matter
			Pyridine (by HPLC)
			Assay: (by HPLC)
			Sterility (MF)
68	90	Ceftazidime Injection IP 250 mg	Description
			Identification A (by HPLC))
			Identification B
			pH

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Bacterial endotoxins
			Average net content
			Uniformity of weight
			Loss on drying
			Clarity of solution test a and b
			Particulate matter
			Pyridine (by HPLC)
			Assay: (by HPLC)
			Sterility (MF)
69	91	Ceftazidime Injection IP 500 mg	Description
			Identification A (by HPLC))
			Identification B
			pH
			Bacterial endotoxins
			Average net content
			Uniformity of weight
			Loss on drying
			Clarity of solution test a and b
			Particulate matter
			Pyridine (by HPLC)
			Assay: (by HPLC)
			Sterility (MF)
70	93	Ceftriaxone Injection IP 1gm /vial	Description
			Identification A (by IR)
			Identification B (by HPLC)
			Identification C
			Appearance of solution
			pH
			Related substances (by HPLC)
			Bacterial endotoxins
			Water
			Average weight
			Uniformity of weight
			Particulate matter
			Clarity of solution A and B
			Sterility
			Assay: (by HPLC)
71	94	Ceftriaxone Injection IP 250 mg/ vial	Description
			Identification A (by IR)
			Identification B (by HPLC)
			Identification C
			Appearance of solution
			pH
			Related substances (by HPLC)
			Bacterial endotoxins

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Water
			Average weight
			Uniformity of weight
			Particulate matter
			Clarity of solution A and B
			Sterility
			Assay: (by HPLC)
72	95	Ceftriaxone Injection IP 500mg/vial	Description
			Identification A (by IR)
			Identification B (by HPLC)
			Identification C
			Appearance of solution
			pH
			Related substances (by HPLC)
			Bacterial endotoxins
			Water
			Average weight
			Uniformity of weight
			Particulate matter
			Clarity of solution A and B
			Sterility
			Assay: (by HPLC)
73	96	Cephalexin Capsules IP 250 mg	Description
			Identification A (by IR)
			Identification B (by HPLC)
			Average net content
			Uniformity of weight
			Related substances (by TLC)
			Contents of Packaged Dosage Forms
			Dissolution (by UV)
			Water
			Assay: (by HPLC)
74	97	Cephalexin Capsules IP 500 mg	Description
			Identification A (by IR)
			Identification B (by HPLC)
			Average net content
			Uniformity of weight
			Related substances (by TLC)
			Contents of Packaged Dosage Forms
			Dissolution (by UV)
			Water
			Assay: (by HPLC)
75	98	Chloroquine Phosphate Injection IP 40mg/ml	Description
			Identification A (by IR)

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Identification B: Melting Point
			Identification C
			pH
			Extractable volume
			Particulate matter
			Assay: Chloroquine Phosphate (titration)
			Sterility (by MF)
76	99	Chloroquine Phosphate Tab. IP 250mg (≅155 mg of Chloroquine base) (Film Coated)	Description
			Identification A (by IR)
			Identification B: Melting Point
			Identification C
			Average weight
			Uniformity of weight
			Related substances by TLC
			Contents of Packaged Dosage Forms
			Dissolution (by UV)
			Assay: (by HPLC)
77	101	Ciprofloxacin Injection IP 200mg/100ml	Description
			Identification A (by TLC)
			pH
			Ciprofloxacin ethylenediamine analog (by HPLC)
			Bacterial endotoxins
			Particulate contamination (by particle counter)
			Lactic Acid (HPLC)
			Extractable volume
			Assay: (by HPLC)
			Sterility (by MF)
78	102	Ciprofloxacin Tablets IP 250 mg (Film Coated)	Description
			Identification A (by HPLC)
			Identification B (by TLC)
			Average weight
			Uniformity of weight
			Contents of Packaged Dosage Forms
			Dissolution (by UV)
			Assay: (by HPLC)
			Identification of colour
79	103	Ciprofloxacin Tablets IP 500 mg (Film Coated)	Description
			Identification A (by HPLC)
			Identification B (by TLC)
			Average weight
			Uniformity of weight

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Contents of Packaged Dosage Forms
			Dissolution (by UV)
			Assay: (by HPLC)
			Identification of colour
80	104	Clotrimazole Cream IP 2% w/w	Description
			Identification A (by UV)
			Identification B (by TLC)
			2-Chlotritanol (by HPLC)
			Content of package dosage forms
			Assay: (by HPLC)
81	105	Clotrimazole Vaginal Tablets IP 500 mg	Description
			Identification A (by UV)
			Identification B (by TLC)
			Average weight
			Uniformity of weight
			Related substances (by HPLC)
			Disintegration time
			Content of package dosage form
			Assay: (by HPLC)
82	106	Compound Benzoic Acid Ointment IP [Benzoic Acid 6%+ Salicylic Acid 3%]	Description
			Identification (by TLC)
			Content of package dosage form
			Assay:
			For Benzoic acid (by titration)
			For Salicylic acid (by UV)
83	107	Co-trimoxazole Oral suspension IP Each 5 ml contains Trimethoprim 40 mg and Sulphamethoxazole 200 mg	Description
			Identification (by TLC)
			Weight per ml
			pH
			Contents of Packaged Dosage Forms
			Identification of colour (by TLC)
			Assay:
			Sulphamethoxazole (by titration)
			Trimethoprim (by UV)
			Microbial Examination
			Total aerobic count
			Total fungal count
			E. coli
84	108	Co-trimoxazole Tablets IP Trimethoprim 40 mg and Sulphamethoxazole 200 mg	Description
			Identification A (by IR)
			Identification B (by IR)
			Identification C (by TLC)
			Average weight

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Contents of Packaged Dosage Forms
			Uniformity of weight
			Disintegration Time
			Assay:
			Trimethoprim (by UV)
			Sulphamethoxazole (by titration)
85	110	Diethylcarbamazine Tablets IP 100 mg	Description
			Identification (by IR)
			Average weight
			Uniformity of weight
			Dissolution (by HPLC)
			Contents of Packaged Dosage Forms
			N,N'-Dimethylpiperazine and N-methylpiperazine (by TLC)
			Assay: (by HPLC)
86	111	Doxycycline Capsules IP 100 mg	Description
			Identification A (by TLC)
			Identification B
			Identification C
			Light absorbing impurities (by UV)
			Average net content
			Uniformity of weight
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms
			Disintegration time
			Loss on drying
			Assay: (by HPLC)
87	114A	Fluconazole Tab. IP150mg.	Description
			Identification (by HPLC)
			Average weight
			Uniformity of weight
			Dissolution (by HPLC)
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
			Identification of colour
88	116	Gentamicin Injection IP 80mg/2ml (IM/ IV use)	Description
			Identification A (by TLC)
			Identification B (by HPLC)
			pH
			Composition of gentamicin sulphate (by HPLC)
			Extractable volume

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Particulate matter
			Bacterial endotoxins
			Assay: (by Microbiological assay)
			Sterility (by MF)
89	118	Itraconazole Capsules 100 mg	Description
			Identification (by HPLC)
			Average weight
			Uniformity of weight
			Disintegration time
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
			Identification of colour
90	119	Meropenem Injection IP 500 mg	Description
			Identification (by HPLC)
			pH
			Bacterial endotoxins
			Average net content
			Uniformity of weight
			Loss on drying
			Related Substances (by HPLC)
			Content of Sodium
			Clarity of solution test a and b
			Particulate matter
			Assay: (by HPLC)
			Sterility (by MF)
91	120	Metronidazole Injection IP 500 mg/100ml	Description
			Identification A (by IR)
			Identification B
			pH
			Related substances (by HPLC)
			Extractable volume
			Particulate contamination (by particle counter)
			Bacterial endotoxins
			Assay: (by UV)
			Sterility (by MF)
92	121	Metronidazole Benzoate Oral Suspension IP 100 mg of base/5ml	Description
			Identification A (by UV)
			Identification B
			Weight per ml
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
			Identification of colour
			Microbial Examination

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Total aerobic count
			Total fungal count
			E. coli
93	122	Metronidazole Tablets IP 200 mg (Film Coated)	Description
			Identification A (by IR)
			Identification B
			Identification C: Melting Point
			Average weight
			Uniformity of weight
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms
			Dissolution (by UV)
			Assay: Metronidazole
94	123	Metronidazole Tablets IP 400 mg (Film Coated)	Description
			Identification A (by IR)
			Identification B
			Identification C: Melting Point
			Average weight
			Uniformity of weight
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms
			Dissolution (by UV)
			Assay: Metronidazole
95	124	Norfloxacin Tablets IP 400 mg Film Coated	Description
			Identification A (by TLC)
			Identification B (by HPLC)
			Average weight
			Uniformity of weight
			Contents of Packaged Dosage Forms
			Dissolution (by UV)
			Assay: (by HPLC)
			Identification of colour
96	125	Ofloxacin Tablets IP 200 mg	Description
			Identification (by HPLC)
			Average weight
			Uniformity of weight
			Contents of Packaged Dosage Forms
			Dissolution (by UV)
			Related substances (by HPLC)
			Assay: (by HPLC)
97	128	Primaquine Tablets IP 2.5 mg	Description
			Identification A (by IR)
			Identification B

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Average weight
			Dissolution (by HPLC)
			Uniformity of content (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
			Identification of colour
98	129	Primaquine Tablets IP 7.5 mg	Description
			Identification A (by IR)
			Identification B
			Average weight
			Dissolution (by HPLC)
			Uniformity of content (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
			Identification of colour
99	131	Quinine Dihydrochloride Injection IP 300 mg/ ml	Description
			Identification A (by TLC)
			Identification B
			Identification C
			pH
			Other cinchona alkaloids (by HPLC)
			Particulate matter
			Extractable volume
			Assay: by titration
			Sterility (by MF)
100	132	Quinine sulphate Tablets IP 300mg (Film Coated)	Description
			Identification A (by TLC)
			Identification B
			Identification C
			Identification D
			Average weight
			Uniformity of weight
			Dissolution (by UV)
			Other cinchona alkaloids (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: Quinine sulphate
			Identification of colour
101	133	Azathioprine Tablets IP 50 mg	Description
			Identification A (by TLC)
			Identification B
			Average weight
			Uniformity of weight
			Contents of Packaged Dosage Forms

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Related Substances by TLC
			Assay by UV
102	134	Bleomycin Injection IP 15 mg (Bleomycin Sulphate Injection 15 units)	Description
			Identification A by IR
			Identification B
			pH
			Copper
			Content of Bleomycin by HPLC
			Average Weight
			Uniformity of Weight
			Bacterial endotoxins
			Loss on drying
			Clarity of solution test a and b
			Particulate Matter
			Assay by Microbiology
			Sterility (by MF)
103	137	Cisplatin Injection IP/BP 50 mg/50ml	Description
			Identification A (by UV)
			Identification B (by HPLC)
			pH
			Trichloroammineplatinate (by HPLC)
			Bacterial Endotoxins
			Extractable volume
			Particulate matter
			Assay: (by HPLC)
			Sterility (by MF)
104	138	Cyclophosphamide Injection IP 200 mg	Description
			Identification A (by IR)
			Identification B
			Identification C
			pH
			Bacterial Endotoxins
			Average net content
			Uniformity of weight
			Related Substances (by TLC)
			Clarity of solution test a and b
			Particulate matter
			Assay: (by HPLC)
			Sterility (by MF)
105	139	Cyclophosphamide Injection IP 500 mg	Description
			Identification A (by IR)
			Identification B
			Identification C
			pH
			Bacterial Endotoxins

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Average net content
			Uniformity of weight
			Related Substances (by TLC)
			Clarity of solution test a and b
			Particulate matter
			Assay: (by HPLC)
			Sterility (by MF)
106	141	Cytarabine Injection 500 mg	Description
			Identification (by IR)
			(Acidity) pH
			Related substances (by TLC)
			Particulate matter
			Extractable volume
			Assay: (by HPLC)
			Sterility (by MF)
107	142	Danazol Capsules IP 50 mg	Description
			Identification (by IR)
			Average net content
			Uniformity of weight
			Dissolution (by UV)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
108	143	Daunorubicin Injection IP 20 mg	Description
			Identification (by HPLC)
			Average net content
			Uniformity of weight
			pH
			Water
			Clarity of solution test a and b
			Particulate matter
			Bacterial endotoxins
			Assay: (by HPLC)
			Sterility (by MF)
109	144	Doxorubicin Injection IP 50 mg/ 25 ml	Description
			Identification (by HPLC)
			Average net content
			Uniformity of weight
			pH
			Clarity of solution test a and b
			Particulate matter
			Bacterial endotoxins
			Assay: (by HPLC)
			Sterility (by MF)
110	146	Etoposide Injection IP 100 mg	Description
			Identification A (by TLC)

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Identification B (by HPLC)
			pH
			cis-Etoposide (by HPLC)
			Bacterial endotoxins
			Extractable volume
			Particulate matter
			Assay: (by HPLC)
			Sterility (by MF)
111	147	Flunarizine Tablets 5 mg	Description
			Identification (by UV)
			Average weight
			Disintegration Time
			Uniformity of content (by UV)
			Contents of Packaged Dosage Forms
			Assay: (by UV)
			Identification of colour
112	148	Fluorouracil Injection IP 250 mg/ 5ml	Description
			Identification A (by IR)
			Identification B (by UV)
			Identification C
			pH
			Related Substances (by TLC)
			Urea (by TLC)
			Extractable volume
			Particulate matter
			Bacterial endotoxins
			Assay: (by UV)
			Sterility (by MF)
113	150	Leucovorin Calcium Injection IP/Calcium Folate Injection IP 10 mg /ml	Description
			Identification by IR
			pH
			Related Substances by HPLC
			Particulate Matter
			Extractable volume
			Assay by HPLC
			Sterility (by MF)
114	151	Melphalan Tablets IP 5 mg	Description
			Identification A (by UV)
			Identification B
			Average weight
			Uniformity of content (by HPLC)
			Disintegration time
			Assay: (by HPLC)
			Content of package dosage forms
115	152	Mercaptopurine Tablets IP 50 mg	Description

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Identification (by UV)
			Average weight
			Uniformity of weight
			Dissolution (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by UV)
116	153	Methotrexate Injection IP 50 mg/ 2 ml	Description
			Identification by UV
			pH
			Related Substances by HPLC
			Bacterial endotoxins
			Particulate Matter
			Extractable volume
			Assay by HPLC
			Sterility (by MF)
117	154	Methotrexate Tablets IP 2.5 mg	Description
			Identification by UV
			Average weight
			Uniformity of Content by HPLC
			Related substances (by HPLC)
			Dissolution by UV
			Contents of Packaged Dosage Forms
			Assay by HPLC
118	155	Paclitaxel Injection IP 260 mg	Description
			Identification by HPLC
			pH
			Light absorbtion
			Related Substances by HPLC
			Particulate Matter
			Extractable volume
			Bacterial endotoxins
			Assay by HPLC
			Sterility (by MF)
119	156	Paclitaxel Injection IP 100 mg	Description
			Identification by HPLC
			pH
			Light absorbtion
			Related Substances by HPLC
			Particulate Matter
			Extractable volume
			Bacterial endotoxins
			Assay by HPLC
			Sterility (by MF)
120	157	Tamoxifen Tablets IP 10 mg	Description

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Identification A by IR Identification B by UV Identification C by TLC Identification D E-Isomer and Related Substances by HPLC Uniformity of Content by UV Average Weight Content of package dosages forms Assay by UV
121	158	Vinblastine Injection IP 10mg	Description Identification A (by UV) Identification B (TLC) Identification C pH Related Substances (by TLC) Particulate matter Clarity of solution test a and b Average Net Content Uniformity of Weight Bacterial endotoxins Assay: (by UV) Sterility (by MF)
122	159	Vincristine Injection IP 1 mg (Vial) / Vincristine Injection USP 1 mg/ml (Amp)	Description Identification A (by HPLC) Identification B Appearance of solution Average net content pH Related substances (by HPLC) Uniformity of content (by HPLC) Clarity of solution test a and b Particulate matter Bacterial endotoxins Assay: (by UV) Sterility (by MF)
123	160	Levodopa and Carbidopa Tablets IP [Levodopa 100 mg + Carbidopa 10 mg]	Description Identification A (by HPLC) Identification B Identification C Uniformity of content: Carbidopa (by HPLC) Average weight Uniformity of weight Disintegration time Assay:

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			For Levodopa (by HPLC)
			For Carbidopa (by HPLC)
			Content of package dosages forms
124	161	Levodopa 250mg and Carbidopa 25 mg Tab IP	Description
			Identification A (by HPLC)
			Identification B
			Identification C
			Uniformity of content: Carbidopa (by HPLC)
			Average weight
			Uniformity of weight
			Disintegration time
			Assay:
			For Levodopa (by HPLC)
			For Carbidopa (by HPLC)
			Content of package dosages forms
125	162	Trihexyphenidyl Hydrochloride Tablets IP 2 mg	Description
			Identification A
			Identification B (by TLC)
			Uniformity of content (by HPLC)
			Average weight
			Disintegration time
			Content of package dosages forms
			Assay: (by HPLC)
126	163	Acenocoumarol Tablets IP 2 mg (Nicoumalone Tab IP)	Description
			Identification A (by IR)
			Identification B (by UV)
			Identification C
			Average weight
			Related substances (by TLC)
			Uniformity of content (by UV)
			Disintegration Time
			Contents of Packaged Dosage Forms
			Assay: (by UV)
127	165	Deferasirox Tablets 100 mg	Description
			Identification (by HPLC)
			Average weight
			Uniformity of weight
			Contents of Packaged Dosage Forms
			Disintegration time
			Assay: (by HPLC)
128	166	Deferasirox Tablets 500 mg	Description
			Identification (by HPLC)
			Average weight
			Uniformity of weight

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Contents of Packaged Dosage Forms
			Disintegration time
			Assay: (by HPLC)
129	167	Deferiprone Capsules 250 mg	Description
			Identification (by UV)
			Average net content
			Uniformity of weight
			Contents of Packaged Dosage Forms
			Disintegration time
			Water
			Assay: (by UV)
130	168	Deferiprone Capsules 500 mg	Description
			Identification (by UV)
			Average net content
			Uniformity of weight
			Contents of Packaged Dosage Forms
			Disintegration time
			Water
			Assay: (by UV)
131	169	Desferrioxamine Injection IP 500 mg / Vial (For I.M. Inj and I.V., S.C. Infusion)	Description
			Identification A (by IR)
			Identification B
			Average net content
			Uniformity of weight
			Related substances (by HPLC)
			Clarity of solution test a and b
			Particulate matter
			Bacterial endotoxins
			Assay: (by UV)
			Sterility (by MF)
132	173	Ethamsylate Injection 250 mg/ 2ml (IM/IV)	Description
			Identification (by UV)
			pH
			Extractable volume
			Particulate matter
			Assay: (by UV)
			Sterility (by MF)
133	180	Vitamin K Injection Each ml Contains Menadione Sodium Bisulphite 10 mg Equivalent to 5.2 mg of Menadione (Aqueous Solution)	Description
			Identification (by HPLC)
			pH
			Particulate matter
			Extractable volume
			Assay: (by HPLC)

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Sterility (by MF)
134	181	Amiodarone Tablets IP 100 mg	Description
			Identification A (by IR)
			Identification B (by HPLC)
			Average weight
			Uniformity of weight
			Disintegration Time
			Related substances (by TLC)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
135	182	Amiodarone Tablets IP 200 mg	Description
			Identification A (by IR)
			Identification B (by HPLC)
			Average weight
			Uniformity of weight
			Disintegration Time
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
136	183	Amiodarone Hydrochloride Injection 50 mg/ml	Description
			Identification A (by IR)
			Identification B (by HPLC)
			Particulate matter
			Extractable volume
			Appearance of solution
			Related substances (by TLC)
			Iodides (by UV)
			Assay: (by HPLC)
			Sterility (by MF)
137	184	Amlodipine Tablets IP 2.5 mg	Description
			Identification (by HPLC)
			Average weight
			Related substances (by HPLC)
			Uniformity of content (by HPLC)
			Dissolution (by UV)
			Contents of Packaged Dosage Forms
Assay: (by HPLC)			
138	185	Amlodipine Tablets IP 5 mg	Description
			Identification (by HPLC)
			Average weight
			Related substances (by HPLC)
			Uniformity of content (by HPLC)
			Dissolution (by UV)

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
139	186	Atenolol Tablets IP 50 mg	Description
			Identification A (by IR)
			Identification B (by UV)
			Average weight
			Uniformity of weight
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms
			Disintegration time
			Assay: (by UV)
140	187	Atorvastatin Tablets IP 10 mg	Description
			Identification (by HPLC)
			Average weight
			Related substances (by HPLC)
			Dissolution (by HPLC)
			Uniformity of content (by HPLC)
			Contents of Packaged Dosage Forms
			Assay:
			Atorvastatin (by HPLC)
			Identification of colour
141	189	Digoxin Injection IP 0.25 mg/ml	Description
			Identification
			pH
			Extractable volume
			Particulate matter
			Bacterial endotoxins
			Assay: (by UV)
			Sterility (by MF)
142	190	Digoxin Tablets IP 0.25 mg.	Description
			Identification
			pH
			Extractable volume
			Particulate matter
			Bacterial endotoxins
			Assay: (by UV)
			Sterility (by MF)
143	191	Diltiazem Tabs IP 30 mg Film Coated	Description
			Identification (by HPLC)
			Average weight
			Uniformity of weight
			Contents of Packaged Dosage Forms
			Dissolution B (by UV)

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Assay: (by HPLC)
			Identification of colour
144	192	Dobutamine Injection IP/BP 250 mg (Vial) / Dobutamine Injection USP 250 mg/5ml (Amp)	Description
			Identification A (by HPLC)
			Identification B by TLC
			pH
			Appearance of solution
			Light absorption (by UV)
			Related substances (by HPLC)
			Extractable volume
			Particulate matter
			Water
			Assay: (by HPLC)
			Sterility (by MF)
			Identification B by TLC
			Bacterial Endotoxins
			pH
			Particulate matter
			Volume in container
			Assay: (by HPLC)
			Sterility (by MF)
145	193	Dopamine Hydrochloride Injection 40 mg/ml	Description
			Identification A (by IR)
			Identification B
			pH
			5-Hydroxymethylfurfural (by HPLC)
			Related substances (by HPLC)
			Particulate matter
			Extractable volume
			Bacterial endotoxins
			Assay: (by HPLC)
			Sterility (by MF)
146	194	Enalapril Maleate Tablets IP 5mg	Description
			Identification (by HPLC)
			Average weight
			Dissolution (by HPLC)
			Uniformity of content (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
147	195	Enalapril Maleate Tablets IP 2.5mg	Description
			Identification (by HPLC)
			Average weight
			Dissolution (by HPLC)
			Uniformity of content (by HPLC)

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
148	197	Isosorbide dinitrate Tablets IP 5 mg	Description
			Identification A (by TLC)
			Identification B
			Average weight
			Uniformity of content (by HPLC)
			Inorganic nitrate (by TLC)
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms
			Dissolution (by HPLC)
			Assay: (by HPLC)
149	198	Isosorbide mononitrate Tabs IP 20 mg	Description
			Identification A (by TLC)
			Identification B (by HPLC)
			Average weight
			Uniformity of weight
			Inorganic nitrate (by TLC)
			Related substances (by HPLC)
			Dissolution (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
150	199	Lisinopril Tablets IP 5 mg	Description
			Identification (by HPLC)
			Average weight
			Related substances (by HPLC)
			Uniformity of content (by HPLC)
			Dissolution (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
151	200	Losartan Tablets IP 50 mg	Description
			Identification (by HPLC)
			Average weight
			Related substances (by HPLC)
			Uniformity of weight
			Dissolution (by UV)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
152	201	Magnesium Sulphate Injection IP 500mg/ml (50%w/v)	Description
			Identification A
			Identification B
			pH

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Extractable volume
			Particulate matter
			Assay: (by Chemical)
			Sterility (by MF)
153	203	Nifedipine capsules IP 5mg	Description
			Identification (by TLC)
			Average net content
			Contents of Packaged Dosage Forms
			Disintegration time
			Uniformity of content (by UV)
			Assay: (by UV)
154	204	Nifedipine Tablets IP 10 mg. (Sustained Release)	Description
			Identification (by TLC)
			Average weight
			Dissolution A (by UV)
			Dissolution B (by UV)
			Uniformity of content (by UV)
			Contents of Packaged Dosage Forms
			Assay: (by UV)
			Identification of colour
155	205	Nitroglycerin Injection 5 mg/ ml	Description
			Identification by HPLC
			Particulate matter
			Extractable volume
			Assay by HPLC
			Sterility (by MF)
156	207	Propranolol Tablets IP 40 mg	Description
			Identification A (by IR)
			Identification B (by UV)
			Average weight
			Uniformity of weight
			Related substances (by HPLC)
			Dissolution (by UV)
			Contents of Packaged Dosage Forms
			Assay: (by UV)
157	211	Verapamil Tablets IP 40 mg (Film Coated)	Description
			Identification A (by IR)
			Identification B
			Identification C
			Average weight
			Uniformity of weight
			Related substances (by HPLC)
			Disintegration Time

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Contents of Packaged Dosage Forms
			Assay: (by UV)
			Identification of colour
158	213	Acyclovir Cream 5%	Description
			Identification (by UV)
			Identification (by TLC)
			Guanine (by TLC)
			Uniformity of weight (mass)
			Assay: (by UV)
159	217	Glycerin IP	Description
			Identification B
			Identification C
			Identification D: Refractive index
			Appearance of solution
			Acidity or alkalinity
			Heavy metals
			Iron
			Chlorides
			Sulphates
			Aldehydes and reducing substances
			Ester
			Ethylene glycol, diethylene glycol and related substances (by GC)
			sugars
			Sulphated ash
			water
			Net content
			Assay: Glycerin
160	218	Liquid Paraffin IP	Description
			Weight per ml
			Dynamic viscosity
			Acidity or alkalinity
			Light absorption (by UV)
			Readily Carbonisable substances
			Solid paraffins
			Sulphur compounds
			Net content
161	219	Ointment containing : Lidocaine IP 3%, Zinc oxide IP 5% , Hydrocortisone IP 0.25%, Allantoin IP 0.5%	Description
			Identification of Lidocaine
			Identification of Hydrocortisone
			Identification of Zinc
			Identification of Allantoin
			Contents of Packaged Dosage Forms
			Assay:

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Lidocaine
			Hydrocortisone (by UV)
			Zinc oxide
			Allantoin (by UV)
162	220	Miconazole Nitrate Cream IP 2%	Description
			Identification A (by UV)
			Identification B (by GC)
			Contents of Packaged Dosage Forms
			Related substances (by HPLC)
			Assay: (by GC)
163	221	Povidone Iodine ointment 5%	Description
			Identification A
			Identification B
			Minimum fill
			pH
			Assay: (by potentiometer)
164	222	Povidone Iodine solution IP 5%	Description
			Identification A
			Identification B
			Identification C
			Contents of Packaged Dosage Forms
			pH
			Assay: Povidone iodine
165	223	Powder Neomycin Bacitracin with Sulphacetamide (Neomycin 5 mg, Bacitracin 250 units, Sulphacetamide 60 mg)	Description
			Identification of Neomycin sulphate
			Identification of Bacitracin zinc
			Identification of Sulphacetamide
			Contents of Packaged Dosage Forms
			Assay:
			Neomycin (by Microbiological assay)
			Bacitracin (by Microbiological assay)
			Sulphacetamide (by UV)
166	224	Silver Sulphadiazine cream IP 1%	Description
			Identification (by TLC)
			pH of 5%w/v resulting solution
			Contents of Packaged Dosage Forms
			Microbial contamination
			Escherichia coli
			Staphylococcus species
			Pseudomonas aeruginosa
			Salmonella species

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Shigella
			Assay: (by HPLC)
167	232	Diatrizoate Meglumine and Diatrizoate Sodium Inj USP 60% (iodine conc = 292 mg/ml)	Description
			Identification A by TLC
			Identification B
			Bacterial endotoxins
			pH
			Free Atomic Amine
			Iodine and Iodide
			Heavy Metals
			Particulate matter
			Extractable volume
			Assay Diatrizoate Meglumine by Optical Rotation
			Assay of Iodine
			Sterility (by MF)
168	233	Diatrizoate Meglumine and Diatrizoate Sodium Inj USP 76%w/v (iodine conc =370 mg/ml)	Description
			Identification A by TLC
			Identification B
			Bacterial endotoxins
			pH
			Free Atomic Amine
			Iodine and Iodide
			Heavy Metals
			Particulate matter
			Extractable volume
			Assay Diatrizoate Meglumine by Optical Rotation
			Assay of Iodine
			Sterility (by MF)
169	241	Tropicamide Eye Drops IP 1%	Description
			Identification A (by IR)
			Identification B (by UV)
			pH
			Contents of Packaged Dosage Forms
			Related substances (by TLC)
			Assay: (by UV)
			Sterility (by MF)
170	245	Formaldehyde Solution (34.5% - 38%)	Description
			Weight per ml
			Contents of Packaged Dosage Forms
			Assay: (by titration method)
171	246	Gentian Violet Topical Solution USP 1%	Description
			Identification A
			Identification B

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Solution of residue in alcohol
			Net content
			Alcohol content
			Assay: Gentian violet (by titration)
172	247	Gluteraldehyde solution 2 %	Description
			Identification
			pH
			Mercury
			Assay:
173	248	Hydrogen Peroxide Solution IP 6% (20 Vol)	Description
			Identification A
			Identification B
			Acidity
			Organic stabilizers
			Non-volatile matter
			Volume in container
			Assay: Hydrogen peroxide
174	249	Lysol (Cresol with Soap Solution) IP Cresol 50% + Soap 50%	Description
			Appearance of solution
			Alkalinity
			Hydrocarbons and volatile bases
			Hydrocarbons
			Volatile bases
			Volume in container
			Sulphur compounds
			Assay: Cresol
175	250	Povidone Iodine Scrub Solution / cleansing solution 7.5% w/v Povidone Iodine (suitable for hand wash)	Description
			Identification A
			Identification B
			Net content
			pH
			Assay: Povidone iodine
176	252	Surgical Spirit IP/BP	Description
			Identification A
			Identification B
			Weight/ml
			Net content
			Assay:
			For Methyl Salicylate (by UV)
			For Diethyl Phthalate (by UV)
177	253	Acetazolamide Tablets IP 250mg	Description
			Identification A (by IR)
			Identification B
			Identification C
			Average weight

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Uniformity of weight
			Disintegration time
			Related substances (by TLC)
			Contents of Packaged Dosage Forms
			Assay: Acetazolamide
178	254	Frusemide Tablets IP 40 mg.	Description
			Identification A (by UV)
			Identification B
			Average weight
			Uniformity of weight
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms
			Dissolution (by UV)
			Assay: (by UV)
179	255	Furosemide Injection IP 10mg/ml (IM & IV use)	Description
			Identification A (by UV)
			Identification B
			pH
			Related substances (by HPLC)
			Extractable volume
			Particulate matter
			Bacterial endotoxins
			Assay: (by UV)
			Sterility (by MF)
180	256	Hydrochlorthiazide Tablets IP 12.5 mg	Description
			Identification (by TLC)
			Average weight
			Related substances (by HPLC)
			Dissolution (by UV)
			Uniformity of weight
			Contents of Packaged Dosage Forms
			Assay: (by UV)
181	258	Spironolactone Tablets IP 25 mg	Description
			Identification A (by IR)
			Identification B (by TLC)
			Identification C
			Average weight
			Uniformity of weight
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms
			Dissolution (by UV)
			Assay: (by UV)
182	259	Torsamide Tablets 10 mg	Description

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Identification (by HPLC)
			Average weight
			Related substances (by HPLC)
			Uniformity of content (by HPLC)
			Contents of Packaged Dosage Forms
			Dissolution (by HPLC)
			Assay: (by HPLC)
			Identification of colour
183	262	Bisacodyl Tablets IP 5 mg	Description
			Identification A
			Identification B
			Identification C
			Average weight
			Related substances (by HPLC)
			Uniformity of content (by HPLC)
			Contents of Packaged Dosage Forms
			Disintegration time
			Assay: (by HPLC)
			Identification of colour
184	263	Dicyclomine Tablets IP 10 mg	Description
			Identification A (by IR)
			Identification B
			Identification C
			Average weight
			Related substances (by TLC)
			Disintegration time
			Uniformity of content
			Contents of Packaged Dosage Forms
			Assay: Dicyclomine hydrochloride
185	264	Dicyclomine Injection IP 10 mg /ml	Description
			Identification A (by IR)
			Identification B (by HPLC)
			Extractable volume
			Particulate matter
			Bacterial endotoxins
			Assay: (by HPLC)
			Sterility (by MF)
186	265	Dicyclomine Hydrochloride Oral Solution IP 10mg /5ml	Description
			Identification A (by IR)
			Identification B
			Weight per ml
			Contents of Packaged Dosage Forms
			Assay: Dicyclomine Hydrochloride

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Identification of colour
			Microbiological Examination
			Total Aerobic count
			Total Fungal count
			E. coli
187	266	Domperidone Suspension IP 5 mg/5ml	Description
			Identification (by HPLC)
			Contents of Packaged Dosage Forms
			Identification of colour by TLC
			Assay: (by HPLC)
			Microbiological Examination
			Total Aerobic count
			Total Fungal count
			E. coli
188	267	Domperidone Tablets IP 10 mg	Description
			Identification A (by TLC)
			Identification B (by HPLC)
			Average weight
			Uniformity of content (by HPLC)
			Dissolution (by UV)
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
189	268	Hyoscine Butylbromide Injection IP 20 mg/ml	Description
			Identification A (by IR)
			Identification B (by UV)
			Identification C
			pH
			Extractable volume
			Particulate matter
			Hyoscine (by HPLC)
			Related substances (by TLC)
			Assay: (by HPLC)
			Sterility (by MF)
190	269	Loperamide Tablets IP 2 mg	Description
			Identification A (by UV)
			Identification B (by HPLC)
			Average weight
			Dissolution (by HPLC)
			Uniformity of content (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
191	270	Metoclopramide Injection IP 10mg/2ml	Description

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Identification A (by UV)
			Identification B
			Identification C
			pH
			Related substances (by HPLC)
			Bacterial endotoxins
			Particulate matter
			Extractable volume
			Assay: (by UV)
			Sterility (by MF)
192	271	Metoclopramide Tablets IP 10 mg	Description
			Identification A (by UV)
			Identification B
			Average weight
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms
			Disintegration time
			Uniformity of content (by HPLC)
			Assay: (by HPLC)
193	272	Omeprazole Capsules IP 20 mg	Description
			Identification A (by UV)
			Identification B (by HPLC)
			Average net content
			Uniformity of content (by HPLC)
			Dissolution A (by HPLC)
			Dissolution B (by HPLC)
			Loss on drying
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
194	273	Ondansetron Injection IP 2mg/ml	Description
			Identification (by HPLC)
			pH
			Bacterial endotoxins
			Extractable volume
			Particulate matter
			Related substances (by HPLC)
			Assay: (by HPLC)
			Sterility (by MF)
195	274	ORS Powder IP	Description
			Identification A
			Identification B
			Identification C
			Identification D

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Contents of Packaged Dosage Forms
			Seal test
			Assay:
			Total Sodium
			Potassium
			Citrate
			Total chloride
			Dextrose (Anhydrous)
196	275	Pantoprazole Injection 40 mg	Description
			Identification (by HPLC)
			Average net content
			Uniformity of weight
			Clarity of solution test a and b
			Particulate matter
			Bacterial endotoxins
			Assay: (by HPLC)
			Sterility (by MF)
197	276	Ranitidine HCL Injection IP 50mg/2ml	Description
			Identification A (by IR)
			Identification B (by HPLC)
			pH
			Related substances (by HPLC)
			Extractable volume
			Particulate matter
			Assay: (by HPLC)
			Sterility (by MF)
198	277	Ranitidine Tablets IP 150mg Film coated	Description
			Identification A (by IR)
			Identification B (by HPLC)
			Average weight
			Uniformity of weight
			Disintegration Time
			Related substances (by HPLC)
			Uniformity of container contents: Contents of Packaged Dosage Forms
			Assay: (by HPLC)
			Identification of colour
199	278	Sodium Phosphates Enema BP Each 100ml contains Sodium Dihydrogen phosphate Dihydrate 10%, Disodium Hydrogen Phosphate Dodecahydrate 8%	Description
			Identification A
			Identification B
			Clarity and colour of solution
			Acidity: pH
			Net content
			Assay:

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Sodium hydrogen phosphate
			Disodium hydrogen phosphate
200	280	Carbimazole Tabs IP 5 mg (Film Coated)	Description
			Identification A (by IR)
			Identification B
			Average weight
			Uniformity of content (by UV)
			Disintegration time
			Thiamazole and other related substances (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by UV)
201	282	Clomifene Tablets IP 25 mg	Description
			Identification A (by UV)
			Identification B
			Average weight
			Uniformity of content (by UV)
			Z-isomer (by HPLC)
			Contents of Packaged Dosage Forms
			Dissolution (by UV)
			Assay: (by UV)
202	283	Clomiphene Tablets IP 50 mg	Description
			Identification A (by UV)
			Identification B
			Average weight
			Uniformity of content (by UV)
			Z-isomer (by HPLC)
			Contents of Packaged Dosage Forms
			Dissolution (by UV)
			Assay: (by UV)
203	284	Conjugated Estrogen Tabs USP 0.625 mg.	Description
			Identification A by HPLC
			Identification B by HPLC
			Average Weight
			Uniformity of dosage units by HPLC
			Contents of Packaged Dosage Forms
			Dissolution by HPLC
			After 2 Hour
			After 5 Hour
			After 8 Hour
			Assay by HPLC
204	285	Dinoprostone Cream/Gel 0.5 mg Dinoprostone in syringe	Description
			Identification by HPLC

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Contents of Packaged Dosage Forms: Net Content
			Assay by HPLC
205	286	Ethinylestradiol Tabs IP 50 mcg	Description
			Identification A (by TLC)
			Identification B
			Average weight
			Uniformity of content (by HPLC)
			Disintegration Time
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
206	287	Glibenclamide Tablets IP 5 mg	Description
			Identification A (by HPLC)
			Identification B (by TLC)
			Average weight
			Related substances (by TLC)
			Uniformity of content (by HPLC)
			Disintegration Time
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
207	288	Gliclazide Tablets IP 40 mg	Description
			Identification (by IR)
			Average weight
			Dissolution (by UV)
			Uniformity of weight
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
208	289	Glimepiride Tablets IP 2 mg	Description
			Identification (by HPLC)
			Average weight
			Uniformity of content (by HPLC)
			Dissolution (by HPLC)
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
209	290	Glimepiride Tablets IP 1 mg	Description
			Identification (by HPLC)
			Average weight
			Uniformity of content (by HPLC)
			Dissolution (by HPLC)
			Related substances (by HPLC)

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
210	291	Glipizide Tablets IP 5mg	Description
			Identification A (by IR)
			Identification B (by UV)
			Average weight
			Disintegration Time
			Related substances (TLC)
			Uniformity of content (by UV)
			Contents of Packaged Dosage Forms
			Assay: (by UV)
211	293	Hydroxyprogesterone Injection IP 250mg/ ml	Description
			Identification A (by TLC)
			Identification B: Melting Point
			Extractable volume
			Particulate matter
			Assay: (by UV)
			Sterility (by MF)
212	295	Metformin Tablets IP 500 mg. (Film Coated)	Description
			Identification A (by IR)
			Identification B
			Identification C
			Average weight
			Uniformity of weight
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms
			Dissolution (by UV)
			Assay: (by UV)
213	296	Norethisterone Tablets IP 5 mg	Description
			Identification (by TLC)
			Average weight
			Uniformity of content (by HPLC)
			Disintegration time
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
214	297	Pioglitazone Tablets IP 15 mg	Description
			Identification A (by IR)
			Identification B (by HPLC)
			Average weight
			Uniformity of content (by HPLC)
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Dissolution (by UV)
			Assay (by HPLC)
215	301	Thyroxine Sodium Tablets IP 100mcg	Description
			Identification A
			Identification B (by HPLC)
			Average weight
			Uniformity of content (by HPLC)
			Contents of Packaged Dosage Forms
			Disintegration time
			Assay (by HPLC)
216	311	Atracurium Injection 10 mg/ml	Description
			Identification (by HPLC)
			pH
			Related Substance by HPLC
			Bacterial endotoxins
			Extractable volume
			Particulate matter
			Assay: (by HPLC)
			Sterility (by MF)
217	312	Glycopyrrolate Injection USP 0.2 mg/ml	Description
			Identification (by TLC)
			pH
			Bacterial endotoxins
			Extractable volume
			Particulate matter
			Assay: (by HPLC)
			Sterility (by MF)
218	313	Midazolam Injection IP 1 mg/ml	Description
			Identification (by IR)
			pH
			Related substances (by HPLC)
			Extractable volume
			Particulate matter
			Assay: (by HPLC)
			Sterility (by MF)
219	314	Neostigmine Injection IP 0.5 mg/ml	Description
			Identification A (by UV)
			Identification B (by TLC)
			Identification C
			pH
			3-Hydroxy trimethylanilinium methyl sulphate (by HPLC)
			Extractable volume
			Particulate matter
			Assay: (by UV)

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Sterility (by MF)
220	317	Succinylcholine Injection IP 50 mg/ml (IV use)	Description
			Identification
			pH
			hydrolysis product (by titration)
			Particulate matter
			Extractable volume
			Bacterial endotoxines
			Assay: (by titration)
			Sterility (by MF)
221	318	Valethamate Bromide Injection 8mg /ml	Description
			Identification of Valethamate Bromide
			pH
			Particulate matter
			Extractable volume
			Bacterial endotoxines
			Assay: Valethamate Bromide
			Sterility (by MF)
222	319	Atropine Eye Ointment IP 1%	Description
			Identification (by TLC)
			Particle size
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
			Sterility (by MF)
223	320	Atropine Sulphate Ophthalmic Solution USP 1%	Description
			Identification A (by IR)
			Identification B
			pH
			Net content
			Assay: (by GLC)
			Sterility (by MF)
224	321	Chloramphenicol Eye Drops IP 0.5%	Description
			Identification A (by TLC)
			Identification B
			pH
			Contents of Packaged Dosage Forms
			Assay: by HPLC)
			Sterility (by MF)
225	322	Ciprofloxacin Eye Drops 0.3% w/v	Description
			Identification A (by HPLC)
			Identification B
			pH
			Contents of Packaged Dosage Forms

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Assay: by HPLC)
			Sterility (by MF)
226	323	Ciprofloxacin Ophthalmic Ointment USP 0.3%	Description
			Identification A (by HPLC)
			Minimum fill
			Metal particle in ophthalmic ointment
			Assay: (by HPLC)
			Sterility (by MF)
227	324	Hydroxypropylmethyl cellulose Solution 20 mg/ ml	Description
			Identification A
			Identification B
			pH
			Net content
			Assay: (by UV)
			Sterility (by MF)
228	330	Tobramycin and Dexamethasone Ophthalmic Suspension USP 0.3%+0.1%	Description
			Identification A (by TLC)
			Identification B (by HPLC)
			pH
			Net content
			Assay:
			Tobramycin (by HPLC)
			Dexamethasone (by HPLC)
			Sterility (by MF)
229	331	Tobramycin Eye Drops 0.3%	Description
			Identification A (by TLC)
			Identification B (by HPLC)
			pH
			Net content
			Assay: (by HPLC)
			Sterility (by MF)
230	332	Tobramycin Ophthalmic Ointment USP 0.3%	Description
			Identification A (by TLC)
			Water
			Minimum fill
			Metal particles in ophthalmic ointment
			Assay: (by HPLC)
			Sterility (by MF)
231	333	Isoxsuprine Injection IP 5 mg/ml	Description
			Identification A (by IR)
			Identification B (by UV)
			pH
			Extractable volume
			Particulate matter

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Bacterial endotoxins
			Assay: (by UV)
			Sterility (by MF)
232	334	Isoxsuprine Tablets IP 20 mg	Description
			Identification A (by IR)
			Identification B (by UV)
			Average weight
			Uniformity of weight
			Disintegration Time
			Contents of Packaged Dosage Forms
			Assay: (by UV)
233	335	Methylethergometrine Injection IP 0.2 mg/ml	Description
			Identification A (by TLC)
			Identification B
			Identification C
			pH
			Related substances (by TLC)
			Particulate matter
			Extractable volume
			Assay: (by UV)
			Sterility (by MF)
234	336	Methylethergometrine Tablet IP 0.125 mg	Description
			Identification A (by TLC)
			Identification B
			Identification C
			Average weight
			Related substances (by TLC)
			Uniformity of content (by UV)
			Disintegration time
			Contents of Packaged Dosage Forms
			Assay: (by UV)
235	337	Misoprostol Tablets IP 200 mcg	Description
			Identification (by HPLC)
			Average weight
			Uniformity of content (by HPLC)
			Disintegration Time
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
236	338	Oxytocin Injection IP 5 IU/ml	Description
			Identification by HPLC
			pH
			Bacterial Endotoxine
			Particulate matter

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Extractable volume
			Assay: (by HPLC)
			Sterility (by MF)
237	339	Alprazolam Tablets IP 0.25 mg	Description
			Identification (by HPLC)
			Average weight
			Uniformity of content (by HPLC)
			Dissolution (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
238	340	Alprazolam Tablets IP 0.5mg	Description
			Identification (by HPLC)
			Average weight
			Uniformity of content (by HPLC)
			Dissolution (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
239	341	Amitriptyline Tablets IP 25 mg Film Coated	Description
			Identification A (by UV)
			Identification B
			Identification C
			Average weight
			Uniformity of Weight
			Related substances (by TLC)
			Dissolution (by UV)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
240	342	Chlordiazepoxide Tablets IP 10mg	Description
			Identification A (by UV)
			Identification B
			Average weight
			Related substances (by TLC)
			Uniformity of content (by UV)
			Disintegration Time
			Contents of Packaged Dosage Forms
			Assay: (by UV)
			Identification of colour
241	343	Chlorpromazine Tablets IP 100 mg (Coated Tablet)	Description
			Identification A (by IR)
			Identification B (by UV)
			Identification C
			Average weight
			Related substances (by TLC)

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Uniformity of Weight
			Disintegration Time
			Contents of Packaged Dosage Forms
			Assay: (by UV)
			Identification of colour
242	344	Chlorpromazine Tablets IP 25 mg (Sugar-Coated)	Description
			Identification A (by IR)
			Identification B (by UV)
			Identification C
			Average weight
			Related substances (by TLC)
			Uniformity of Weight
			Disintegration Time
			Contents of Packaged Dosage Forms
			Assay: (by UV)
			Identification of colour
243	345	Chlorpromazine Tabs IP 50 mg. (Coated Tablets)	Description
			Identification A (by IR)
			Identification B (by UV)
			Identification C
			Average weight
			Related substances (by TLC)
			Uniformity of Weight
			Disintegration Time
			Contents of Packaged Dosage Forms
			Assay: (by UV)
			Identification of colour
244	349	Diazepam Injection IP 10mg/2ml (1M/IV use)	Description
			Identification A (by TLC)
			Identification B (by UV)
			pH
			Bacterial endotoxins
			Extractable volume
			Particulate matter
			Assay: (by UV)
			Sterility (by MF)
245	350	Diazepam Tablets IP 5 mg	Description
			Identification A (by TLC)
			Identification B (by UV)
			Average weight
			Related substances & decomposition products (by TLC)
			Contents of Packaged Dosage Forms

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Uniformity of content (by UV)
			Dissolution (by UV)
			Assay: (by UV)
246	351	Escitalopram Tablets IP 10 mg	Description
			Identification (by HPLC)
			Average weight
			Uniformity of content (by HPLC)
			Dissolution (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
			Identification of colour
247	352	Fluoxetine Capsules IP 20 mg	Description
			Identification A (by IR)
			Identification B (by HPLC)
			Average net content
			Uniformity of weight
			Contents of Packaged Dosage Forms
			Dissolution (by HPLC)
			Related Substances (by HPLC)
			Assay: (by HPLC)
248	353	Haloperidol Injection IP 5 mg/ml	Description
			Identification A (by IR)
			Identification B (by UV)
			pH
			Related substances (by TLC)
			Particulate matter
			Extractable volume
			Bacterial endotoxins
			Assay: (by UV)
			Sterility (by MF)
249	354	Haloperidol Tablets IP 1.5 mg	Description
			Identification A (by IR)
			Identification B (by TLC)
			Related substances (by TLC)
			Average weight
			Disintegration time
			Uniformity of content (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
250	355	Haloperidol Tablets IP 5 mg	Description
			Identification A (by IR)
			Identification B (by TLC)
			Related substances (by TLC)

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Average weight
			Disintegration time
			Uniformity of content (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
251	356	Imipramine Tablets IP 25 mg (Coated Tablets)	Description
			Identification A
			Identification B
			Identification C
			Average weight
			Uniformity of weight
			Related substances (by TLC)
			Contents of Packaged Dosage Forms
			Disintegration time
			Assay: (by UV)
			Identification of colour
252	357	Imipramine Tablets IP 75 mg (Coated)	Description
			Identification A
			Identification B
			Identification C
			Average weight
			Uniformity of weight
			Related substances (by TLC)
			Contents of Packaged Dosage Forms
			Disintegration time
			Assay: (by UV)
			Identification of colour
253	358	Lithium Carbonate Tablets IP 300 mg	Description
			Identification
			Average weight
			Uniformity of weight
			Dissolution (by Flam photometer)
			Contents of Packaged Dosage Forms
			Assay: Chemical
254	359	Lorazepam Injection 2 mg/ml	Description
			Identification A (by TLC)
			Identification B (by HPLC)
			Extractable volume
			Particulate matter
			Related substances (by TLC)
			Assay: (by HPLC)
			Sterility (by MF)
255	360	Olanzapine Tablets IP 5 mg	Description

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Identification (by HPLC)
			Average weight
			Uniformity of content (by HPLC)
			Dissolution (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
256	361	Risperidone Tablets 2 mg	Description
			Identification A (by IR)
			Identification A (by HPLC)
			Average weight
			Uniformity of dosage units (content Uniformity) (by HPLC)
			Dissolution (by HPLC)
			Related substances (by HPLC)
			Assay: (by HPLC)
			Identification of colour
257	362	Risperidone Tablets 1 mg	Description
			Identification A (by IR)
			Identification A (by HPLC)
			Average weight
			Uniformity of dosage units (content Uniformity) (by HPLC)
			Dissolution (by HPLC)
			Related substances (by HPLC)
			Assay: (by HPLC)
			Identification of colour
258	363	Sertraline Tablets 50 mg	Description
			Identification (by IR)
			Average weight
			Uniformity of Weight
			Dissolution (by HPLC)
			Related substances (by HPLC)
			Enantiomeric Purity by HPLC
			Assay: (by HPLC)
			Contents of Packaged Dosage Forms
259	364	Trifluoperazine Tablets IP 5 mg (Coated)	Description
			Identification A (by IR)
			Identification B
			Average weight
			Uniformity of content (by UV)
			Disintegration Time
			Contents of Packaged Dosage Forms
			Assay: (by UV)
			Identification of colour

Sr	Code No.	Name of item with specification	Test proposed to be carried out
260	365	Aminophylline Injection IP 25 mg/ml	Description
			Identification A (by IR)
			Identification B
			Identification C
			Identification D: Melting Point
			pH
			Bacterial endotoxins
			Extractable volume
			Particulate matter
			Assay:
			Theophylline (by HPLC)
			Ethylenediamine
			Sterility (by MF)
261	366	Beclomethasone Inhalation IP 200 mcg/ dose	Description
			Identification A (by IR)
			Identification B (By HPLC)
			Related substance by TLC
			Leak Test
			Number of Deliveries of Content
			Uniformity of Deliver Dose
			Assay by HPLC
262	367	Budesonide Nebulizer Suspension 0.25mg/ ml	Description
			Identification A (by IR)
			Identification B (By HPLC)
			PH
			Related substance by HPLC
			Epimer A (By HPLC)
			Contents of Packaged Dosage Forms
			Microbiological Examination
			Total Arobic Count
			Total Fungal count
263	368	Cough Syrup Each 5ml	Description
			Identification of Chlorpheniramine maleate
			Identification of Ammonium salt
			Identification of Sodium citrate
			Identification of Chloride
			Identification of Menthol
			pH
			Contents of Packaged Dosage Forms
			Identification of colour
			Assay:
			Chlorpheniramine maleate (by UV)
			Ammonium chloride

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Sodium citrate (by FP)
			Menthol (by UV)
			Microbiological Examination
			Total Aerobic count
			Total Fungal count
			E. coli
264	369	Ipratropium Bromide Nebulizer Solution 250 mcg/	Description
			Identification A (by IR)
			Identification B
			PH
			Related substance by HPLC
			Osmolality
			Contents of Packaged Dosage Forms
			Microbiological Examination
			Total Arohic Count
			Total Fungal count
			Assay by HPLC
265	370	Salbutamol Tablets IP 4 mg	Description
			Identification A (by TLC)
			Identification B
			Identification C
			Average weight
			Related substances (by TLC)
			Uniformity of content (by HPLC)
			Disintegration time
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
266	371	Salbutamol Inhalation 100 mcg /dose	Description
			Identification A (by IR)
			Identification B (By TLC)
			Related substance by TLC
			Leak Test
			Number of Deliveries of Content
			Uniformity of Deliver Dose
			Assay by HPLC
267	372	Salbutamol Nebuliser solution BP 5 mg/ml	Description
			Identification A (by UV)
			Identification B (by HPLC)
			Identification C
			PH
			Related substance by HPLC
			Salbutamol Ketone by HPLC
			Contents of Packaged Dosage Forms

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Microbiological Examination
			Total Arobic Count
			Total Fungal count
			Assay (by UV)
268	373	Salbutamol Tablets IP 2 mg	Description
			Identification A (by TLC)
			Identification B
			Identification C
			Average weight
			Related substances (by TLC)
			Uniformity of content (by HPLC)
			Disintegration time
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
269	374	Theophylline and Etofylline Injection (Anhydrous Theophylline 50.6mg + Etofylline 169.4 mg)	Description
			Identification of Etofylline (by HPLC)
			Identification of Theophylline (by HPLC)
			pH
			Particulate matter
			Extractable volume
			Assay:
			Etofylline (by HPLC)
			Theophylline (by HPLC)
			Sterility (by MF)
270	375	Theophylline and Etofylline Tablets (Theophylline IP 23mg + Etofylline IP 77 mg)	Description
			Identification of Etofylline (by HPLC)
			Identification of Theophylline (by HPLC)
			Average weight
			Uniformity of weight
			Disintegration time
			Contents of Packaged Dosage Forms
			Assay:
			Etofylline (by HPLC)
			Theophylline (by HPLC)
271	376	Theophylline Tablets 400 mg Sustained release/controlled release (Theophylline prolonged Release Tablets IP)	Description
			Identification A (by HPLC)
			Identification B
			Average weight
			Uniformity of weight
			Related substances (by TLC)
			Dissolution: (by UV)

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			1 st time point
			2 nd time point
			3 rd time point
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
272	377	Compound Sodium Lactate inj. IP	Description
			Identification A
			Identification B
			Identification C
			pH
			Particulate contamination (by particle counter)
			Extractable volume
			Bacterial endotoxins
			Assay:
			For sodium (by flam photometer)
			For potassium (by flam photometer)
			For total chloride
			For calcium chloride
			For lactate
			Sterility (by MF)
273	378	Dextrose Injection IP 25 % w/v	Description
			Identification A
			Identification B (by optical rotation)
			5-Hydroxymethylfurfural and related substances (by UV)
			pH
			Heavy metals
			Particulate contamination (by particle counter)
			Extractable volume
			Bacterial endotoxins
			Assay: (by optical rotation)
			Sterility (by MF)
274	379	Dextrose injection IP 10%	Description
			Identification A
			Identification B (by optical rotation)
			5-Hydroxymethylfurfural and related substances (by UV)
			pH
			Heavy metals
			Particulate contamination (by particle counter)
			Extractable volume
			Bacterial endotoxins
			Assay: (by optical rotation)

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Sterility (by MF)
275	380	Dextrose injection IP 5%	Description
			Identification A
			Identification B (by optical rotation)
			pH
			5-Hydroxymethylfurfural and related substances (by UV)
			Heavy metals
			Particulate contamination (by particle counter)
			Extractable volume
			Bacterial endotoxins
			Assay: (by optical rotation)
			Sterility (by MF)
276	381	Multiple Electrolytes & Dextrose Injection Type I IP (Electrolyte 'P' Injection)	Description
			Identification A
			Identification B
			For acetate
			For chloride
			For phosphates
			For sodium salts
			For potassium salts
			For magnesium salts
			pH
			5-Hydroxymethylfurfural and related substances (by UV)
			Particulate contamination (by particle counter)
			Extractable volume
			Bacterial endotoxins
			Assay:
			For sodium (by FP)
			For total potassium (by FP)
			For magnesium
			For acetate (by HPLC)
			For phosphates (by UV)
			For total chloride
			For dextrose (by optical rotation)
			Sterility (by MF)
277	382	Multiple Electrolytes & Dextrose Injection Type III IP Electrolyte "M" Injection (I.V.)	Description
			Identification A
			Identification B
			For acetate
			For chloride
			For phosphates
			For sodium salts
			For potassium salts

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			pH
			5-Hydroxymethylfurfural and related substances (by UV)
			Particulate contamination (by particle counter)
			Extractable volume
			Bacterial endotoxins
			Assay:
			For total sodium (by FP)
			For potassium (by FP)
			For acetate (by HPLC)
			For phosphates (by UV)
			For total chloride
			For dextrose (by optical rotation)
			Sterility (by MF)
278	383	Potassium Chloride Injection 0.15 gm/ml	Description
			Identification
			Acidity or alkalinity (pH)
			Extractable volume
			Bacterial endotoxins
			Assay: Potassium Chloride
			Sterility (by MF)
279	384	Potassium chloride Oral Solution U.S.P 500mg/	Description
			Identification A
			Identification B
			Weight per ml
			Contents of Packaged Dosage Forms
			Assay by Aas
			Microbial Examination
280	385	Sodium Chloride and Dextrose Inj. I.P (0.9% +5%)	Description
			Identification A
			Identification B
			Heavy metals
			pH
			5-Hydroxymethylfurfural and related substances (by UV)
			Particulate contamination (by particle counter)
			Extractable volume
			Bacterial endotoxins
			Assay:
			For sodium chloride
			For dextrose (by optical rotation)
			Sterility (by MF)
281	386	Sodium Chloride Injection IP	Description
			Identification

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Heavy metals
			pH
			Particulate contamination (by particle counter)
			Extractable volume
			Bacterial endotoxins
			Assay: Sodium chloride
			Sterility (by MF)
282	387	Ascorbic Acid Tablets IP 500 mg	Description
			Identification A
			Identification B
			Identification C
			Average weight
			Uniformity of weight
			Contents of Packaged Dosage Forms
			Assay:
			Ascorbic Acid
			Identification of colour
283	388	Calcium Gluconate Injection IP 10% (IV use)	Description
			Identification A (by TLC)
			Identification B
			Identification C
			pH
			Extractable volume
			Particulate matter
			Bacterial endotoxins
			Assay: Calcium gluconate
			Sterility (by MF)
284	390	Ferrous Sulphate and Folic Acid Tab IP	Description
			Identification of Folic acid (by HPLC)
			Identification of dried ferrous sulphate
			Average weight
			Uniformity of weight
			Ferric iron
			Uniformity of content: Folic acid (by HPLC)
			Disintegration Time
			Contents of Packaged Dosage Forms
			Assay:
			Folic acid (by HPLC)
			Dried ferrous sulphate calculated as elemental iron
			Identification of colour
285	391	Ferrous Sulphate with Folic Acid Tab.	Description

Sr	Code No.	Name of item with specification	Test proposed to be carried out
		(Paediatric) IP	Identification of Folic acid (by HPLC) Identification of dried ferrous sulphate Average weight Uniformity of weight Ferric iron Uniformity of content: Folic acid (by HPLC) Disintegration Time Contents of Packaged Dosage Forms Assay: Folic acid (by HPLC) Dried ferrous sulphate calculated as elemental iron Identification of colour
286	392	Folic Acid Tablets IP 5 mg	Description Identification A (by TLC) Identification B Average weight Disintegration time Uniformity of content (by HPLC) Hydrolysis products (by HPLC) Contents of Packaged Dosage Forms Assay: (by HPLC)
287	393	Multivitamin Drops	Description pH Contents of Packaged Dosage Forms Assay: Vitamin A (by UV) Vitamin D3 (by HPLC) Thiamine hydrochloride (by UV) Riboflavin sodium phosphate (by UV) Pyridoxine hydrochloride (by UV) Cyanocobalamin (by Microbiological assay) D-Panthenol (by UV) Niacinamide (by UV) L-Lysine hydrochloride (by UV) Identification of colour Microbial Examination Total aerobic count Total fungal count E. coli

Sr	Code No.	Name of item with specification	Test proposed to be carried out
288	394	Multivitamin Tablets NFI	Description
			Average weight
			Uniformity of weight
			Contents of Packaged Dosage Forms
			Disintegration Time
			Assay:
			Vitamin A (by UV)
			Vitamin B1 (by UV)
			Vitamin B6 (by UV)
			Vitamin C
			Calcium Pantothenate (by HPLC)
			Vitamin D3 (by HPLC)
			Vitamin B2 (by UV)
			Niacinamide 25 mg (by UV)
Folic acid 0.2 mg (by UV)			
Identification of colour			
289	395	Vitamin B Complex Injection NFI	Description
			pH
			Particulate matter
			Extractable volume
			Assay:
			Thiamine hydrochloride (by UV)
			Riboflavine sodium phosphate calculated as Riboflavine (by UV)
			Pyridoxine hydrochloride (by UV)
			Nicotinamide (by UV)
			D-Panthenol (by UV)
Sterility (by MF)			
290	397	Vitamin – B complex tablet NFI	Description
			Average weight
			Uniformity of weight
			Contents of Packaged Dosage Forms
			Disintegration Time
			Assay:
			Vitamin B1 (by UV)
			Vitamin B2 (by UV)
			Vitamin B6 (by UV)
			Niacinamide (by UV)
			Calcium pantothenate (by HPLC)
291	398	Black Disinfectant Fluid (Phenyl) (As per Schedule "O" Grade – III)	Description
			Stability after dilution
			Germicidal Value (Rideal Walker Coefficient)
			Weight per ml
292	399	Concentrated Solution for Haemodialysis B.P	Description

Sr	Code No.	Name of item with specification	Test proposed to be carried out
		Acetate concentrate in 10 Litre Cans.	Sodium as Na
			Potassium as K
			Calcium as Ca
			Magnesium as Mg
			Total chloride as Cl
			Acetate as CH ₃ COO
			Net content
			Bacterial Endotoxins
			Microbial contamination
293	401	Peritoneal Dialysis Solution IP	Description
			Identification A
			Identification B
			Identification C
			Identification D
			Identification E
			Appearance of solution
			PH
			Alluminium
			5-Hydroxymethylfurfural and related substances (by UV)
			Particulate contamination (by particle counter)
			Extractable volume
			Bacterial endotoxins
			Assay:
			For sodium by AAS
			For total potassium (by FP)
			For magnesium
			For Calcium (by FP)
			For Sodium bicarbonate (by Potentiometry)
			For total chloride
			For dextrose (by optical rotation)
			For Lactate & bicarbonate (by HPLC)
			Sterility (by MF)
294	402	Sodium Bicarbonate Injection IP 7.5% w/v	Description
			Identification A
			Identification B
			PH
			Bacterial endotoxins
			Extractable volume
			Particulate matter
			Assay:
			Sterility (by MF)
295	404	Water for injection I.P.	Description
			Appearance of solution

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Acidity or alkalinity
			Ammonium
			Calcium and magnesium
			Heavy metals
			Chlorides
			Nitrates
			Sulphates
			Oxidisable substances
			Residue on evaporation
			Particulate contamination
			Bacterial endotoxins
			Extractable volume
			Sterility (by MF)
296	405	Polygeline 3.5% Solution with electrolytes for I.V. Infusion	Description
			Microbial Test
			Particulate Matter
			Sterility
			Nominal Value
			Volume
			Ph
			Relative viscosity
			Sodium (by AAS)
			Potassium (By AAS)
			Calcium (by AAS)
			Titration Curve
297	409	Vitamin A Paediatric oral solution IP Vitamin A Concentrate Oil IP Each ml contains vitamin A 100000 IU	Description
			Identification B
			Identification C (by HPLC)
			Identification D (by UV)
			Weight per ml
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
			Microbial Examination
			Total aerobic count
			Total fungal count
			E. coli
298	410	Labetalol Tablets IP 100mg	Description
			Identification A (by IR)
			Identification B (by UV)
			Identification C
			Average weight
			Uniformity of weight
			Diastereoisomer ratio (by GC)
			Related substances (by TLC)

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Contents of Packaged Dosage Forms
			Disintegration time
			Assay: (by UV)
			Identification of colour
299	411	Labetalol Hydrochloride Injection IP 20mg/4ml	Description
			Identification A (by IR)
			Identification B (by UV)
			pH
			Extractable volume
			Particulate matter
			Free carboxylic acid and other related substances (by TLC)
			Assay: (by UV)
			Sterility (by MF)
300	412	Ampicillin Capsules IP 500 mg	Description
			Identification A (by IR)
			Identification B (by HPLC)
			Average net content
			Uniformity of weight
			Contents of Packaged Dosage Forms
			Dissolution (by UV)
			Assay: (by HPLC)
301	413	Nitrofurantoin Tablets IP 100mg	Description
			Identification (by UV)
			Average weight
			Uniformity of weight
			Disintegration Time
			Contents of Packaged Dosage Forms
			Related substances (by TLC)
			Assay: (by UV)
302	414	Hyoscine Butylbromide Tablets IP 10mg	Description
			Identification A (by IR)
			Identification C
			Average weight
			Hyoscine (by HPLC)
			Related substances (by TLC)
			Uniformity of content (by HPLC)
			Disintegration Time
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
			Identification of colour
303	415	Drotaverine Tablets IP 40 mg	Description
			Identification (by HPLC)

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Average weight
			Uniformity of weight
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
304	416	Hydroxyethyl Starch (130/0.4) 6% w/v with Sodium Chloride 0.9% w/v Intravenous Infusion	Description
			Identification by Chemical
			Identification by HES by HPLC Reverse Phase Chromatography Method
			Extractable volume
			PH
			Particulate Matter by LPC (Particulate Contamination)
			Average Molecular weight by HPLC
			Bacterial Endotoxins
			Sterility
			Assay by Chemical
			Hydroxethyl Starch
			Sodium Chloride
305	417	Cloxacillin sodium Injection IP 500 mg	Description
			Identification A (by IR)
			Identification B
			pH
			Bacterial endotoxins
			Average net content
			Uniformity of weight
			Water
			Clarity of solution test a and b
			Particulate matter
			Assay: (by HPLC)
			Sterility (by MF)
306	418	Betamethasone Sodium Phosphate injection IP 4mg/ml	Description
			Identification A (by TLC)
			Identification B (by UV)
			pH
			Extractable volume
			Particulate matter
			Assay: (by UV)
			Sterility (by MF)
307	419	Vecuronium Bromide for Injection 4 mg (Freeze Dried)	Description
			Identification A (by HPLC)
			pH
			Light absorption (by UV)
			Water
			Bacterial Endotoxins
			Average net content

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Uniformity of weight
			Related substances (by HPLC)
			Clarity of solution test a and b
			Particulate matter
			Assay: (by HPLC)
			Sterility (by MF)
308	420	Phenobarbitone Injection IP 200mg/ml	Description
			Identification A (by IR)
			Identification B
			pH
			Weight per ml
			Extractable volume
			Particulate matter
			Bacterial endotoxins
			Assay: Phenobarbital sodium
			Sterility (by MF)
309	421	Flurbiprofen Sodium Ophthalmic Solution USP 0.03% w/v / Flurbiprofen Eye Drops IP 0.03% w/v	Description
			Identification A (by TLC)
			Identification B (by HPLC)
			pH
			2-(biphenyl-4-yl) propionic acid (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
			Sterility (by MF)
310	424	Lidocaine Hydrochloride Topical Solution USP 4%	Description
			Identification (by IR)
			pH
			Net content
			Assay: (by HPLC)
311	425	Fluconazole Eye Drops 0.3%	Description
			Identification (by HPLC)
			pH
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
			Sterility (by MF)
312	427	Cephalexin Oral Suspension IP (Cephalexin Dry Syrup IP) 125 mg/ 5 ml	Description
			Identification A (by HPLC)
			Identification B
			Contents of Packaged Dosage Forms
			Weight per ml
			Assay: (by HPLC)
			Stability of suspension (by HPLC)
			Identification of colour

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Microbial Examination
			Total aerobic count
			Total fungal count
			E. coli
313	428	Ofloxacin Suspension 50mg/ 5ml	Description
			Identification (by HPLC)
			Contents of Packaged Dosage Forms
			Weight per ml
			Assay: (by HPLC)
			Identification of colour
			Microbial Examination
			Total aerobic count
			Total fungal count
			E. coli
314	430	Tinidazole Tablets IP 300 mg (Film Coated)	Description
			Identification A (by UV)
			Identification B
			Identification C: Melting Point
			Average weight
			Uniformity of weight
			Disintegration time
			Contents of Packaged Dosage Forms
			Assay: (by UV)
			Identification of colour
315	431	Tinidazole Tablets IP 500 mg (Film Coated)	Description
			Identification A (by UV)
			Identification B
			Identification C: Melting Point
			Average weight
			Uniformity of weight
			Disintegration time
			Contents of Packaged Dosage Forms
			Assay: (by UV)
			Identification of colour
316	432	Salbutamol Syrup IP 2mg/ 5ml	Description
			Identification A
			Identification B
			pH
			2-tert-butylamino-1-(4-hydroxy-3-methylphenyl) ethanol (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by UV)
			Identification of colour

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Microbial Examination
			Total aerobic count
			Total fungal count
			E. coli
317	433	Ranitidine Tablets IP 300mg (Film Coated)	Description
			Identification A (by IR)
			Identification B (by HPLC)
			Average weight
			Uniformity of weight
			Disintegration Time
			Related substances (by HPLC)
			Uniformity of container contents: Contents of Packaged Dosage Forms
			Assay: (by HPLC)
			Identification of colour
318	436	Indomethacin Capsules IP 25 mg	Description
			Identification A (by IR)
			Identification B (by UV)
			Identification C
			Average net content
			Uniformity of weight
			Related substances (by TLC)
			Contents of Packaged Dosage Forms
			Dissolution (by UV)
			Assay: (by UV)
319	437	Diclofenac Prolonged Release Tablet IP 100 mg	Description
			Identification (by IR)
			Average weight
			Uniformity of weight
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms
			Dissolution (by UV)
			1 st time point
			2 nd time point
			3 rd time point
			Assay: (by HPLC)
			Identification of colour
320	438	Dicyclomine Hydrochloride and Activated Dimethicone suspension.	Description
			Identification of Polydimethylsiloxane (by IR)
			Identification of Dicyclomine hydrochloride
			pH

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Contents of Packaged Dosage Forms
			Assay:
			Dicyclomine Hydrochloride
			Polydimethylsiloxane (by IR)
			Identification of colour
			Microbiological Examination
			Total Aerobic count
			Total Fungal count
			E. coli
321	440	Dextromethorphan Hydrobromide Syrup IP 13.5mg / 5ml	Description
			Identification A (by optical rotation)
			Identification B
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
			Identification of colour
			Microbial Examination
			Total aerobic count
			Total fungal count
			E. coli
322	441	Calcium & Vitamin D3 Suspension	Description
			Identification of Calcium and carbonate
			Identification of Vitamin D3 (by HPLC)
			pH
			Contents of Packaged Dosage Forms
			Weight per ml
			Assay:
			Vitamin D3 125 IU (by HPLC)
			Calcium carbonate calculated as calcium
			Identification of colour
			Microbial Examination
			Total aerobic count
			Total fungal count
			E. coli
323	442	Saline Nasal Solution (Drops) (Sodium chloride 0.65%)	Description
			Identification of Sodium
			Identification of Chloride
			pH
			Contents of Packaged Dosage Forms
			Assay: Sodium chloride
324	443	Clotrimazole mouth paint (Clotrimazole 1%)	Description

Sr	Code No.	Name of item with specification	Test proposed to be carried out
		w/v)	Identification of Clotrimazole (by HPLC)
			pH
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
325	444	Aspirin Delayed Release Tablets / Aspirin Gastro resistant Tablets. Each enteric coated tablet contains Acetyl Salicylic Acid 75 mg	Description
			Identification
			Average weight
			Dissolution A (by UV) Acid stage
			Dissolution B (by UV) Buffer stage
			Uniformity of weight
			Salicylic acid (by HPLC)
			Assay: (by HPLC)
			Identification of colours (by TLC)
326	445	Beclomethasone, Neomycin and Clotrimazole Cream	Description
			Identification of Neomycin sulphate (by TLC)
			Identification of Beclomethasone dipropionate (by HPLC)
			Identification of Clotrimazole (by HPLC)
			Contents of Packaged Dosage Forms
			Assay:
			Neomycin sulphate 0.5%w/w (by Microbiological assay)
			Beclomethasone dipropionate 0.025%w/w (by HPLC)
			Clotrimazole 1%w/w (by HPLC)
327	446	Gamma Benzene Hexachloride Lotion 1% (Lindane lotion USP) (Lindane Application BP)	Description
			Identification
			PH
			Contents of Packaged Dosage Forms
			Assay by HPLC
328	447	Chlorhexidine Gluconate Solution 5%	Description
			Identification of chlorhexidine (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
			Identification of colours (by TLC)
329	448	Iron and Folic Acid Suspension.	Description
			Identification of Ferrous Fumerate
			Identification of folic acid (by HPLC)
			Weight per ml
			pH

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Contents of Packaged Dosage Forms
			Assay:
			Folic acid (by HPLC)
			Ferrous Fumerate calculated as elemental iron
			Identification of colour
			Microbial Contamination
			Total aerobic viable count
			E. coli
330	449	Surgical Spirit IP/BP	Description
			Identification A
			Identification B
			Weight/ml
			Net content
			Assay:
			For Methyl Salisylate (by UV)
			For Diethyl Phthalate (by UV)
331	450	Povidone Iodine solution IP 5%	Description
			Identification A
			Identification B
			Identification C
			Contents of Packaged Dosage Forms
			pH
			Assay: Povidone iodine
332	451	Metformin Hydrochloride Sustained Release Tablets IP 1000 mg	Description
			Identification A (by IR)
			Identification B
			Average weight
			Uniformity of weight
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms
			Dissolution (by UV)
			1 st time point
			2 nd time point
			3 rd time point
			Assay: (by UV)
333	452	Glipizide and Metformin Hydrochloride tablets USP (Glipizide 5mg, Metformin Hydrochloride 500 mg)	Description
			Identification A (by IR)
			Identification B (by HPLC)
			Identification C (by HPLC)
			Average weight
			Uniformity of weight
			Organic Impurity by HPLC

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Contents of Packaged Dosage Forms
			Dissolution (by HPLC)
			1 st time point
			2 nd time point
			Assay: (by HPLC)
			Metformin
			Glipizide
334	453	Glibenclamide and Metformin Hydrochloride (SR) Tablets	Description
			Identification of Glibenclamide (by HPLC)
			Identification of Metformin hydrochloride (by UV)
			Average weight
			Uniformity of weight
			Uniformity of content of Glibenclamide (by HPLC)
			Dissolution of Metformin hydrochloride (by UV)
			1 st time point
			2 nd time point
			3 rd time point
			Contents of Packaged Dosage Forms
			Assay:
			Metformin hydrochloride (by UV)
			Glibenclamide (by HPLC)
			Identification of colour
335	454	Metformin Hydrochloride (Sustained Release) and Glimperiride Tablets {Metformin Hydrochloride (Sustained Release) 500 mg, Glimipiride 1 mg}	Description
			Identification of Metformin hydrochloride (by UV)
			Identification of Glimperiride (by HPLC)
			Average weight
			Uniformity of weight
			Uniformity of content:
			Glimperiride (by HPLC)
			Dissolution of Metformin hydrochloride (by UV)
			1 st time point
			2 nd time point
			3 rd time point
			Contents of Packaged Dosage Forms
			Assay:
			Glimperiride (by HPLC)
			Metformin hydrochloride (by UV)
			Identification of colour

Sr	Code No.	Name of item with specification	Test proposed to be carried out
336	455	Metformin Hydrochloride (Sustained Release) and Glimepiride Tablets {Metformin Hydrochloride (Sustained Release) 500 mg, Glimepiride 2 mg}	Description
			Identification of Metformin hydrochloride (by UV)
			Identification of Glimepiride (by HPLC)
			Average weight
			Uniformity of weight
			Uniformity of content:
			Glimepiride (by HPLC)
			Dissolution of Metformin hydrochloride (by UV)
			1 st time point
			2 nd time point
			3 rd time point
			Contents of Packaged Dosage Forms
			Assay:
			Glimepiride (by HPLC)
Metformin hydrochloride (by UV)			
Identification of colour			
337	456	Glimperiride, Pioglitazone and Metformin Hydrochloride (Sustained Release) Tablets	Description
			Identification of Metformin hydrochloride (by UV)
			Identification of Glimepiride (by HPLC)
			Identification of Pioglitazone hydrochloride (by HPLC)
			Average weight
			Uniformity of weight
			Uniformity of content:
			Pioglitazone (by HPLC)
			Glimepiride (by HPLC)
			Dissolution of Metformin hydrochloride (by UV)
			1 st time point
			2 nd time point
			3 rd time point
			Contents of Packaged Dosage Forms
Assay:			
Glimepiride (by HPLC)			
Metformin hydrochloride (by UV)			
Pioglitazone (by HPLC)			
Identification of colour			
338	457	Amlodipine and Enalapril Maleate Tablets	Description
			Identification of amlodipine besylete (by HPLC)

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Identification of enalapril maleate (by HPLC) Average weight Uniformity of content : Amlodipine besylete (by HPLC) Enalapril maleate (by HPLC) Disintegration time Contents of Packaged Dosage Forms Assay: Amlodipine besylete (by HPLC) Enalapril maleate (by HPLC)
339	458	Losarton Potassium & Amlodipine tablets IP	Description Identification (by HPLC) Average weight Uniformity of weight Uniformity of content: amlodipine (by HPLC) Dissolution: Losartan potassium (by HPLC) Amlodipine (by HPLC) Contents of Packaged Dosage Forms Assay: Amlodipine (by HPLC) Losartan potassium (by HPLC)
340	459	Losarton Potassium & Hydrochlorothiazide Tablets IP (Losartan Potassium 50 mg, Hydrochlorothiazide 12.5 mg)	Description Identification (by HPLC) Average weight Uniformity of weight Uniformity of content of Hydrochlorothiazide (by HPLC) Dissolution Losartan potassium (by HPLC) Hydrochlorothiazide (by HPLC) Uniformity of content of Hydrochlorothiazide (by HPLC) Contents of Packaged Dosage Forms Assay: Hydrochlorothiazide (by HPLC) Losartan potassium (by HPLC) Identification of colours
341	460	Amlodipine and Lisinopril Tablets [Amlodipine Besilate equivalent to Amlodipine 5 mg, Lisinopril eq. to lisinopril (anhydrous) 5mg]	Description Identification of Amlodipine (by HPLC) Identification of Lisinopril (by HPLC)

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Average weight
			Uniformity of weight
			Uniformity of content:
			Amlodipine (by HPLC)
			Lisinopril (by HPLC)
			Disintegration time
			Contents of Packaged Dosage Forms
			Assay:
			Amlodipine (by HPLC)
			Lisinopril (by HPLC)
342	461	Amlodipine and Atenolol Tablets	Description
			Identification of amlodipine (by HPLC)
			Identification of Atenolol (by HPLC)
			Average weight
			Uniformity of weight
			Disintegration time
			Uniformity of content:
			Amlodipine (by HPLC)
			Contents of Packaged Dosage Forms
			Assay:
			Amlodipine (by HPLC)
			Atenolol (by HPLC)
343	462	Atenolol Tablets IP 25 mg	Description
			Identification A (by IR)
			Identification B (by UV)
			Average weight
			Uniformity of weight
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms
			Disintegration time
			Assay: (by UV)
344	463	Enalapril Maleate Tablets IP 10 mg	Description
			Identification (by HPLC)
			Average weight
			Dissolution (by HPLC)
			Uniformity of content (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
345	464	Hydrochlorothiazide Tablets IP 25 mg	Description
			Identification (by TLC)
			Average weight
			Uniformity of weight

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Related substances (by HPLC)
			Dissolution (by UV)
			Contents of Packaged Dosage Forms
			Assay: (by UV)
346	465	Lisinopril Tablets IP 10 mg	Description
			Identification (by HPLC)
			Average weight
			Related substances (by HPLC)
			Uniformity of content (by HPLC)
			Dissolution (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
347	466	Lisinopril Tablets IP 2.5 mg	Description
			Identification (by HPLC)
			Average weight
			Related substances (by HPLC)
			Uniformity of content (by HPLC)
			Dissolution (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
348	467	Losartan Tablets IP 25 mg	Description
			Identification (by HPLC)
			Average weight
			Related substances (by HPLC)
			Uniformity of weight
			Dissolution by UV
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
349	468	Piperacillin and Tazobactam for Injection USP 4 gm + 500 mg	Description
			Identification (by HPLC)
			pH
			Bacterial endotoxins
			Average net content
			Uniformity of dosage units (weight variation)
			Water
			Organic impurities (by HPLC)
			Completeness and clarity of solution of test a and b
			Particulate matter (by Particle counter)
			Particulate matter
			Assay:
			Piperacillin (by HPLC)

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Tazobactam (by HPLC)
			Sterility (by MF)
350	469	Prednisolone Tablets IP 10 mg	Description
			Identification A (by IR)
			Identification B (by TLC)
			Average weight
			Related substances (by HPLC)
			Uniformity of content (by UV)
			Dissolution (by UV)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
351	470	Prednisolone Tablets 20 mg	Description
			Identification A (by IR)
			Identification B (by TLC)
			Average weight
			Related substances (by HPLC)
			Uniformity of weight
			Dissolution (by UV)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
352	472	Zinc Sulphate Dispersible Tablets IP Elemental Zinc 10 mg	Description
			Identification A
			Identification B
			Average weight
			Uniformity of content
			Contents of Packaged Dosage Forms
			Uniformity of dispersion
			Disintegration time
			Assay: Elemental Zinc
353	473	Amoxicillin Oral Suspension IP (Dry Syrup) 125 mg/ 5 ml	Description
			Identification (by HPLC)
			pH
			Contents of Packaged Dosage Forms
			Weight per ml
			Assay: (by HPLC)
			Stability of suspension (by HPLC)
			Identification of colour
			Microbial Contamination
			Total aerobic viable count
			Total fungal count
			E. coli
354	474	Carbamazepine Oral Suspension USP 100 mg/5ml	Description
			Identification (by IR)

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Deliverable volume
			Assay: (by HPLC)
			Microbial enumeration tests and tests for specified microorganisms
			Total bacterial count
			Salmonella
			E. coli
355	475	Cefpodoxime Dispersible Tablets 50 mg	Description
			Identification (by HPLC)
			Average weight
			Uniformity of weight
			Disintegration time
			Uniformity of dispersion
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
356	476	Cephalexin Tablets 125 mg (Dispersible Tablets)	Description
			Identification (by HPLC)
			Average weight
			Uniformity of weight
			Disintegration time
			Uniformity of dispersion
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
357	477	Ibuprofen Oral Suspension BP/USP 100 mg/ 5 ml	Description
			Identification A (by IR)
			Identification B (by TLC)
			Assay: (by HPLC)
			Uniformity of mass
			Identification of colour
			Microbial Examination
			Total aerobic count
			Total fungal count
			E. coli
358	478	Metoclopramide Hydrochloride Syrup IP 5 mg/	Description
			Identification A (by UV)
			Identification B
			Identification C
			pH
			Contents of Packaged Dosage Forms
			Related substances (by HPLC)
			Identification of colour
			Assay: (by UV)
			Microbial Examination
			Total aerobic count

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Total fungal count
			E. coli
359	479	Sodium Valproate Oral Solution IP 200 mg / 5 ml	Description
			Identification A (by IR)
			Identification B
			Related substances (by GC)
			Weight/ml
			Contents of Packaged Dosage Forms
			Identification of colour
			Assay: Sodium valproate
			Microbial Examination
			Total aerobic count
			Total fungal count
			E. coli
360	481	Meropenem Injection IP 1 g	Description
			Identification (by HPLC)
			pH
			Bacterial endotoxins
			Average net content
			Uniformity of weight
			Loss on drying
			Related Substances (by HPLC)
			Content of Sodium
			Clarity of solution test a and b
			Particulate matter
			Assay: (by HPLC)
			Sterility (by MF)
361	482	Iohexol USP (Solution for Injection) Non Ionic contrast medium in Sterile aqueous solution 300 mg Iodine/ml.	Description
			Identification by HPLC
			Bacterial endotoxins
			pH
			Free Iodide
			Organic Impurities by HPLC
			Particulate matter
			Extractable volume
			Assay
			Sterility (by MF)
362	483	Diclofenac Sodium and Paracetamol Tablets	Description
			Identification of Diclofenac Sodium (by HPLC)
			Identification of Paracetamol (by HPLC)
			Average weight
			Uniformity of weight
			Disintegration Time

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Contents of Packaged Dosage Forms
			Assay:
			Diclofenac sodium (by HPLC)
			Paracetamol (by HPLC)
363	484	Timolol Eye Drops IP 0.5% w/v	Description
			Identification A (by IR)
			Identification B
			pH
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by UV)
			Sterility (by MF)
364	485	Homatropine Eye Drops IP 2 %	Description
			Identification A (by IR)
			Identification B
			Related substances (by TLC)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
			Sterility (by MF)
365	486	Travoprost Eye Drops IP 0.004%	Description
			Identification A (by HPLC)
			Identification B (by TIC)
			pH
			Related substance by HPLC
			Net content
			Assay: by HPLC
			Sterility (by MF)
366	487	Brimonidine Tartrate and Timolol Maleate Eye Drops 0.15% + 0.5%	Description
			Identification of Brimonidine tartrate (by HPLC)
			Identification of Timolol Maleate (by HPLC)
			pH
			Net content
			Assay:
			Brimonidine tartrate (by HPLC)
			Timolol maleate (by HPLC)
			Sterility (by MF)
367	488	Iron Sucrose Injection USP/BP 20mg/ml (For IV Use)	Identification
			Iron by chemically
			Sucrose by HPLC
			Molecular Weight Determination (by HPLC)
			Specific Rotation

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Bacterial Endotoxins
			Alkalinity
			pH
			Osmolarity
			Absence of low molecular weight Fe(II) and Fe(III) complexes
			Turbidity
			Particulate matter
			Limit of iron (II)
			Content of chloride
			Sterility
			Extractable volume (Content)
			Assay of Sucrose by HPLC
			Assay of Iron by AAS/UV
368	491	Sevoflurane	Description
			Identification A(by IR)
			Identification B(by Chemically)
			Identification C(by GC)
			Refractive Index
			Water Determination
			Acidity or alkalinity
			Assay (by GC)
369	492	Aceclofenac and Paracetamol Tablets Aceclofenac 100 mg and Paracetamol 325 mg	Description
			Identification of aceclofenac
			Identification of Paracetamol
			Average weight
			Uniformity of weight
			Disintegration Time
			Contents of Packaged Dosage Forms
			Assay:
			Aceclofenac (by HPLC)
			Paracetamol (by HPLC)
370	493	Diclofenac Gel: Diclofenac Diethylamine 1.16%, Methyl salicylate 10%, Linseed oil 3% and Menthol 5%	Description
			Identification of Diclofenac (by HPLC)
			Identification of Linseed oil (by GC)
			Identification of Menthol (by GC)
			Identification of Methyl salicylate (by GC)
			Contents of Packaged Dosage Forms
			Assay:
			Diclofenac (by HPLC)
			Linseed oil (by GC)
			Menthol (by GC)
			Methyl salicylate (by GC)

Sr	Code No.	Name of item with specification	Test proposed to be carried out
371	495	Etoricoxib Tablets IP 120 mg	Description
			Identification (by HPLC)
			Average weight
			Dissolution (by HPLC)
			Uniformity of weight
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
372	496	Mefenamic Acid Tablets BP 500 mg	Description
			Identification (by IR)
			Average weight
			Uniformity of mass
			Related substances (by TLC)
			2,3-Dimethylaniline (by TLC)
			Assay: Mefenamic acid
373	497	Anticold syrup:	Description
			Identification of Paracetamol (by UV)
			Identification of Phenylephrine hydrochloride (by UV)
			Identification of Chlorpheniramine maleate (by UV)
			pH
			Contents of Packaged Dosage Forms
			Assay:
			Paracetamol (by UV)
			Phenylephrine hydrochloride (by UV)
			Chlorpheniramine maleate (by UV)
			Identification of colour
			Microbiological Examination
			Total Aerobic count
			Total Fungal count
E. coli			
374	498	Cetirizine, Phenylephrine & Paracetamol Tablets	Description
			Identification of Cetirizine hydrochloride (by HPLC)
			Identification of Phenylephrine hydrochloride (by UV)
			Identification of Paracetamol (by UV)
			Average weight
			Uniformity of weight
			Uniformity of content:
			Cetirizine hydrochloride (by HPLC)

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Phenylephrine hydrochloride (by HPLC)
			Contents of Packaged Dosage Forms
			Assay:
			Cetirizine hydrochloride (by HPLC)
			Phenylephrine hydrochloride (by UV)
			Paracetamol (by UV)
			Identification of colour
375	499	Cetirizine syrup IP 5 mg/ 5ml	Description
			Identification (by HPLC)
			Weight per ml
			pH
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
			Identification of colour
			Microbiological Examination
376	500	Acetylcystine Solution USP (Injection) 200 mg/ ml	Description
			Identification (by IR)
			pH
			Extractable volume
			Particulate Matter
			Assay: (by HPLC)
			Sterility (by MF)
377	502	Acyclovir Intravenous Infusion IP 250 mg	Description
			Identification A (by UV)
			Identification B (by TLC)
			Identification C
			pH
			Bacterial endotoxins
			Average net content
			Uniformity of weight
			Appearance of Solution
			Guanine (by TLC)
			Related Substances (by TLC)
			Clarity of solution test a and b
			Particulate matter
			Assay: (by UV)
			Sterility (by MF)
378	503	Acyclovir Intravenous Infusion IP 500 mg	Description
			Identification A (by UV)
			Identification B (by TLC)
			Identification C
			pH
			Bacterial endotoxins

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Average net content
			Uniformity of weight
			Appearance of Solution
			Guanine (by TLC)
			Related Substances (by TLC)
			Clarity of solution test a and b
			Particulate matter
			Assay: (by UV)
			Sterility (by MF)
379	504	Amikacin Injection IP 250 mg	Description
			Identification A by TLC
			Identification B
			Identification C
			pH
			Bacterial endotoxins
			Related substances by HPLC
			Particulate matter
			Extractable volume
			Sterility
			Assay: Microbiological assay
380	505	Amoxicillin and Potassium Clavulante Injection IP 600 mg	Description
			Identification (by TLC)
			Identification (by HPLC)
			pH
			Bacterial Endotoxins
			Average net content
			Uniformity of weight
			Water
			Clarity of solution test a and b
			Particulate matter
			Assay:
			Amoxycillin (by HPLC)
			Clavulanic acid (by HPLC)
			Sterility (by MF)
381	506	Amoxicillin and Potassium Clavulante Injection IP 1.2 g	Description
			Identification (by TLC)
			Identification (by HPLC)
			pH
			Bacterial Endotoxins
			Average net content
			Uniformity of weight
			Water
			Clarity of solution test a and b
			Particulate matter
			Assay:

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Amoxicillin (by HPLC)
			Clavulanic acid (by HPLC)
			Sterility (by MF)
382	507	Amoxicillin and Potassium Clavulante Oral Suspension IP 200 mg + 28.5 mg per 5 ml	Description
			Identification (by HPLC)
			pH
			Contents of Packaged Dosage Forms
			Water
			Assay:
			Amoxicillin (by HPLC)
			Clavulanic acid (by HPLC)
			Stability of suspension on 7th day
			Amoxicillin (by HPLC)
			Clavulanic acid (by HPLC)
			Microbial Examination
			Total aerobic count
			Total fungal count
			E. coli
383	509	Aztreonam Injection USP 500 mg	Description
			Identification by HPLC
			Average Fill
			Uniformity of Weight
			Pyrogen Test
			Sterility
			pH
			Particulate matter
			Assay by HPLC
			Clarity of solution test a and b
384	510	Cefepime Injection IP 500 mg	Description
			Identification (A) TLC
			Identification (B) HPLC
			pH
			N-Methylpyrrolidine (By LC)
			Related substances (By LC)
			Uniformity of fill
			Water
			Average fill
			Bacterial endotoxins
			Sterility
			Clarity of solution
			Particulate matter
			Assay by HPLC
385	511	Cefixime Oral Suspension IP 25 mg/ ml (Paediatric Drops)	Description
			Identification (by HPLC)
			pH

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Contents of Packaged Dosage Forms
			Water
			Weight per ml
			Assay: (by HPLC)
			Stability of suspension (by HPLC)
			Identification of colour
			Microbial Examination
			Total aerobic count
			Total fungal count
			E. coli
386	512	Cefuroxime Axetil Tablets IP 250 mg	Description
			Identification A (by IR)
			Identification B (by HPLC)
			Average weight
			Uniformity of weight
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms
			Dissolution (by UV)
			Assay: (by HPLC)
			Identification of colour
387	513	Clindamycin Capsules IP 150 mg	Description
			Identification A (by IR)
			Identification B (by HPLC)
			Average net content
			Uniformity of weight
			Disintegration time
			Contents of Packaged Dosage Forms
			Water
			Related substances (by HPLC)
			Assay: (by HPLC)
388	514	Clindamycin Capsules IP 300 mg	Description
			Identification A (by IR)
			Identification B (by HPLC)
			Average net content
			Uniformity of weight
			Disintegration time
			Contents of Packaged Dosage Forms
			Water
			Related substances (by HPLC)
			Assay: (by HPLC)
389	515	Levofloxacin Tablets IP 250 mg	Description
			Identification A (by HPLC)
			Average weight

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Uniformity of weight
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms
			Dissolution (by UV)
			Assay: (by HPLC)
			Identification of colours
390	516	Linezolid Tablets IP 600 mg	Description
			Identification (by HPLC)
			Average weight
			Uniformity of weight
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms
			Dissolution (by UV)
			Assay: (by HPLC)
			Identification of colour
391	517	Linezolid Injection 200 mg/ 100 ml	Description
			Identification A (by HPLC)
			pH
			Bacterial endotoxins
			Particulate Contamination (by particle counter)
			Extractable volume
			Sterility
			Assay: (by HPLC)
392	518	Mefloquine Tablets IP 250 mg	Description
			Identification A (by TLC)
			Identification B (by HPLC)
			Identification C
			Average weight
			Uniformity of weight
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms
			Dissolution (by UV)
			Assay: (by HPLC)
393	520	Ofloxacin and Ornidazole Tablets (Ofloxacin 200 mg and Ornidazole 500 mg)	Description
			Identification of Ofloxacin (by HPLC)
			Identification of Ornidazole (by HPLC)
			Average weight
			Uniformity of weight
			Disintegration Time
			Contents of Packaged Dosage Forms
			Assay:

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Ofloxacin 200 mg (by HPLC)
			Ornidazole 500 mg (by HPLC)
			Identification of colour
394	521	Ofloxacin Infusion IP 200mg/ 100 ml (in NaCl Inj)	Description
			Identification A (by HPLC)
			pH
			Bacterial endotoxins
			Particulate Contamination (by particle counter)
			Extractable volume
			Assay: (by HPLC)
			Sterility
395	523	Vancomycin for Intravenous Infusion IP 500 mg	Description
			Identification A (by HPLC)
			Identification B
			pH
			Bacterial endotoxins
			Average net content
			Uniformity of weight
			Water
			Related Substances (by HPLC)
			Vancomycin B (by HPLC)
			Appearance of solution
			Clarity of solution test a and b
			Particulate matter
			Assay: (by Microbiological assay)
			Sterility (by MF)
396	524	Vancomycin for Intravenous Infusion IP 1 gm	Description
			Identification A (by HPLC)
			Identification B
			pH
			Bacterial endotoxins
			Average net content
			Uniformity of weight
			Water
			Related Substances (by HPLC)
			Vancomycin B (by HPLC)
			Appearance of solution
			Clarity of solution test a and b
			Particulate matter
			Assay: (by Microbiological assay)
			Sterility (by MF)
397	526	Carboplatin Injection 150 mg	Description
			Identification A by TLC
			Identification B by HPLC
			Acidity:pH

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Limit of Cyclobutane-1,1-Dicarboxylic acid by HPLC
			Bacterial Endotoxins
			Sterility
			Extractable volume
			Particulate Matter
			Assay by HPLC
398	527	Carboplatin Injection 450 mg	Description
			Identification A by TLC
			Identification B by HPLC
			Acidity:pH
			Limit of Cyclobutane-1,1-Dicarboxylic acid by HPLC
			Bacterial Endotoxins
			Sterility
			Extractable volume
			Particulate Matter
			Assay by HPLC
399	528	Cisplatin Injection IP 10 mg/ 10 ml	Description
			Identification A (by UV)
			Identification B (by TLC)
			pH
			Related Substances (by TLC)
			Bacterial Endotoxins
			Average net content
			Uniformity of weight
			Clarity of solution test a and b
			Particulate matter
			Assay: (by HPLC)
			Sterility (by MF)
400	529	Dacarbazine Injection 500 mg USP/ BP	Description
			Identification A by TLC
			Identification B
			Identification C
			pH
			Water
			Bacterial endotoxins
			Limit of 2-azahypoxanthine BY HPLC
			Average Fill
			Completeness and clarity of solution of test a and b
			Particulate matter of constituted solution
			Uniformity of dosage units (weight variation)
			Sterility
			Assay by UV

Sr	Code No.	Name of item with specification	Test proposed to be carried out
401	531	Gemcitabine for Injection 200 mg	IdentificationBy HPLC
			Related Substance by HPLC
			Clarity of solution
			pH
			Particulate matter
			Average fill
			Sterility
			Uniformity of Dosage Unit
			Bacterial endotoxins
			Assay by HPLC
402	532	Gemcitabine for Injection IP 1gm [532]	IdentificationBy HPLC
			Related Substance by HPLC
			Clarity of solution
			pH
			Particulate matter
			Average fill
			Sterility
			Uniformity of Dosage Unit
			Bacterial endotoxins
			Assay by HPLC
403	533	Ifosfamide Injection USP/ BP 1 gm	Description
			Identification A by TLC
			Identification B by HPLC
			pH
			Average Fill
			Water
			Bacterial endotoxins
			Completeness and clarity of solution of test a and b
			Particulate matter of constituted solution
			Uniformity of Dosage Units
			Assay by HPLC
			Sterility
404	534	Imatinib Tablets 400 mg	Description
			Identification (by HPLC)
			Average weight
			Uniformity of weight
			Dissolution (by HPLC)
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
405	536	Methotrexate Tablets IP 10 mg	Description
			Identification (by UV)
			Average weight

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Uniformity of content (by HPLC)
			Dissolution (by UV)
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
406	538	Oxaliplatin Injection USP 50 mg	Description
			Identification (A) (By U.V)
			Identification (B) (By HPLC)
			pH
			Particulate matter
			Impurities (By LC)
			Procedure 1
			Limit of Oxalic acid (By LC)
			Procedure 2
			Platinum & Unspecified impurity (By LC)
			Bacterial endotoxins
			Extractable volume
			Sterility
			Assay Oxaliplatin by HPLC
407	540	Bromocriptine Tablets IP 2.5 mg	Description
			Identification A (by IR)
			Identification B (by UV)
			Identification C (by TLC)
			Average weight
			Uniformity of content (by UV)
			Related substances (by TLC)
			Disintegration time
			Contents of Packaged Dosage Forms
			Assay: (by UV)
408	541	Betahistine Tablets IP 8 mg	Description
			Identification A (by IR)
			Identification B (by HPLC)
			Average weight
			Uniformity of content (by HPLC)
			Dissolution (by UV)
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
409	542	Betahistine Tablets IP 16 mg	Description
			Identification A (by IR)
			Identification B (by HPLC)
			Average weight
			Uniformity of Weight

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Dissolution (by UV)
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
410	543	Cinnarizine Tablets IP 25 mg	Description
			Identification A (by IR)
			Identification B (by HPLC)
			Average weight
			Uniformity of weight
			Dissolution (by UV)
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
411	544	Cinnarizine Tablets IP 75 mg	Description
			Identification A (by IR)
			Identification B (by HPLC)
			Average weight
			Uniformity of weight
			Dissolution (by UV)
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
412	545	Tranexamic Acid Tablets IP/BP 500 mg	Description
			Identification A (by IR)
			Identification B
			Identification C (by melting point)
			Average weight
			Uniformity of weight
			Disintegration Time
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: by Titration
413	546	Warfarin Sodium Tablets IP 5 mg	Description
			Identification A (by IR)
			Identification B by melting point
			Average weight
			Uniformity of content (by HPLC)
			Dissolution (by UV)
			Related substances (by TLC)
			Contents of Packaged Dosage Forms
			Assay: (by UV)
414	547	Adenosine Injection 6 mg/ 2 ml	Description

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Identification (by HPLC)
			Organic impurities (by HPLC)
			pH
			Particulate matter (by Particle counter)
			Bacterial endotoxines
			Net content
			Assay: (by HPLC)
			Sterility (by MF)
415	548	Atorvastatin Tablets IP 40 mg	Description
			Identification (by HPLC)
			Average weight
			Related substances (by HPLC)
			Dissolution (by HPLC)
			Uniformity of Weight
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
			Identification of colour
416	549	Clopidogrel and Aspirin Tablets Clopidogrel 75 mg and Aspirin 75 mg	Description
			Identification of clopidogrel bisulphate (by HPLC)
			Identification of aspirin (by HPLC)
			Average weight
			Uniformity of weight
			Disintegration Time
			Contents of Packaged Dosage Forms
			Assay:
			Clopidogrel (by HPLC)
			Aspirin (by HPLC)
			Identification of colour
417	552	Metoprolol Tablets IP 25 mg	Description
			Identification by IR
			Average weight
			Uniformity of weight
			Dissolution by UV
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by UV)
418	553	Metoprolol Succinate Extended Release Tablets USP 50 mg	Description
			Identification A (by IR)
			Identification B (by IR)
			Average Weight
			Dissolution: (by HPLC)
			After 1 hour

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			After 4 hours
			After 8 hours
			After 20 hours
			Uniformity of dosage units: Content uniformity (by HPLC)
			Assay: (by HPLC)
419	554	Noradrenaline Injection IP 2 mg/ ml	Description
			Identification
			pH
			Particulate matter
			Extractable volume
			Assay: (by UV)
			Sterility (by MF)
420	555	Prazosin Tablets (Extended Release) 2.5 mg	Description
			Identification (by HPLC)
			Average weight
			Uniformity of weight
			Dissolution (by HPLC)
			1 st time point
			2 nd time point
			3 rd time point
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
421	556	Telmisartan Tablets IP 40 mg	Description
			Identification (by HPLC)
			Average weight
			Uniformity of weight
			Related substances (by HPLC)
			Dissolution (by UV)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
422	558	Betamethasone Dipropionate Cream IP 0.05%	Description
			Identification (by TLC)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
423	559	Betamethasone Lotion IP 0.05%	Description
			Identification (by TLC)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
424	560	Clindamycin Phosphate Gel USP 1%	Description
			Identification (by HPLC)
			Minimum fill
			pH

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Assay: (by HPLC)
425	561	Clobetasol Propionate Cream 0.05%	Description
			Identification A (by TLC)
			Identification B (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
426	564	Glycerin IP	Description
			Identification B
			Identification C
			Identification D: Refractive index
			Appearance of solution
			Acidity or alkalinity
			Heavy metals
			Iron
			Chlorides
			Sulphates
			Aldehydes and reducing substances
			Ester
			Ethylene glycol, diethylene glycol and related substances (by GC)
			sugars
			Sulphated ash
			water
			Net content
Assay: Glycerin			
427	565	Ketoconazole Cream 2%	Description
			Identification (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
428	568	Permethrin Lotion 5%	Description
			Identification (by HPLC)
			Weight per ml
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
429	569	Permethrin Cream 5%	Description
			Identification (by HPLC)
			Uniformity of weight: Contents of Packaged Dosage Forms
			Assay: (by HPLC)
430	570	Tretinoin Cream USP 0.025%	Description
			Identification (by HPLC)
			Minimum fill
			Assay: (by HPLC)
431	571	Povidone Iodine Ointment USP 5%	Description

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Identification A
			Identification B
			Minimum fill
			pH
			Assay: (by potentiometer)
432	572	Povidone Iodine Solution IP 10%	Description
			Identification A
			Identification B
			Identification C
			Contents of Packaged Dosage Forms
			pH
			Assay: Povidone iodine
433	573	Silver Sulphadiazine Cream IP 1%	Description
			Identification (by TLC)
			pH of 5%w/v resulting solution
			Contents of Packaged Dosage Forms
			Microbial contamination
			Escherichia coli
			Staphylococcus species
			Pseudomonas aeruginosa
			Salmonella species
			Shigella
			Assay: (by HPLC)
434	574	Spirolactone Tablets IP 50 mg	Description
			Identification A (by IR)
			Identification B (by TLC)
			Identification C
			Average weight
			Uniformity of weight
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms
			Dissolution (by UV)
			Assay: (by UV)
435	575	Finasteride Tablets IP 5 mg	Description
			Identification (by HPLC)
			Average weight
			Uniformity of content (by HPLC)
			Dissolution (by HPLC)
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
436	576	Tamsulosin HCl Tablets/Capsule 0.4 mg	Description
			Identification (by HPLC)

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Average weight
			Uniformity of content (by HPLC)
			Disintegration time
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
437	579	Flavoxate Tablets IP/BP 200 mg (Coated Tablet)	Description
			Identification A (by IR)
			Identification B (by TLC)
			Average weight
			Uniformity of weight
			Disintegration Time
			Related substances (by TLC)
			3-Methylflavone-8-carboxylic acid (by TLC)
			Assay: (by UV)
			Identification of colours
438	580	Chlorhexidine Mouthwash IP/BP 0.2%	Description
			Identification (by HPLC)
			4-Chloroaniline (by GC)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
			Identification of colours
439	581	Dental Gel: Choline salicylate 8.7%, Benzalkonium Chloride 0.01%, Lignocaine HCl 2% (flavoured gel base)	Description
			Identification of Choline salicylate (by HPLC)
			Identification of Lignocaine hydrochloride (by HPLC)
			Contents of Packaged Dosage Forms
			Assay:
			Choline salicylate (by HPLC)
			Lignocaine hydrochloride (by HPLC)
440	582	Tooth Gel: Sodium Monofluorophosphate 0.7% and Potassium Nitrate 5% (in flavoured base)	Description
			For Potassium Nitrate (by Flame Photometer)
			For Sodium Monofluorophosphate
			Net Weight
			Assay (by fame Photometer)
441	583	Gum Paint containg Tannic acid 2%, Cetrimide 0.1%, Zinc Chloride 1%	Description
			Identification
			Weight
			Nominal Value
			Microbial Examination
			Total aerobic count
			Total fungal count
			E. coli

Sr	Code No.	Name of item with specification	Test proposed to be carried out
442	584	Metronidazole 1% and Chlorhexidine gluconate 0.25% Gel	Description
			Identification of Metronidazole benzoate (by HPLC)
			Identification of Chlorhexidine gluconate (by HPLC)
			Contents of Packaged Dosage Forms
			Assay:
			Metronidazole (by HPLC)
			Chlorhexidine gluconate (by HPLC)
443	585	Ciprofloxacin 0.3% and Dexamethasone 0.1% Ear Drops Ciprofloxacin and Dexamethasone Otic Suspension USP	Description
			Identification of ciprofloxacin (by HPLC)
			Identification of dexamethasone (by HPLC)
			pH
			Contents of Packaged Dosage Forms
			Assay:
			Ciprofloxacin (by HPLC)
Dexamethasone (by HPLC)			
444	586	Clotrimazole 1% with Beclomethasone Dipropionate 0.025% Ear Drops	Description
			Identification of Beclomethasone Dipropionate (by HPLC)
			Identification of Clotrimazole (by HPLC)
			pH
			Contents of Packaged Dosage Forms
			Assay:
			Beclomethasone Dipropionate (by HPLC)
Clotrimazole (by HPLC)			
445	588	Neomycin, Polymixin B and Hydrocortisone Ear Drops	Description
			Identification (by TLC)
			pH
			Net content
			Assay:
			Neomycin sulphate (by Microbiological assay)
			Polymixin B Sulphate (by Microbiological assay)
			Hydrocortisone (by HPLC)
			Sterility
446	589	Ceruminolytic Drops (Wax dissolving ear drops): Paradichlorobenzene 2%, Benzocaine 2.7%, Chlorbutol 5%, Turpentine oil 15%	Description
			Identification of Benzocaine (by GC)
			Identification of Chlorbutol (by GC)
			Identification of Turpentine oil (by GC)

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Identification of Paradichlorobenzene (by GC)
			Weight per ml
			Contents of Packaged Dosage Forms
			Assay:
			Benzocaine (by GC)
			Chlobutol (by GC)
			Turpentine oil (by GC)
			Paradichlorobenzene (by GC)
447	590	Domeperidone Oral Drops 10 mg/ ml	Description
			Identification (by HPLC)
			pH
			Contents of Packaged Dosage Forms
			Identification of colour by TLC
			Assay: (by HPLC)
			Microbial Examination
			Total aerobic count
			Total fungal count
			E. coli
448	591	Drotaverine & Mefenamic Acid Tablets Drotaverine 80 mg and Mefenamic Acid 250 mg	Description
			Identification of Mefenamic acid (by HPLC)
			Identification of Drotaverine hydrochloride (by HPLC)
			Average weight
			Uniformity of weight
			Disintegration Time
			Contents of Packaged Dosage Forms
			Assay:
			Drotaverine Hydrochloride (by HPLC)
			Mefenamic acid (by HPLC)
			Identification of colour
449	592	Lactic Acid Bacillus Tablets 60 million spores	Description
			Identification
			Average weight
			Uniformity of weight
			Contents of Packaged Dosage Forms
			Disintegration time
			Assay: (by Microbiological assay)
450	593	Lactulose solution USP/ BP 10 gm/ 15 ml or 3.35gm/5 ml	Description
			Identification A (by HPLC)
			Identification B
			Organic impurities (by HPLC)

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Fructose
			Galactose
			Epilactose
			Lactose
			Microbial Enumeration Test and tests for specified microorganisms:
			Total bacterial count
			Salmonella
			E. coli
			pH
			Assay: (by HPLC with RI detector)
			Uniformity of dosage units
451	594	Liquid Paraffin IP	Description
			Weight per ml
			Dynamic viscosity
			Acidity or alkalinity
			Light absorption (by UV)
			Readily carbonisable substances
			Solid paraffins
			Sulphur compounds
			Net content
452	595	Ondansetron Orally Disintegrating Tablets IP 4 mg	Description
			Identification (by HPLC)
			Average weight
			Disintegration Time
			Dissolution (by HPLC)
			Related substances (by HPLC)
			Uniformity of content (by HPLC)
			Contents of packaged dosage forms
			Assay: (by HPLC)
453	596	Pantoprazole 40 mg and Domperidone 30 mg SR Capsules Pantoprazole as enteric coated pellets, and Domperidone as sustained release pellets	Description
			Identification of Pantoprazole (by HPLC)
			Identification of Domperidone (by HPLC)
			Average net content
			Uniformity of weight
			Dissolution
			Acid stage: Pantoprazole (by HPLC)
			Buffer stage: Pantoprazole (by HPLC)
			Dissolution: Release pattern of Domperidone (by HPLC)
			After 1 hour
			After 4 hours
			After 8 hours
			After 12 hours

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Contents of Packaged Dosage Forms
			Assay:
			Pantoprazole (by HPLC)
			Domperidone (by HPLC)
			Identification of colours
454	597	Ursodeoxycholic Acid Tablets 300 mg	Description
			Identification A (by IR)
			Identification B (by HPLC)
			Average weight
			Uniformity of weight
			Contents of Packaged Dosage Forms
			Dissolution (by HPLC)
			Related substances (by TLC)
			Assay: (by HPLC)
			Identification of colour
455	598	Allopurinol Tablets IP 100 mg	Description
			Identification A (by UV)
			Identification B
			Average weight
			Uniformity of weight
			Related substances (by HPLC)
			Dissolution (by UV)
			Contents of Packaged Dosage Forms
			Assay: (by UV)
456	599	Hydroxychloroquine Sulphate Tablets 200 mg	Description
			Identification A (by IR)
			Identification B
			Average weight
			Uniformity of weight
			Related substances (by HPLC)
			Dissolution (by UV)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
			Identification of colour
457	600	Leflunomide Tablets IP/USP 10 mg (Film coated)	Description
			Identification A By UV
			Identification B by HPLC
			Average Weight
			Dissolution by UV
			Uniformity of Content by HPLC
			Contents of Packaged Dosage Forms
			Assay By HPLC

Sr	Code No.	Name of item with specification	Test proposed to be carried out
458	601	Leflunomide Tablets IP/USP 20 mg (Film coated)	Description
			Identification A By UV
			Identification B by HPLC
			Average Weight
			Dissolution by UV
			Uniformity of Weight
			Contents of Packaged Dosage Forms
459	602	Sulfasalazine Delayed Release Tablets USP/ Gastroresistant Sulfasalazine Tablets BP 500 mg	Description
			Identification A by IR
			Identification B by HPLC
			Average weight
			Contents of Packaged Dosage Forms
			Uniformity of Weight
			Related Substances by HPLC
			Salicylic Acid and Sulfapyridine by HPLC
			Dissolution by UV
			Impurities by HPLC
			Assay by UV
460	603	Gliclazide and Metformin Tablets Gliclazide 80 mg and Metformin Hydrochloride 500 mg	Description
			Identification of Gliclazide (By HPLC)
			Identification of Metformin hydrochloride (By UV)
			Average weight
			Uniformity of weight
			Disintegration Time
			Contents of Packaged Dosage Forms
			Assay:
			Gliclazide (by HPLC)
			Metformin hydrochloride (by UV)
461	604	Glucagon for Injection USP 1 mg	Description
			Identification By HPLC
			Uniformity of weight
			Bacterial endotoxins
			pH
			Particulate matter
			Average Weight
			Clarity of Solution
			Sterility
Assay by HPLC			
462	605	Medroxyprogesterone acetate Tablets IP 10 mg	Description
			Identification (by IR)

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Average weight
			Related substances (by HPLC)
			Impurity F (by TLC)
			Uniformity of content (by UV)
			Dissolution (by UV)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
463	607	Thyroxine Tablets IP 50 mcg	Description
			Identification A
			Identification B (by HPLC)
			Average weight
			Uniformity of content (by HPLC)
			Contents of Packaged Dosage Forms
			Disintegration time
			Assay (by HPLC)
464	608	Octreotide Injection 50 mcg/ ml	Description
			Identification by HPLC
			Particulate matter
			Extractable volume
			Assay by HPLC
			Sterility
465	610	Chlorzoxazone , Diclofenac Sodium & Paracetamol Tablets (Chlorzoxazone 250 mg, Diclofenac Sodium 50 mg & Paracetamol 325 mg)	Description
			Identification of Chlorzoxazone (by HPLC)
			Identification of Diclofenac sodium (by HPLC)
			Identification of Paracetamol (by HPLC)
			Average weight
			Uniformity of weight
			Disintegration Time
			Contents of Packaged Dosage Forms
			Assay:
			Chlorzoxazone (by HPLC)
			Diclofenac sodium (by HPLC)
			Paracetamol (by HPLC)
466	613	Carboxymethylcellulose Eye Drops 0.5%	Description
			Identification A
			Identification B
			Identification C
			pH
			Contents of Packaged Dosage Forms
			Assay: (by UV)
			Sterility

Sr	Code No.	Name of item with specification	Test proposed to be carried out			
467	615	Mifepristone Tablets IP 200 mg	Description			
			Identification A (by HPLC)			
			Identification B (by UV)			
			Average weight			
			Uniformity of weight			
			Dissolution (by UV)			
			Related substances (by HPLC)			
			Contents of Packaged Dosage Forms			
			Assay: (by HPLC)			
468	616	Formoterol Fumerate and Budesonide Powder for Inhalation IP 6 mcg + 200 mcg	Description			
			Identification (by HPLC)			
			Average weight			
			Uniformity of delivered dose of: (by HPLC)			
			Formoterol Fumerate			
			Budesonide			
			Contents of Packaged Dosage Forms			
						Assay:
			Formoterol Fumerate (by HPLC)			
Budesonide (by HPLC)						
469	617	Budesonide Powder for Inhalation 200 mcg	Description			
			Identification A (by UV)			
			Identification B (by HPLC)			
			Average weight			
			Epimer A (by HPLC)			
			Uniformity of delivered dose (by HPLC)			
			Related substances (by HPLC)			
			Number of deliveries per container			
						Assay: (by HPLC)
						Microbial contamination
						E.Coli
						S. Aureues
			Psedu. Auroginosa			
470	618	Ipratropium Powder for Inhalation IP 40 mcg	Description			
			Identification A (by TLC)			
			Identification B (by Chemically)			
			Identification B (by HPLC)			
			Average weight			
			Average Fill			
			Uniformity of content			
			Assay: (by HPLC)			
471	619	Terbutaline Tablets IP 2.5 mg	Description			
			Identification A (by UV)			
			Identification B (by TLC)			

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Average weight
			Uniformity of content (by UV)
			Dissolution (by UV)
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by UV)
472	620	Xylometazoline Nasal Drops IP 0.1 %	Description
			Identification A (by IR)
			Identification B
			pH
			Contents of Packaged Dosage Forms
			N-(2-Aminoethyl)-4-Tert -butyl-2,6-Xylylacetamide (by TLC)
			Assay:
			Xylometazoline hydrochloride (by UV)
473	621	Sodium Chloride Injection IP	Description
			Identification
			Heavy metals
			pH
			Particulate contamination (by particle counter)
			Extractable volume
			Bacterial endotoxins
			Assay: Sodium chloride
			Sterility (by MF)
474	622	Calcium Carbonate & vitamin D3 Tablets/Calcium with Vitamin D Tablets USP/ Calcium and Colecalciferol Tablets BP	Description
			Identification A (by HPLC)
			Identification B
			Average weight
			Uniformity of mass
			Uniformity of content: (Vitamin D3) (by HPLC)
			Assay:
			Calcium carbonate (by titration)
			Vitamin D3 (by HPLC)
475	623	Cholecalciferol granules 60, 000 IU/ gm	Description
			Identification (by HPLC)
			Uniformity of content (by HPLC)
			Seal test
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
476	624	Mecobalamin Injection 500 mcg/ ml	Description
			Identification (by UV)
			pH

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Bacterial endotoxins
			Extractable volume
			Particulate matter
			Assay: (by HPLC)
			Sterility (by MF)
477	627	Pyridoxine Tablets IP 40 mg	Description
			Identification A (by UV)
			Identification B
			Average weight
			Related substances (by TLC)
			Uniformity of weight
			Disintegration Time
			Contents of Packaged Dosage Forms
			Assay: by UV)
478	629	Thiamine Tablets IP 100 mg	Description
			Identification A
			Identification B
			Identification C
			Average weight
			Uniformity of content (by UV)
			Disintegration time
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
479	630	Calcitriol Capsules IP 0.25 mcg	Description
			Identification by HPLC
			Average weight
			Disintegration
			uniformity of container content packaged dosage form
			Uniformity of content
			Assay by HPLC
480	631	Alendronate Sodium Tablets USP / BP 35 mg	Description
			Identification A by TLC
			Identification B by HPLC
			Average weight
			Uniformity of Weight
			Dissolution by HPLC
			Contents of Packaged Dosage Forms
			Related Substances by HPLC
			4-Aminobutanoic Acid by HPLC
			Assay by HPLC
481	632	Mannitol with Glycerin Injection 10% +10% w/v (For Intravenous Infusion)	Description
			Identification of mannitol (by TLC)
			Identification of glycerin

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			pH
			Particulate contamination (by particle counter)
			Bacterial endotoxins
			Extractable volume
			Assay:
			Mannitol (by volumetric analysis)
			Glycerin (by volumetric analysis)
			Sterility
482	634	Pregabalin Capsules IP 75 mg	Description
			Identification (by HPLC)
			Average net content
			Uniformity of weight
			Dissolution (by HPLC)
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
483	636	Ramipril Tablet IP 2.5 mg	Description
			Identification (by IR)
			Average weight
			Uniformity of content (by HPLC)
			Dissolution (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
484	638	Neostigmine Injection IP 2.5 mg/5 ml	Description
			Identification A (by UV)
			Identification B (by TLC)
			Identification C
			pH
			3-Hydroxy trimethylanilinium methyl sulphate (by HPLC)
			Extractable volume
			Particulate matter
			Assay: (by UV)
			Sterility (by MF)
485	639	Oseltamivir Capsule IP 75 mg	Description
		[Each Capsule contains Oseltamivir	Identification (by HPLC)
		Phosphate equivalent to Oseltamivir	Average net content
		75 mg]	Uniformity of weight
			Contents of Packaged Dosage Forms
			Dissolution (by UV)
			Related substances (by HPLC)
			Assay: (by HPLC)
486	640	Oseltamivir Capsule IP 45 mg	Description

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Identification (by HPLC)
			Average net content
			Uniformity of weight
			Contents of Packaged Dosage Forms
			Dissolution (by UV)
			Related substances (by HPLC)
			Assay: (by HPLC)
487	641	Oseltamivir Capsule IP 30 mg	Description
			Identification (by HPLC)
			Average net content
			Uniformity of weight
			Contents of Packaged Dosage Forms
			Dissolution (by UV)
			Related substances (by HPLC)
			Assay: (by HPLC)
488	642	Oseltamivir Phosphate for Oral Suspension IP 12 mg/ml.	Description
			Identification A (by HPLC)
			Identification B
			Water
			pH
			Contents of Packaged Dosage Forms
			Weight per ml
			Related substances (by HPLC)
			Assay: (by HPLC)
			Stability of suspension (by HPLC)
			Microbial Examination
			Total aerobic count
			Total fungal count
			E. coli
489	644	Vitamin K1 (Phytomenadione) Injection 1 mg/0.5 ml Ampoule	Description
			Identification A (by UV)
			Identification B (by UV)
			pH
			Particulate Matter
			Extractable volume
			Sterility
			Assay by HPLC
490	645	ACT Containing 3 tablet of Artesunate (each tablet of artesunate 25 mg strength) and 1 tablet of Sulphadoxine Pyrimethamine (250 mg +12.5 mg)	Artesunate tablets
			Description
			Identification (by HPLC)
			Average weight
			Uniformity of weight
			Disintegration time

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Contents of Packaged Dosage Forms Assay: (by HPLC) Pyrimethamine and sulphadoxine tablets IP Description Identification (by TLC) Average weight Uniformity of weight Disintegration time Uniformity of content: pyrimethamine (by HPLC) Contents of Packaged Dosage Forms Assay: Pyrimethamine (by HPLC) Sulphadoxine (by HPLC)
491	646	ACT Containing 3 tablets of Artesunate (50mg each) and 1 tablet of Sulphadoxine and Pyrimethamine (500+25)mg	Artesunate tablets Description Identification (by HPLC) Average weight Uniformity of weight Disintegration time Contents of Packaged Dosage Forms Assay: (by HPLC) Pyrimethamine and sulphadoxine tablets IP Description Identification (by TLC) Average weight Uniformity of weight Disintegration time Uniformity of content: pyrimethamine (by HPLC) Contents of Packaged Dosage Forms Assay: Pyrimethamine (by HPLC) Sulphadoxine (by HPLC)
492	647	ACT Containing 3 tablets of Artesunate(100mg each) and 1 tablet of Sulphadoxine Pyremethamine (750+37.5) mg, ACT Containing 3 tablets of Artesunate 150mg and 2 tablets of Sulphadoxine	Artesunate tablets Description Identification (by HPLC) Average weight Uniformity of weight Disintegration time

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
			Pyrimethamine and sulphadoxine tablets IP
			Description
			Identification (by TLC)
			Average weight
			Uniformity of weight
			Disintegration time
			Uniformity of content: pyrimethamine (by HPLC)
			Contents of Packaged Dosage Forms
			Assay:
			Pyrimethamine (by HPLC)
			Sulphadoxine (by HPLC)
493	648	ACT Containing 3 tablets of Artesunate 150mg and 2 tablets of Sulphadoxine Pyremethamine(500mg+25mg)	Artesunate tablets
			Description
			Identification (by HPLC)
			Average weight
			Uniformity of weight
			Disintegration time
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
			Pyrimethamine and sulphadoxine tablets IP
			Description
			Identification (by TLC)
			Average weight
			Uniformity of weight
			Disintegration time
			Uniformity of content: pyrimethamine (by HPLC)
			Contents of Packaged Dosage Forms
			Assay:
			Pyrimethamine (by HPLC)
			Sulphadoxine (by HPLC)
494	649	ACT Containing 3 tablets of Artesunate (each 200 mg) and 2 tablets of Sulphadoxine Pyremethamine (750+37.5) mg each or 3 tablets Sulphadoxine Pyremethamine (500+25)mg each	Artesunate tablets
			Description
			Identification (by HPLC)
			Average weight
			Uniformity of weight
			Disintegration time

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
			Pyrimethamine and sulphadoxine tablets IP
			Description
			Identification (by TLC)
			Average weight
			Uniformity of weight
			Disintegration time
			Uniformity of content: pyrimethamine (by HPLC)
			Contents of Packaged Dosage Forms
			Assay:
			Pyrimethamine (by HPLC)
			Sulphadoxine (by HPLC)
495	650	Glyceryl Trinitrate Tablets IP 2.6 mg Controlled	Description
			Identification B by HPLC
			Average Weight
			Uniformity of Content by HPLC
			Dissolution
			1 Hour
			2 hour
			3 hour
			Assay by HPLC
			Contents of Packaged Dosage Forms
496	651	Artemether and Leumefantrin Tablets (80 mg + 480 mg)	Description
			Identification of:
			Artemether (by HPLC)
			Lumefantrine (by HPLC)
			Average weight
			Uniformity of weight
			Dissolution by HPLC
			Artemether
			Lumefantrine
			Related Substances (By HPLC)
			Contents of Packaged Dosage Forms
			Assay:
			Lumefantrine (by HPLC)
			Artemether (by HPLC)
497	652	Methylcobalmine 500 mcg Tablets	Description
			Identification (by HPLC)
			Average weight

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Uniformity of content (by HPLC)
			Contents of Packaged Dosage Forms
			Disintegration time
			Assay: (by HPLC)
			Identification of colour
498	653	Methylcobalmine 1500 mcg Tablets	Description
			Identification (by HPLC)
			Average weight
			Uniformity of content (by HPLC)
			Contents of Packaged Dosage Forms
			Disintegration time
			Assay: (by HPLC)
			Identification of colour
499	654	Atropine Sulphate Injection IP 0.6 mg/ml (SC/IM/IV use)	Description
			Identification A (by TLC)
			Identification B (by HPLC)
			pH
			Bacterial endotoxins
			Extractable volume
			Particulate matter
			Assay: (by HPLC)
			Sterility
500	655	Fentanyl Citrate Injection IP 50 mcg/ml	Description
			Identification A (by UV)
			Identification B (by HPLC)
			Identification C (Chemical)
			Related Substances (By HPLC)
			Bacterial endotoxins
			Particulate matter
			Extractable volume
			Assay: (by HPLC)
			Sterility
501	656	Naproxen Tab IP 500 mg	Description
			Identification A (by IR)
			Identification B (by UV)
			Average weight
			Uniformity of weight
			Dissolution (by UV)
			Related substances (by TLC)
			Contents of Packaged Dosage Forms
			Assay: (by UV)
502	657	Naproxen Tab IP 250 mg	Description
			Identification A (by IR)

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Identification B (by UV)
			Average weight
			Uniformity of weight
			Dissolution (by UV)
			Related substances (by TLC)
			Contents of Packaged Dosage Forms
			Assay: (by UV)
503	658	Etoricoxib Tablets IP 90 mg	Description
			Identification (by HPLC)
			Average weight
			Dissolution (by HPLC)
			Uniformity of weight
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
			Identification of colour
504	659	Levocetirizine Tablet 5 mg	Description
			Identification A (by HPLC)
			Average weight
			Uniformity of content by HPLC
			Dissolution (by HPLC)
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
505	661	Sodium Valproate (Gastro-resistant) IP 500 mg Tab	Description
			Identification (by IR)
			Average weight
			Uniformity of Weight
			Disintegration Time
			Related substances (by GC)
			Contents of Packaged Dosage Forms
			Assay: (by GC)
506	662	Clobazam 5 mg Tablet/Capsule	Description
			Identification (by IR)
			Average weight
			Uniformity of Content
			Dissolution (by HPLC)
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)

Sr	Code No.	Name of item with specification	Test proposed to be carried out
507	663	Clobazam 10 mg Tablet/Capsule	Description
			Identification (by IR)
			Average weight
			Uniformity of Content
			Dissolution (by HPLC)
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
508	660	Montelukast (10 mg) +Levocetrazine (5mg) Tablets	Description
			Identification (HPLC)
			Montelukast
			Levocetrazine
			Average weight
			Dissolution of:
			Montelukast (by HPLC)
			Levocetrazine (by HPLC)
			Related substances (by HPLC)
			Content uniformity of:
			Montelukast (by HPLC)
			Levocetrazine (by HPLC)
			Content of package dosage form
			Assay:
Montelukast (by HPLC)			
Levocetrazine (by HPLC)			
509	664	Levetiracetam 500 mg Tablets IP	Description
			Identification A (by IR)
			Identification B (by HPLC)
			Average weight
			Uniformity Of Weight
			Dissolution (by HPLC)
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
510	665	Levetiracetam 100 mg/ml oral solution	Description
			Identification (by HPLC)
			pH
			Relates substances (by HPLC)
			Weight per ml
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
			Identification of colour (by TLC)
			Microbial Examination
			Total aerobic count
			Total fungal count

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			E. coli
511	666	Levetiracetam Injection 500 mg/5ml USP	Description
			Identification (by HPLC)
			Organic Impurity (by HPLC)
			pH
			Bacterial endotoxins
			Extractable volume
			Clarity of Solution
			Particulate matter (by Liquid particle analyser)
			Assay: (by HPLC)
			Sterility
512	667	Gabapentin Tablets 100 mg	Description
			Identification A (by IR)
			Identification B (by HPLC)
			Average net content
			Uniformity of weight
			Dissolution (by HPLC)
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
513	668	Gabapentin Cap 300 mg	Description
			Identification A (by IR)
			Identification B (by HPLC)
			Average weight
			Uniformity of weight
			Dissolution (by HPLC)
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
514	669	Co-trimoxazole Tablets IP Trimethoprim 160 mg and Sulphamethoxazole 800 mg	Description
			Identification A (by IR)
			Identification B (by IR)
			Identification C (by TLC)
			Average weight
			Contents of Packaged Dosage Forms
			Uniformity of weight
			Disintegration Time
			Assay: by HPLC
			Trimethoprim (by UV)
			Sulphamethoxazole (by titration)
515	670	Coal tar 6% & Salicylic Acid 3% Ointment	Description
			Identification of Coal Tar

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Identification of Salicyclic acid (by UV)
			Contents of Packaged Dosage Forms
			Assay:
			Coal Tar
			Salicyclic acid (by UV)
516	671	Calamine Lotion IP	Description
			Identification A
			Identification B
			Contents of Packaged Dosage Forms
			Microbial Contamination
			Staphylococcus aureus
			Pseudomonas aeruginosa
			Additional test: Content of
			Total Zinc oxide Volumetric analysis
			Glycerin Volumetric analysis
			Sodium citrate (by UV)
517	672	Iohexol USP (Solution for injection) Non Ionic contrast medium in Sterile aqueous solution 350 mg Iodine/ml.	Description
			Identification by HPLC
			Bacterial endotoxins
			pH
			Free Iodide
			Organic Impurities by HPLC
			Particulate matter
			Extractable volume
			Assay
			Sterility (by MF)
518	674	Quetiapine Tab IP 50 mg	Description
			Identification (by HPLC)
			Average weight
			Uniformity of Weight
			Dissolution (by UV)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
519	675	Quetiapine Tab IP 25 mg	Description
			Identification (by HPLC)
			Average weight
			Uniformity of Weight
			Dissolution (by UV)
			Contents of Packaged Dosage Forms

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Assay: (by HPLC)
520	676	Vitamin D3 Oral Solution 60000 IU	Description
			Identification (by HPLC)
			Weight per ml
			Acid value
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
			Microbial Examination
			Total aerobic count
			Salmonella
			Total fungal count
			E. coli
521	677	Cyclosporin Capsules IP 50 mg	Description
			Identification (by HPLC)
			Average net content
			Uniformity of weight
			Dissolution (by HPLC)
			Water
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
522	678	Clonazepam Tablets IP 0.5 mg	Description
			Identification A (by IR)
			Identification B (by HPLC)
			Average weight
			Uniformity of content (by HPLC)
			Dissolution (by HPLC)
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
523	679	Aspirin Tablets IP (Gastro-resistant) 150 mg	Description
			Identification (Chemical)
			Average weight
			Dissolution A:
			At acid stage (by UV)
			Dissolution B:
			At buffer stage (by UV)
			Uniformity of weight
			Contents of Packaged Dosage Forms
			Salicylic acid (by HPLC)
			Assay: (by HPLC)
			Identification of colours (by TLC)
			524

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Identification of Teneiglipitin (by HPLC)
			Average weight
			Uniformity of weight
			Related substances (by HPLC)
			Dissolution (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
525	683	Aztreonam Injection 1 gm	Description
			Identification (HPLC)
			Average fill weight
			Content of Arginine (HPLC)
			Uniformaty of Dosage Units
			Constituted Solution
			Water
			Clarity of solution test a and b
			pH
			Bacterial endotoxins
			Particulate matter
			Assay: by HPLC
			Sterility
526	684	Framycetin Sulphate Cream 1%	Description
			Identification
			Framycetin Sulphate
			Methyl Paraben (By HPLC)
			Propyl Paraben (By HPLC)
			Check for Particulate matter
			Average fill weight
			Contents of Packaged Dosage Forms
			Assay:
			Framycetin Sulphate (Microbial Assay)
			Methyl Paraben (By HPLC)
			Propyl Paraben (By HPLC)
527	685	Framycetin Sulphate Cream 1%	Description
			Identification
			Framycetin Sulphate
			Methyl Paraben (By HPLC)
			Propyl Paraben (By HPLC)
			Check for Particulate matter
			Average fill weight
			Contents of Packaged Dosage Forms
			Assay:
			Framycetin Sulphate (Microbial Assay)
			Methyl Paraben (By HPLC)

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Propyl Paraben (By HPLC)
528	686	Artemether and Lumefantrine Tablets (40 mg + 240 mg)	Description
			Identification of:
			Artemether (by HPLC)
			Lumefantrine (by HPLC)
			Average weight
			Uniformity of weight
			Dissolution by HPLC
			Artemether
			Lumefantrine
			Related Substances (By HPLC)
			Contents of Packaged Dosage Forms
			Assay:
			Lumefantrine (by HPLC)
Artemether (by HPLC)			
529	687	Concentrated Solution for Haemodialysis B.P Sodium Hydrogen carbonate concentrate in 10 Litre Cans.	Description
			Identification for
			Potassium
			Calcium
			Sodium
			Chlorides
			Lactates
			Carbonates and hydrogen carbonates
			Magnesium
			Glucose
			Tests for
			Appearance of solution
			Aluminium
			Extractable volume
			Microbial contamination: TAMC.
			Bacterial endotoxins
			Assay for:
			Sodium by AAS & AES
			Potassium by AAS
			Calcium by AAS
			Magnesium by AAS
Total chloride by titration			
Acetate by potentiometric titration			
Lactate by potentiometric titration			
Sodium hydrogen carbonate by potentiometric titration			
Reducing sugars by titration			
530	692	Cough Syrup/Expectorant Each 5ml contains Ambroxol 15mg, Terbutaline Sulphate IP 1.5mg, Guaphenesin IP 50mg, Menthol IP 1mg.	Description
			Identification of:
			Ambroxol Salt

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Guaphenesin
			Terbutaline
			Menthol
			Sulphate
			Chlorides
			pH
			Weight per ml
			Contents of Packaged Dosage Forms
			Identification of colour
			Assay:
			Ambroxol (by HPLC)
			Guaphenesin (by Chemical)
			Terbutaline (blank titration)
			Menthol (by UV)
			Microbiological Examination
			Total Aerobic count
			Total Fungal count
			E. coli
531	791	Intravenous Fat Emulsion 20% w/v (PL/TG Ratio 0.06) 250ml	Description
			Identification
			Extractable volume
			pH
			Density
			Globule Size (A) By Microscopre
			Globule Size (A) By Master Size
			Potential Impurities
			(A) Peroxide Value (By Titration)
			(B) Free Fatty Acid (By HPLC)
			Bacterial endotoxins
			Assay
			Long Chain Triglycerides (BY HPLC)
			Medium Chain Triglycerides (BY HPLC)
			Glycerol (BY Titration)
			phospholipids
			Egg Lecithin (BY UV)
			Sterility
532	797	Tab Dasatinib 100mg	Description
			Identification (by HPLC)
			Average weight
			Uniformity of weight
			Related Substances (By HPLC)
			Dissolution (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Identification of colour
533	489B	Iron and folic Acid tablet Each sugar-coated tablet containing 60mg elemental iron+500mcg folic acid, , blue colour	Description
			Identification of:
			Folic acid (by HPLC)
			Dried Ferrous sulphate
			Average weight
			Uniformity of weight
			Free Ferric iron compound
			Uniformity of content: Folic acid (by HPLC)
			Disintegration Time
			Contents of Packaged Dosage Forms
			Assay:
			Folic acid (by HPLC)
			Dried ferrous sulphate calculated as elemental iron
Identification of colour			
534	490R	Iron and folic Acid tablet each Sugar-coated tablet containing 60mg elemental Iron+500mcg folic Acid, red colour	Description
			Identification of:
			Folic acid (by HPLC)
			Dried Ferrous sulphate
			Average weight
			Uniformity of weight
			Ferric iron
			Uniformity of content: Folic acid (by HPLC)
			Disintegration Time
			Contents of Packaged Dosage Forms
			Assay:
			Folic acid (by HPLC)
			Dried ferrous sulphate calculated as elemental iron
Identification of colour			
535	100A	Chloroquine Phosphate Suspension IP 50 mg/5ml	Description
			Identification (by IR)
			pH
			Contents of Packaged Dosage Forms
			Identification of colour (by TLC)
			Assay: Chloroquine phosphate (volumetric analysis)
			Microbial Examination
			Total aerobic count
Total fungal count			
E. coli			
536	215A	Certimide Cream IP 0.5%	Description
			Identification A
			Identification B

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Contents of Packaged Dosage Forms
			Assay: Cetrimide (titration)
537	216A	Fusidic Acid Cream IP 2%	Description
			Identification A by TLC
			Identification B by HPLC
			pH
			Related Substances (by HPLC)
			Uniformity of Weight (Content)
			Assay by HPLC
538	257A	Mannitol Injection IP 20% w/v	Description
			Identification A (by melting point)
			Identification B (by TLC)
			Identification C
			pH
			Particulate contamination (by particle counter)
			Bacterial endotoxins
			Extractable volume
			Assay: volumetric analysis
			Sterility
539	260A	Antacid Tablets	Description
			Identification for Aluminium
			Identification for Magnesium
			Average weight
			Uniformity of weight
			Acid neutralizing capacity
			Contents of Packaged Dosage Forms
			Assay:
			Dried aluminium hydroxide gel (titration)
			Magnesium trisilicate (titration)
			Identification of colour (by TLC)
540	261A	Antacid Liquid	Description
			Identification for aluminium
			Identification for magnesium
			Identification for polydimethylsiloxane (by IR)
			pH
			Acid neutralizing capacity
			Contents of Packaged Dosage Forms
			Assay:
			Dried aluminium hydroxide gel (titration)
			Magnesium hydroxide (titration)
			Polydimethylsiloxane (by IR)

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Identification of colour (by TLC)
			Microbial Examination
			Total aerobic count
			Total fungal count
			E. coli
541	439A	Dicyclomine and Paracetamol Tablets Dicyclomine Hydrochloride 20 mg + Paracetamol 325 mg Tablets	Description
			Identification of Dicyclomine hydrochloride
			Identification of Paracetamol
			Average weight
			Uniformity of weight
			Uniformity of content: Dicyclomine Hydrochloride (by UV)
			Disintegration Time
			Uniformity of container contents: Contents of Packaged Dosage Forms
			Assay:
			Dicyclomine Hydrochloride (by UV)
			Paracetamol 500 mg (by UV)
542	448W	IRON AND FOLIC ACID SYRUP IP	Description
			Identification A
			Identification B
			Identification C (by HPLC)
			Weight per ml
			pH
			Contents of Packaged Dosage Forms
			Microbial Contamination
			Total aerobic viable count
			E. coli
			Assay: Folic acid 0.5 mg (by HPLC)
			Ferrous sulphate calculated as elemental iron
			Identification of colour (by TLC)
543	490W	IRON AND FOLIC ACID TABLETS (WIFS JUNIOR)	Description
			Identification of Folic acid (by HPLC)
			Identification of dried ferrous sulphate
			Average weight
			Uniformity of weight
			Ferric iron
			Uniformity of content: Folic acid (by HPLC)
			Disintegration Time
			Contents of Packaged Dosage Forms

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Assay:
			Folic acid (by HPLC)
			Dried ferrous sulphate calculated as elemental iron
			Identification of colour
544	508A	Artesunate Injection 60 mg (I.M./I.V. Use) Each	Description
		Combo Pack contains Artesunate Injection 60 mg Vial, Sodium Bicarbonate Injection IP 5% w/v (1 ml ampoule), Sodium chloride Injection IP 0.9% w/v (5 ml ampoule)	Artesunate Injection
			Description
			Identification (by HPLC)
			Average net content
			Uniformity of weight
			Clarity of solution test a and b
			Particulate matter
			Assay: (by HPLC)
			Sterility (by MF)
			Sodium Bicarbonate
			Description
			Identification A
			Identification B
			pH
			Extractable volume
			Particulate matter
			Bacterial endotoxins
			Assay: Sodium bicarbonate
			Sterility (by MF)
			Sodium chloride
			Description
			Identification
			Heavy metals
			pH
			Extractable volume
			Bacterial endotoxins
			Assay: Sodium chloride
			Sterility (by MF)
545	66A	Albendazole Tablets IP 400 mg (Colour: Sunset Yellow FCF in suitable Flavoured Base)	Description
			Identification A (by TLC)
			Identification B (by UV)
			Average weight
			Uniformity of weight
			Contents of Packaged Dosage Forms
			Assay: (by UV)
			Identification of colour
546	78A	Azithromycin Tablets 100 mg Dispersible	Description

Sr	Code No.	Name of item with specification	Test proposed to be carried out
		Tablets	Identification (by HPLC)
			Average weight
			Uniformity of weight
			Water
			Contents of Packaged Dosage Forms
			Disintegration time
			Uniformity of dispersion
			Assay: (by HPLC)
547	79A	Azithromycin Tablets IP 250 mg	Description
			Identification (by HPLC)
			Average weight
			Uniformity of weight
			Water
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms
			Dissolution (by HPLC)
			Assay: (by HPLC)
			Identification of colour
548	80A	Azithromycin Tablets IP 500 mg	Description
			Identification (by HPLC)
			Average weight
			Uniformity of weight
			Water
			Related substances (by HPLC)
			Contents of Packaged Dosage Forms
			Dissolution (by HPLC)
			Assay: (by HPLC)
			Identification of colour
549	NRD-186	Ceftriaxone and Sulbactam 1.5g Inj.	Description
			Identification (by HPLC)
			Ceftriaxone
			Salbactam
			pH
			Bacterial Endotoxins
			Average net content
			Uniformity of weight
			Clarity of solution test a and b
			Particulate matter
			Assay: (by HPLC)
			Ceftriaxone
			Salbactam
			Sterility
550	NRD-	Cefuroxime Inj. IP 1Gm	Description

Sr	Code No.	Name of item with specification	Test proposed to be carried out
	188		Identification A (by HPLC) Identification B pH Related substances (by HPLC) Bacterial endotoxins Water Average weight Uniformity of weight Particulate matter Clarity of solution A and B Assay: (by HPLC) Sterility
551	NRD-233	Fentanyl Transdermal Patch 25mg	As per STP of Firm
552	NRD-234	Fentanyl Transdermal Patch 50mg	As per STP of Firm
553	NRD-241	Folic acid Cyanocobalamine and Nicotinamide Inj. (Each ml contains Folic Acid 15mg, Cyanocobalamine 500mg, Nicotinamide 200mg) 10ml vial	Description Identification (by HPLC) Folic acid Cyanocobalamine Nicotinamide pH Bacterial Endotoxins Average net content Uniformity of weight Clarity of solution test a and b Particulate matter Assay: (by HPLC) Folic acid Cyanocobalamine Nicotinamide Sterility
554	NRD-259	Mefenamic acid 250mg+ dicyclomine hydrochloride 10mg Each Tablet contain Mefenamic acid 250mg+ dicyclomine hydrochloride 10mg	Description Identification Mefenamic Acid (By UV) Dicyclomine Hydrochloride (by HPLC) Average weight Uniformity of weight Dissolution Mefenamic Acid (By UV) Dicyclomine Hydrochloride (by HPLC) Uniformity of content: Dicyclomine Hydrochloride (by HPLC) Assay: Mefenamic Acid (By UV)

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Dicyclomine Hydrochloride (by HPLC)
			Identification of Colour
555	NRD-275	Lignocaine Inj. IP (preservative free) 2%	Description
			Identification A (Chemical)
			Identification B: Melting Point
			Identification C (Chemical)
			pH
			2,6-Dimethylaniline
			Bacterial endotoxins
			Nominal Volume
			Average Fill Volume
			Uniformity of Volume
			Particulate matter
			Assay: Lignocaine hydrochloride (by titration)
			Sterility
556	NRD-284	Enoxaparin Sodium Injection(Low Molecular Wt. Heparin) 40mg/ 0.4mg	Description
			Identification A (Chemical)
			Identification B (by UV)
			Identification C (Chemical)
			PH
			Benzyl Alcohol (If Present)
			Free Sulphate (Ion Chromatography)
			Bacterial endotoxins
			Extractable volume
			Particulate matter
			(Anti Factor Xa activity)
			(Anti Factor IIa activity)
			Anti factor Xa to Anti Factor Iia ratio
			Assay:(By UV)
			Sterility
557	NRD-288	Methotrexate Inj. IP 250 mg	Description
			Identification (by UV)
			pH
			Average net Content
			Uniformity Of weight
			Related substances (by HPLC)
			Bacterial endotoxins
			Particulate matter
			Extractable volume
			Assay: (by HPLC)
			Sterility
558	NRD-292	Methylprednisolon Acetate Inj. IP 125mg	Description
			Identification A (by IR)
			Identification B (by TLC)

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			pH
			Average net Content
			Uniformity Of weight
			Particulate matter
			Extractable volume
			Assay: (by HPLC)
			Sterility
559	NRD-293	Methotrexate Inj. IP 15mg (Preservative Free)	Description
			Identification (by UV)
			pH
			Average net Content
			Uniformity Of weight
			Related substances (by HPLC)
			Bacterial endotoxins
			Particulate matter
			Extractable volume
			Assay: (by HPLC)
			Sterility
560	NRD-315	Normal Saline 500 ml Glass Bottle IP	Description
			Identification (Chemical)
			Heavy metals
			pH
			Particulate contamination (by particle counter)
			Extractable volume
			Bacterial endotoxins
			Assay: Sodium chloride (Chemical)
			Sterility
561	NRD-316	Normal Saline 1000 ml Glass Bottle IP	Description
			Identification (Chemical)
			Heavy metals
			pH
			Particulate contamination (by particle counter)
			Extractable volume
			Bacterial endotoxins
			Assay: Sodium chloride (Chemical)
			Sterility
562	NRD-324	Inj. Paracetamol infusion 500 mg with both Temper evident caps (Each 100 ml contains Paracetamol 500 mg)	Description
			Identification A (by HPLC)
			Light Absorption
			Related Substances (by HPLC)
			pH
			Average net Content
			Extractable volume

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Particulate contamination (by particle counter)
			Bacterial endotoxins
			Assay:(by HPLC)
			Sterility
563	NRD-362	Ropivacaine Inj. IP 0.75% (Heavy)	Description
			Identification A (by HPLC)
			Identification B (by HPLC)
			Limit of Ropivacaine Related Compound (by HPLC)
			pH
			Enantiomeric Purity (by HPLC)
			Average net Content
			Uniformity Of weight
			Extractable volume
			Particulate matter
			Bacterial endotoxins
			Assay:(by HPLC)
			Sterility
564	NRD-369	Streptomycin Inj. IP 750mg	Description
			Identification A (by TLC)
			Identification B
			Identification C
			Identification D
			pH
			Loss on drying
			Average net Content
			Bacterial endotoxins
			Uniformity Of weight
			Clarity of solution test a and b
			Particulate matter
			Assay: (by Microbiological)
			Sterility
565	NRD-424	Formoterol 6 mcg. + Budesonide 400 mcg. MDI IP	Description
			Identification (by HPLC)
			Formetrol
			Budesonide
			Average weight
			Content of Active Ingredient delivered per actuation
			Uniformity of delivered dose
			Particle Size
			Number of deliveries per container
			leak test
			deposition of the emitted dose
			Contents of Packaged Dosage Forms

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Assay: (by HPLC)
			Formetrol
			Budesonide
566	NRD-438	Neomycin, Polmyxin and Bacitracin zinc ophthalmic Ointment 5 gm	Description
			Identification (by HPLC)
			Neomycin
			Polmyxin
			Bacitracin
			zinc
			pH
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
			Neomycin
			Polmyxin
			Bacitracin
			zinc (by chemical)
			Particle Size
			Sterility
567	NRD-444	Mercurium Chloride paint	Description
			Identification (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
568	NRD-534	6-Mercaptopurine Tab. IP 20 mg	Description
			Identification (by UV)
			Average weight
			Uniformity of weight
			Dissolution (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by UV)
569	NRD-608	Diltiazem CR/prolonged released Tab. BP 90mg	Description
			Identification A (by TCL)
			Identification B (by HPLC)
			Related substances (by HPLC)
			Average weight
			Uniformity of weight
			Disintegration Time
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
570	NRD-677	Methimazole Tab. USP 5 mg	Description
			Identification (by IR)
			Average weight
			Uniformity of Content (by UV)
			Dissolution (by UV)

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Contents of Packaged Dosage Forms
			Assay: (by Chemical)
571	NRD-762	Rifampicin Tab. IP 450 mg	Description
			Identification A (by IR)
			Identification B (by HPLC)
			Average Weight
			Dissolution (by UV)
			Related substances (by HPLC)
			Uniformity of Weight
			Contents of Packaged Dosage Forms
			Assay (by HPLC)
572	NRD-763	Rifampicin Tab. IP 600 mg	Description
			Identification A (by IR)
			Identification B (by HPLC)
			Average Weight
			Dissolution (by UV)
			Related substances (by HPLC)
			Uniformity of Weight
			Contents of Packaged Dosage Forms
			Assay (by HPLC)
573	NRD-811	Verapamil Hydrochloride Sustained Release Tab. IP 120mg	Description
			Identification A (by IR)
			Identification A (by Chemical)
			Average Weight
			Dissolution (by HPLC)
			1 st time point
			2 nd time point
			3 rd time point
			Related substances (by HPLC)
			Uniformity of Weight
			Contents of Packaged Dosage Forms
			Assay (by HPLC)
574	NRD-901	Dapagliflozin 5 mg	Description
			Identification (by HPLC)
			Average weight
			Disintegration Time
			Uniformity of content (by HPLC)
			Contents of Packaged Dosage Forms
			Assay: (by HPLC)
			Identification of colour
575	NRD-902	Chlorthalidone 12.5 mg	Description
			Identification A (by IR)
			Identification B (by UV)

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Identification C
			Average weight
			Dissolution (by UV)
			Related substances (by TLC)
			Contents of Packaged Dosage Forms
			Assay: (by UV)
576	NRD-903	Chlorthalidone 25 mg	Description
			Identification A (by IR)
			Identification B (by UV)
			Identification C
			Average weight
			Dissolution (by UV)
			Related substances (by TLC)
			Contents of Packaged Dosage Forms
			Assay: (by UV)
577	NE1	Buprenorphine 2mg + Naloxone 0.5 mg Tablets	Description
			Identification of:
			Buprenorphine (by HPLC)
			Naloxone (by HPLC)
			Average weight
			Disintegration time
			Content uniformity of:
			Buprenorphine (by HPLC)
			Naloxone (by HPLC)
			Contents of Packaged Dosage Forms
			Assay:
			Buprenorphine (by HPLC)
			Naloxone (by HPLC)
578	NE2	Misoprostol Tablets 200 mcg	Description
			Identification A (by HPLC)
			Average weight
			Uniformity of content (by HPLC)
			Contents of Packaged Dosage Forms
			Disintegration time
			Assay: (by HPLC)
579	NE11	Post exposure prophylaxis drugs for HIV- Drug Combination : Tenofivir 300 mg+ Lamivudine 300 mg + Efavirenz 600 mg	Description
			Identification (by HPLC)
			Average weight
			Uniformity of weight
			Dissolution of: (by HPLC)
			Tenofivir
			Lamivudine
			Efavirenz
			Contents of Packaged Dosage Forms

Sr	Code No.	Name of item with specification	Test proposed to be carried out
			Assay: (by HPLC) Tenofivir Lamivudine Efavirenz
580	NE75	Morphine Sulphate 30 mg SR Tablet	Description Identification A (by HPLC) Identification A (by HPLC) Average Weight Dissolution (by HPLC) 1 st time point 2 nd time point 3 rd time point 4 th time point Related substances (by HPLC) Uniformity of Weight Contents of Packaged Dosage Forms Assay (by HPLC)

ANNEXURE –VIII
Ref: Clause no. 3 (p)

To fill up the remark column of the enclosed Performa to access the existing facilities of your laboratories

A - General requirements and premises

S.N.	Details of the requirement	Remark
1	For Laboratory management a qualified individual known as quality manager or technical manager is appointment.	
2	The Laboratory is designed, contracted and maintained to prevent entry of insects and rodents besides cross contaminations ;	
3	Interior surface (wall, floor, and ceilings) are smooth and free from cracks, and permit easy cleaning and disinfection ;	
4	Adequate provision for space and equipment for carrying out necessary test is provided & also unities like water, power and gas ;	
5	Air ventilations system is provide to ensure dust free environments	
6	The laboratories provided with adequate lighting and ventilation, air conditioning to maintain satisfactory temperature and relative humidity	
7	The faculties of drainage system and to prevent water logging in the laboratory	
8	Tables tops is made of with acid, alkali and solvent resistant material	
9	Adequate space with proper storage conditions in the laboratory shall be provided for keeping Reference and working standards	
10	The air circulation is maintained in the area where sterility test is carried out as per Schedule M.	

B- Personal & Equipment

S.N.	Details of the requirement	Remark
1	Staff in the laboratory shall possess necessary qualification, proper training and shall have Adequate, experience for the assigned duties.	
2	A training record of all the personal shall be maintained.	
3	Head of the laboratory must be high professional standing with experience in drug analysis and laboratories management	
4	The analytical instrument shall be housed in the dust-free environment and with controlled conditions of temperature and humidity	
5	A progress register for non functional equipments and action for procurement of spares and accessories, monitoring there of, shall be maintained	
6	A standard operating procedure for preventive maintenance of machine or equipment or apparatus shall be prepared by the laboratory	
7	Equipments such as burette, pipettes, volumetric flasks, weight boxes, thermometers etc. shall be thoroughly checked for accuracy for calibration before acceptance of use	
8	Equipments, instruments giving anomalous results or defective must be labeled as out of order	
9	Autoclaves must meet the requirements described for operations, safety and validation procedures	
10	Work involving the evolution of harmful and obnoxious vapors shall be	

S.N.	Details of the requirement	Remark
	carried out in a fume cupboard	

Chemicals and Reagents, Good housekeeping and safety

S.N.	Details of the requirement	Remark
1	All reagents and solutions in the laboratory shall be property identified with a label.	
2	A standardization register shall be maintained, with its raw date and SOP for preparation and standardization on stock solutions, standard solutions and volumetric solutions.	
3	Containers of stock solutions and of standard solutions shall bear the details.	
4	The storage and handling of chemicals and reagents shall be done in a manner considering the physicochemical properties substances and the hazard involved in their use.	
5	General and specific written down instructions for safety shall be circulated to each staff member.	
6	SOP for safety, house-keeping and loss prevention.	
7	Drinking, eating and smoking shall not be permitted in the laboratories.	
8	Staff must wear laboratory coats or other protective clothing including gloves and face masks and eye protection wherever required	
9	The laboratories shall have adequate first aid kit and fire fighting equipments.	
10	Operators carrying out sterility tests shall wear sterilized garments including headgear, face masks and shoes.	
11	The staff must be educated in the first aid techniques, emergency care and use of antidotes.	
12	Safety rules in handling cylinders of compressed gases must be observed and staff must be familiar with relevant colors identification codes ;	
13	Protective Precautions - 1- water showered 2- Rubber suction bulbs must be used on manual and siphons ; 3- Warnings, precautions and written Instructions violent, uncontrollable or reactions. 4- Appropriate facilities for the collection, storage and disposal of wastes. 5- Safe disposal of corrosive or dangerous products by neutralization or deactivation. 6- Safety precautions to be adopted while handling potassium cyanide and bromide ; 7- SOP for handling, collection, disposal of chemical and biological wastes.	

Maintenance, calibration, and validation of equipment & Reference materials : Microbiological Cultures :

S.N.	Details of the requirement	Remark
1	All equipments, instruments and other devices used in the laboratory shall use appropriate methods and procedures for all tests or calibrations and they shall be regularly Calibrated and validated.	
2	For most of the equipments and instruments, SOP for calibration and calibration schedule be the laboratory and a logbook shall also be prepared by each laboratory for proper documentation of calibrations results.	
3	Reference material shall be traceable to agency authorized by Government of India or any other International body.	
4	The laboratory shall prepare working standard by comparing with the reference standards and shall be routinely checked for their purity.	
5	Whenever, any new reference material is received by the laboratory following details are to be written - a- Source of supply ; b- Code number of the reference material ; c- Date of receipt ; d- Batch number or identification number of the supplying agency ; e- Details like assay value, water content or information provided ; f- Storage condition of the material ; g- Date of expiry, if any and date of manufacturing if possible.	
6	SOP for maintenance of microbial culture and sub-culture must be prepared by the laboratories ;	

Quality system : & internal quality audits, management review :

S.N.	Details of the requirement	Remark
1	The measurements and calibrations shall fully conform to the compendia requirements and the method demonstrably based on validation protocols are followed.	
2	Remedial action o the observations by internal and external audits are taken appropriately	
3	Documented quality policy for the organization.	
4	Internal audits are done to assure the integrity of the analysis ad such audits shall be conducted periodically	
5	Each activity is audited at least once in a year.	
6	The quality manager shall maintain all the records of the analysis being conducted which includes test system, the type of analysis , date on which analysis is done	
7	Review yearly 1- Report or input 2- Matter arising from previous reviews ; 3- Report of external audits, if any ; 4- Surveillance report, if any ; 5- Result of proficiency testing ; 6- Complaints or feedback received from users 7- Details of in-house quality control checks ; 8- Need of amendment of the quality system and documentation ; 9- Introduction training of new staff.	

Standard operating Procedures

S.N.	Details of the requirement	Remark
1	Shall be written in a chronological order listing different steps leading to an analysis of drugs or calibration of an instruments ;	
2	Shall have SOP manuals and have periodic Review.	
3	<p>Standard Operation Procedures for the followings are required</p> <ul style="list-style-type: none"> (i) Sample handling and accountability ; (ii) Receipt identification, storage, mixing and method sampling of the test and control articles ; (iii) Record keeping, reporting, storage and retrieval of data ; (iv) Coding of different studies, handling of data including use of computerized data system ; (v) Operation of technical audit personnel in performing and reporting audits, inspections and final report reviews ; (vi) Routing inspection of cleaning maintenance, testing, calibration and standardization of instruments ; (vii) Action to be taken in respect of equipment failure ; (viii) Analytical data methods (ix) Health and safety protection ; (x) Date handling and storage retrieval ; (xi) Health and safety protection ; (xii) Animal room preparations ; (xiii) Animal care ; (xiv) Storage and maintenance of microbial cultures ; (xv) Maintenance of sterility room (i.e. constant maintenance and monitoring of Aseptic condition room) ; (xvi) Use and storage of reference standards ; (xvii) Procurement of stores and equipment ; (xviii) Monitoring of testing of samples ; (xix) Method of retention of unexpended samples, their location, maintenance and disposal ; (xx) Document control ; (xxi) Redressal of technical complaints ; (xxii) House- keeping (xxiii) Corrective and preventive action ; (xxv) Calibration manual. (xxvi) Training manual. 	
4	<p>Protocols and specification archive :-</p> <p>List of all the pharmacopeias a file on patent and proprietary medicines (non-Pharmacopeia) test methods to specification prepared and validated by the manufacturer. The test methods shall be submitted to the concerned Drug Control Authority.</p>	
5	<p>Raw data -</p> <p>Date integrity and security shall be maintained Original entry must be saved and the system shall trail for all data.</p>	
6	<p>Storage and archival ;</p> <p>The residual sample shall be retained in proper storage condition for a period of one year after the final report.</p>	
7	The laboratory must establish and maintain procedures for the identification collection, indexing, retrieval, storage, maintenance, and Disposal of all	

S.N.	Details of the requirement	Remark
	quality documents.	
8	All the raw data, documentation, SOP, protocols and final reports are to be retained and there shall be archives of orderly storage and expeditious retrieval of all raw data, documentation, protocols, interim and final report.	
9	The condition under which the original documents are stored must ensure their security and confidentiality.	
10	Raw data on thermal paper might fade away with time ; therefore, a photocopy of the thermal paper shall be retained in the archive.	

Above mentioned information correct as per our record and if found incorrect, RMSC may take action against our firm and reject our bid.

Signature:

Name of the Lab:

Date:

Official Seal:

ANNEXURE –IX
Ref: Clause no. 9 (2)

AGREEMENT

This Deed of Agreement is made on this _____ day of _____ 2025 by M/s. _____ represented by its Proprietor/ Managing partner /Managing Director having its laboratory Premises at _____ (hereinafter referred to as “Service provider” which term shall include its successors, representatives, heirs, executors and administrators unless excluded by the Contract) on one part and Rajasthan Medical Services Corporation Ltd, represented by its Executive Director (P) having is office at Swasthya Bhawan, Tilak Marg, C-Scheme, Jaipur (hereinafter referred to as “The Purchaser” which term shall include its successors, representatives, executors assigns and administrator unless excluded by the Contract) on the other part.

Whereas the Service provider has agreed to test the Drugs and Medicines for RMSC with specifications mentioned in the Schedule attached here to and mentioned at the prices noted there

in and in the manner and under the terms and conditions here in after mentioned and where as the Service provider has deposited with the Purchaser a sum of Rs _____ (Rupees only) as Performance Security Deposit for the due and faithful performance of this Agreement, to be forfeited in the event of the Service provider failing duly and faithfully to perform it. Now these presents witness that for carrying duly and faithfully to perform it. Now these presents witness that for carrying out the said Agreement in this behalf into execution the Service provider and the Purchaser do hereby mutually covenant, declare, contract and agree each of them with the other of them in the manner following, that is to say,

The term “Agreement”, wherever used in this connection, shall mean and include the terms and conditions including amendments contained in the invitation to tender floated for the Empanelment of Analytical Testing Laboratories for the test and Analysis of Drugs for Rajasthan Medical Services Corporation Ltd F.02(425)/RMSCL/ED (P) EMPANELMENT/DTL/NIB-04/2025/ Dated :- the instruction to Bidders, the conditions of Bid, acceptance of Bid, particulars hereinafter defined and those general and special conditions that may be added from time to time.

1. (a) The Agreement is for the test by the Service provider to the Purchaser of the testing of Drug and Medicines specified in the Schedule attached here to at process noted against each therein on the terms and conditions set forth in the Agreement.
- (b) This Agreement shall be deemed to have come into force with effect from the date of issuance of letter of acceptance no.and dated.....and it shall remain in force up to **31.10.2027** and extendable upto 3 months, if required. Firm shall be bound to accept the extension period of Rate Contract.

TERMINATION OF CONTRACT ON BREACH OF CONDITION

1. (a) In case the Service provider fails or neglects or refuse to faithfully perform any of the Covenants on his part herein contained, it shall be lawful for the Purchaser to forfeit the amount deposited by the Service provider as Performance Security and cancel the Contract.
- (b) In case the Service provider fails, neglects, or refuse to observe, perform, fulfill and keep, all or any one or more or any part of any one of the Covenants, stipulation and provisions herein contained, it shall be lawful for the Purchaser on any such failure, neglect or refusal, to put an end to this Agreement and thereupon every article, cause and thing herein contained on the part of the Purchaser shall cease and be void, and in case of any damage, loss, expenses, difference in cost or other moneys from out of any moneys for the time being payable to the Service provider under this and/or any other Contract and in case such last mentioned moneys are insufficient to cover all such damages, losses, expenses, difference in cost and other moneys as aforesaid, it shall be lawful for the Purchaser to appropriate the Performance Security made by the Service provider as herein before mentioned to reimburse all such damages, losses, expenses, difference in cost and other money as the Purchaser shall have sustained, incurred or been put to by reason of the

Service provider having been guilty of any such failure, negligence or refusal as aforesaid or other breach in the performance of this Contract.

(c) If at any time during the course of the Contract, it is found that any information furnished by the Service provider to the Purchaser, either in his Tender or otherwise, is false, the Purchaser may put an end to the Contract/Agreement wholly or in part and thereupon the provisions of Clause (a) above shall apply.

2. The Purchaser reserves the right to terminate without assigning any reasons therefore the Contract/Agreement either wholly or in part without any notice to the Service provider. The Service provider will not be entitled for any compensation whatsoever in respect of such termination of the Contract/Agreement by the Purchaser.

NOTICE ETC, IN WRITING

3. All Certificates or Notice or orders for time or for extra, varied or altered supplies which are to be the subject of extra or varied charges whether so described in the Agreement or not, shall be in writing, and unless in writing, shall not be valid, binding or be of any effect whatsoever.

SERVICE PROVIDER NOT HAVE ANY INTEREST IN THE OFFICERS CONCERNED AND SUBORDINATES

4. The Service provider shall not be in any way interested in or concerned directly or indirectly with, any of the Officers, Subordinate or Servants of the Purchaser. In any trade, business or transactions nor shall the Service provider give or pay or promise to give or pay any such Officer, Subordinate or Servant directly or indirectly any money or fee or other consideration under designation of "Custom" or otherwise; nor shall the Service provider permit any person or persons whomsoever to interfere in the management or performance hereof under power of attorney or otherwise without the consent in writing the consent in writing of the Purchaser obtained in first hand.

BANKRUPTCY OF THE SERVICE PROVIDER

5. In case the Service provider at any time during the continuance of the Contract becomes bankrupt or insolvent or commits any act of bankruptcy or insolvency under the provisions of any law in that behalf for the time being in force, or should compound with his creditors, it shall be lawful for the Purchaser to put an end to the Agreement, and thereupon every article, clause and thing herein contained to be operative on the part of the Purchaser, shall cease and be void and the Purchaser shall have all the rights and remedies given to him under the preceding clauses.

SERVING OF NOTICE ON SERVICE PROVIDER

6. All notice or communication relating to or arising out of this Agreement or any of the terms thereof shall be considered duly served on or given to the Service provider if delivered to him or left at his premises, place of business or abode.
7. And it is hereby agreed and declared between the parties hereto that in case any question of dispute arises touching the construction or wording of any of clause herein contained on the rights, duties, liabilities of the parties hereto or any other way, touching or arising out of the presents, the decision of the Managing Director, Rajasthan Medical Services Corporation Ltd in the matter shall be final and binding.
8. All disputes arising out of this agreement and all questions relating to the interpretation of this agreement shall be decide by the Govt. and the decision of the Govt. shall be final.

SERVICER PROVIDER
(Signature, Name & Full Address)

Executive Director (Procurement),
RAJASTHAN MEDICALSERVICES
CORPORATION LTD.

Witness (Signature, Name & Full Address)

- 1.
- 2.